Cocoa flavanol interactions with intestinal sugar metabolism by Ellam, Samantha Lee
iCocoa flavanol interactions with intestinal sugar
metabolism
Samantha Lee Ellam
Submitted in accordance with the requirements for the degree of Doctor of
Philosophy
The University of Leeds 
School of Food Science and Nutrition
March 2013
Il
*
I
Ill
The candidate confirms that the work submitted is her own, except where 
work which has formed part of jointly authored publications has been 
included. The contribution of the candidate and the other authors to this work 
has been explicitly indicated below. The candidate confirms that appropriate 
credit has been given within the thesis where reference has been made to
the work of others.
This copy has been supplied on the understanding that it is copyright 
material and that no quotation from the thesis may be published without
proper acknowledgment.
The right of Samantha Lee Ellam to be identified as Author of this work has 
been asserted by her in accordance with the Copyright, Designs and Patents
Act 1988.
©2013 The University of Leeds and Samantha Lee Ellam
Further details of the work from jointly authored publications/submitted 
manuscripts and the contributions of the candidate and the other authors to
the work are included below.
iv
. Chapter 1
Ellam, S. and Williamson, G. (2013) ‘Cocoa and Human Health’, Annual 
Review of Nutrition, 33, In press.
Details of authorship contributions:
Ellam: All discussion and illustrations presented here is the authors own 
work.
Williamson: Additional discussion, guidance and editing of the final 
manuscript submitted for publication.
Chapter 2, 3 and 4
Farrell, T.L., Ellam, S.L., Forrelli, T. and Williamson, G. (2013) 'Attenuation 
of glucose transport across Caco-2 cell monolayers by a polyphenol-rich 
herbal extract: Interactions with SGLT1 and GLUT2 transporters’, Biofactors, 
in press.
Details of authorship contributions:
Farrell: Experimental design and method development, except Caco-2 
glucose transport protocol, data analysis, cell culture and practical work, 
data interpretation and primary authorship.
Ellam: Experimental design and method development of Caco-2 glucose 
transport protocol.
Forrelli: Manuscript editing and affiliation with New Chapter Inc., Vermont, 
USA who fully funded the investigations.
Williamson: Guidance and manuscript editing.
VAcknowledgements
I would like to thank Professor Gary Williamson for providing me with the 
opportunity to join his Functional Food group and undertake this PhD. Your 
support, guidance and advice throughout have been essential to the 
completion of this project.
To my Functional Food group colleagues and those from the wider School of 
Food Science and Nutrition, thank you for your support and friendship 
throughout our time in the department together, I have enjoyed working with 
each of you and hope that our friendships continue. Specific thanks are 
directed to Ebru Cetin and Kerstin Zeigler for provision of Caco-2 cells.
To my family, thank you for supporting me in my taught and research 
studies. Your patience and support has motivated and encouraged me 
throughout.
Finally I would like to acknowledge Nestlé PTC, York UK and BBSRC for the 
PhD studentship funding that has made this project possible.
vi
Abstract
The interaction between cocoa polyphenols and sugars was investigated in 
the Caco-2 cell model. Previous investigations have suggested a link 
between sugar content of a food/meal and epicatechin bioavailability. To
i
investigate this hypothesis further, the effect of sucrose, glucose and 
fructose on epicatechin absorption across the Caco-2 monolayer was 
studied, and is presented here. Apical to basolateral transport of epicatechin 
was enhanced by co-incubation with sucrose, but not glucose or fructose. It 
is proposed that sucrose-induced cell signalling stimulated activity of the 
sodium-dependent glucose transporter SGLT1, which lead to widening of 
tight junction pore size. Consequently paracellular permeability of 
epicatechin was enhanced. The presence of glucose or fructose, but not 
sucrose, reduced the total concentration of methylated epicatechin produced 
by Caco-2 cells. Decreased formation of methylated epicatechin is 
hypothesised to be a consequence of catechol-Omethyl transferase 
inhibition (COMT). COMT requires a magnesium cation cofactor, which is 
also required by some glycolytic enzymes. It is suggested that competition 
for the magnesium (II) cofactor leads to reduced epicatechin methylation. 
Flavanol-rich dark chocolate extract also reduced total methylation of 
epicatechin. It is proposed that flavanols with a degree of polymerisation 
greater than monomer compete with epicatechin for methylation.
Dark chocolate is reported to have a low glycaemic index, which was 
hypothesised to be attributable to flavanol inhibition of sucrose hydrolysis 
and/or glucose uptake. In Caco-2 cells the rate of sucrose hydrolysis and the 
rate of glucose transport were attenuated by a flavanol-rich dark chocolate 
extract. Reduced rate of sucrose hydrolysis was partly attributed to the
VII
epicatechin content of the dark chocolate extract, with a synergistic 
contribution from other flavanol components. Similarly, synergy between the 
flavanol components of dark chocolate extract, or those components with a 
degree of polymerisation greater than dimer, is postulated to be responsible 
for reducing the rate of glucose absorption. Moderate concentrations of 
flavanol monomers and B2 dimer enhanced the rate of sucrose hydrolysis; 
proposed to be a consequence of flavanol-enzyme binding, at a site other 
than the active site, resulting in a conformational change that lead to more 
exposed catalytic residues at the active site. Caffeine and theobromine 
increased the rate of cellular glucose uptake. This is suggested to be a 
consequence of stimulated SGLT1 trafficking to the apical membrane 
induced by elevated cyclic adenosine monophosphate concentration within 
the cells as a result of cyclic 3’, 5’-nucleotide phosphodiesterase inhibition.
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1Chapter 1 Literature review
1.1 Cocoa and chocolate
1.1.1 Production
Cocoa is a dry powdered product manufactured from seeds of the 
Theobroma cacao L. tree, and in its unsweetened form is the result of fat 
extraction from cocoa liquor. Cocoa liquor is the material used in chocolate 
confectionery manufacture along with other ingredients such as sugar, 
emulsifier, milk protein, etc. depending on the desired product.
The production of cocoa liquor begins with cleaning the seeds followed by a 
fermentation stage during which the chemical composition of the bean 
begins to alter and once dried the beans are ready to be roasted. Roasting 
may be performed before or after shelling (winnowing), and is a fundamental 
part of the process that affects the flavour characteristics and nutrient profile 
of the final product. The shelled bean, known as the nib, is then ground to a 
paste, which causes the fat to melt and form cocoa liquor. The liquor may 
then be treated with an alkali solution, ‘Dutching’, to increase the pH and 
improve payability. Similar to the roasting process, the alkalising step 
affects the chemical composition of the cocoa liquor such that both stages in 
processing may be refined and strictly controlled to develop a product with a 
specific chemical profile.
1.1.2 Composition and biologically active components
The nutrient composition of cocoa and chocolate is distinct; dark chocolate 
containing 70% cocoa solids contributes more energy, lipid and sugars per 
100 g edible weight than unsweetened cocoa powder. However comparing
2percentage content is less relevant from a physiological perspective as the 
actual amount of dark chocolate and cocoa powder consumed is very 
different. A typical portion size of dark chocolate is approximately 28 g 
whereas a cocoa beverage may only contain around 5.5 g of unsweetened 
cocoa powder. Relative to the serving size, contributions to energy, lipid and 
sugar intake from unsweetened cocoa powder are much lower than from 
dark chocolate and quite insignificant compared with the United Kingdom 
(UK) reference nutrient intake (RNI) values. Similarly, micronutrient 
contribution from cocoa powder is slight with the exception of copper. A 
typical serving of unsweetened cocoa powder contributes approximately 
16% of an adults daily UK RNI for copper (1.2 mg/d). A typical portion of 
70% cocoa solids dark chocolate contributes quite considerably to total fat 
and non-milk extrinsic sugar (NMES) recommended intakes -  16% and 13% 
respectively. Additionally micronutrient contribution towards an adults intake 
are substantial -  copper, 41%; iron and magnesium, each 23% (females); 
phosphorus 16% and zinc 13% (females). Deficiency of copper, magnesium, 
phosphorus and zinc is generally not a problem for the UK adult population 
however iron is a common deficiency in females. Although non-haem iron is 
less well absorbed than haem sources, when the body’s iron reserves are 
low absorption becomes more efficient (Ministry of Agriculture 1995).
Of the non-essential nutrient components of dark chocolate and cocoa the 
most relevant, considering serving size, are caffeine, theobromine and 
flavonoids. Caffeine in cocoa powder is negligible; however a 28 g bar of 
dark chocolate may contain approximately 22 mg (U.S. Department of 
Agriculture 2011). For comparison a teaspoon of regular instant coffee
contains around 31 mg and a cup of tea 47 mg (U.S. Department of
*
3Agriculture 2011). Theobromine, a structurally similar precursor of caffeine in 
plant cells, is abundant In dark chocolate and cocoa. A typical serving of 
70% dark chocolate would provide more than 200 mg whilst a typical serving 
of cocoa powder supplies >100 mg (U.S. Department of Agriculture 2011). 
Flavonoids present in dark chocolate and cocoa have attracted much 
attention in the past decade and are believed to stimulate biological activities 
that may be beneficial to human health. The main flavonoids identified in 
dark chocolate are flavanol monomers (-)-epicatechin and (+)-catechin, and 
polymers of these compounds up to decamer, and ferulic acid. Resveratrol 
and its 3-O-glucoside are also present but in >100-fold lesser amounts. The 
main flavanol present in dark chocolate is (-)-epicatechin, at approximately 
70 mg 100 g‘1 fresh weight (Neveu etal. 2010). The (-)-epicatechin B2 dimer 
and C1 trimer constitute ~36 and 26 mg 100g'1 fresh weight respectively. A 
28 g typical portion of dark chocolate would supply almost 20 mg of (-)- 
epicatechin, 10 mg of the B2 dimer and 7 mg of C1 trimer.
1.1.2.1 Bioavailability of caffeine and theobromine
Caffeine is a 1,3,7-trimethylated xanthine that is metabolised in vivo to 
paraxanthine (1,7-dimethyl xanthine), theophylline (1,3 -dimethyl xanthine), 
theobromine (3,7-dimethyl xanthine) and 1,3,7-trimethyluric acid in pathways 
similar to those described for theobromine (Figure 1.11 (Thorn etal. 2012). 
Caffeine is efficiently absorbed from the small intestine, such that the entire 
dose administered is absorbed with a reported peak in plasma concentration 
at approximately 30 min post-ingestion. The elimination half-life is on 
average 4.5 h but dependent on high individual variations (Blanchard and 
Sawers 1983).
4There have been a limited number of bioavailability studies conducted in 
humans and other animals since the late 1950’s; although the analytical 
methods have changed the metabolic outcomes remain relatively similar. In 
the first of such studies the authors identified unchanged theobromine and 3 
metabolites in 48 h urine following consumption of the pure compound 
(Cornish and Christman 1957). The main metabolite was 7-methylxanthine 
which accounted for up to 30% of the dose, 3-methylxanthine accounted for 
approximately 20% and 7-methyluric acid accounted for around 4% of the 
dose. Later, 3,7-dimethyluric acid and a uracil compound was identified in 
urine following consumption of cocoa powder (Arnaud and Welsch 1979). 
These additional compounds have since been confirmed in human trials and 
the uracil compound identified as 6-amino-5-(N-methylformylamino)-1- 
methyluracil (Tarka et al. 1983). Metabolite recovery of around 80% of the 
ingested dose plus 18% unchanged theobromine have been reported (Tarka 
et al. 1983). Shively et al (1985) also documented a small percentage of 
unchanged theobromine in the faeces of subjects which accounted for less 
than 1.5% of the ingested dose. Pharmacokinetic investigations have 
demonstrated an average half-life of theobromine in plasma of 7.2 h when 
consumed in the form of a gelatin capsule (Lelo et al. 1986) and 10 h when 
ingested from an aqueous solution (Shively et al. 1985) with total clearance 
from plasma measured at 1.2 mL min'1 kg'1 and 0.9 mL min'1 kg'1, 
respectively. The maximum plasma concentration of theobromine from 
chocolate is reached approximately 2 h post-ingestion suggesting that it is 
entirely absorbed in the small intestine (Shively et al. 1985). And although 
the mechanism for absorption through the intestinal epithelium has not been 
described, based on In vitro absorption of caffeine using colon
* M
5adenocarcinoma cells (Caco-2) (Smetanova et al. 2009), it can be surmised 
that theobromine similarly diffuses passively through the enterocytes into the 
hepatic circulation.
Most recent investigations have focused on the mechanisms by which 
theobromine is demethylated and oxidised to methyluric acid. Work 
conducted in the early 1990’s suggested the hepatic cytochrome P450 
pathway with specific involvement of the monooxygenase enzyme (EC 
1.14.14.1) isoforms CYP1A2 and CYP2E1 (Gu et al. 1992, Tassaneeyakul 
et al. 1994, Rodopoulos et al. 1996). The main metabolite present in urine 
accounting for up to 40% of the ingested dose is 7-methyl xanthine which is 
a product of both enzyme isoforms. CYP2E1 appears to be the least specific 
as it also catalyses the formation of 3-methylxanthine and 3,7-dimethyluric 
acid (Gates and Miners 1999). Whilst the 3-methylxanthine isomer may 
undergo slight further metabolism to 3-methyluric acid (~1% of dose) 
(Rodopoulos et al. 1996), 7-methylxanthine is the main substrate, produced 
from theobromine catabolism, for xanthine oxidase (EC 1.17.3.2). Xanthine 
oxidase catalyses oxidation of carbon-8 to form 7-methyluric acid. The 
mechanism of uracil formation is yet to be established.
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Figure 1.1 Metabolic pathway of theobromine
1.1.2.2 Bioavailability of flavanols
Flavanols are a type of phytochemical within the subgroup of flavonoids, 
other types within this subgroup include flavonols, flavones, flavanones, 
anthocyanidins and isoflavones. Phenolic acids and tannins are also a 
subclass of phytochemicals categorised as phenolics and are often 
incorporated in the general discussion of flavonoids. Human intervention 
studies investigating the bioavailability and effects of flavonoids have 
typically focused on phenolics in tea, coffee, red wine, fruit juice, onion and 
soy bean.
Epicatechin is the principal flavanol that has been investigated and to which 
many health benefits arising from consumption of tea and chocolate have 
been attributed.
*
7A number of bioavailability studies in rats and humans have investigated the 
pharmacokinetics of epicatechin either administered as the individual 
compound or in a food matrix such as cocoa and tea. The specific 
mechanism of epicatechin uptake from the small intestine has not been 
elucidated although a transcellular route in vivo has been established 
through detection of phase II metabolites in plasma. In vitro studies 
demonstrate the absence of saturation kinetic properties, and similar 
apparent permeability coefficients (Papp) for apical to basolateral and 
basolateral to apical transport which together suggest a paracellular route 
(Deprez etal. 2001, Kosinska and Andlauer2012).
Epicatechin absorption in vivo predominantly results in the production of 
phase II metabolites; very little, if any, free epicatechin is detected in 
humans. The peak plasma concentration of metabolites is reached 2-4 h 
post-ingestion indicating that absorption occurs mainly in the small intestine. 
There are some discrepancies in the pattern of metabolism between human 
and rat models. In both, epicatechin is predominantly conjugated with D- 
glucuronic acid in either the 3’ or 4’ position, a reaction catalysed by the 
membrane bound enzyme UDP-glucuronosyltransferase (EC 2.4.1.17) 
(Kuhnle et al. 2000, Baba et al. 2001b, Actis-Goretta et al. 2012). 
Methylation of epicatechin and epicatechin-O-D-glucuronides, catalysed by 
catechol-O-methyltransferase (EC 2.1.1.6), have also been reported in rat 
plasma but not human (Baba etal. 2001b). In humans methylated and non- 
methylated epicatechin is also conjugated with a sulphate group by 
sulfotransferase enzymes (EC 2.8.2.1) and some studies have reported the 
detection of sulfated glucuronide conjugates of epicatechin in both humans 
and rats (Baba et al. 2000b, Baba et al. 2001b).
8Polymeric flavanols with a degree of polymerisation up to decamer have 
been identified in dark chocolate and cocoa. Monomeric units are joined by a 
carbon-carbon bond at various locations on the molecule. Currently 
commercial availability of these compounds is limited so many studies have 
focused attention on the B2 dimer and C1 trimer of (-)-epicatechin (Figure 
1.2). or non-specific polymers extracted from cocoa or grape seed extract. In 
vitro studies have demonstrated that trimer to hexamer flavanols from cocoa 
degrade up to 100% to form monomers and dimers when incubated at pH 2 
for up to 3.5 h at 37°C. The dimer degraded by ~20% to monomer. This was 
refuted by the results of a human study in which a cocoa beverage was 
consumed then gastric fluid extracted at ten minute intervals until the 
stomach was empty. The flavanol profile did not alter during the course of 
gastric fluid extraction indicating that there was no degradation of polymeric 
flavanols (Rios et al. 2002). The evidence for absorption of oligomeric 
flavanols is similarly contrasting. Perfusion of rat jejunum with dimeric 
flavanols demonstrated degradation of dimer to monomer with the detection 
of unmetabolised monomer at the serosal side. Some methylated dimer was 
also identified (Spencer et al. 2001). Procyanidin B2 administered to rats 
orally in water following a 12 h fast was detected in plasma along with 
epicatechin and 3’-0-methyl epicatechin; maximum concentration was 
achieved at 30-60 min. Up to 18 h, all three compounds were identified in 
urine along with methylated and non-methylated conjugates (Baba et al. 
2002). Contradictory to this, plasma collected from rats 3 h following 
consumption of a meal prepared with grapeseed extract or the B3 dimer did 
not contain any B3 dimer and catechin and epicatechin were only detected 
in the plasma of rats fed the grapeseed, extract. The concentration of
gcatechin in the plasma following consumption of grapeseed extract was 
comparable with the concentration following consumption of the same 
amount of pure catechin indicating that the dimer was not degraded to its 
monomer constituents (Donovan et al. 2002). A study published more 
recently reported similar results following human consumption of beverages 
containing either (-)-epicatechin only, monomer to decamer flavanols, or 
dimer to decamer. Monomeric flavanols were primarily detected in plasma 
following consumption of the (-)-epicatechin only beverage and the monomer 
to decamer-containing beverage. A small concentration of (-)-epicatechin 
was detected in plasma following ingestion of the dimer to decamer 
beverage but this was commensurate with low levels present in the 
beverage rather than a consequence of polymer degradation (Ottaviani et at. 
2012). It appears that whilst rats may have the capacity to hydrolyse flavanol 
dimers to monomers and absorb some intact dimers, humans do not 
possess the same ability.
Flavanols that are not absorbed in the small intestine pass through to the 
colon where they are substrates for microflora metabolism. Metabolites 
detected in urine approximately 15 h after ingestion of tea included 5- 
(S’^ ’.S’-trihydroxyphenyO-y-valerolactone attributed to epigallocatechin 
metabolism and 5-(3’,4’-dihydroxyphenyl)-Y-valerolactone attributed to 
epicatechin metabolism (Li et at. 2000). In vitro assays of human colonic 
microflora with polymeric flavanols have revealed the formation of various 
phenolic acids including 2-(3-hydroxyphenyl)-acetic acid, 2-(4- 
hydroxyphenyl)-acetic acid, 2-(3,4-dihydroxyphenyl)-acetic acid, 3-phenyl- 
propionic acid, 3-(3-hydroxyphenyl)-propionic acid and 3-(4-hydroxyphenyl)- 
propionic acid (Deprez et at. 2000, Appeldoom et at. 2009a).
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Dimer B2 (epicatechin-(4p->8)-epicatechin)
Figure 1.2 Cocoa flavanol structures
(4p->8)-epicatechin)
1.2 Cocoa and health
1.2.1 Consumption
A recent report by KPMG LLP (KPMG LLP 2012) demonstrated that whilst 
globally economies have been in recession, the chocolate market has 
remained stable, in fact its retail market value has risen marginally each year 
since 2007 and is predicted to continue its growth at a rate of 2% per year 
over the next 5 years. The majority of the global market is held by Western 
Europe (32%) followed by North America (20%), Asia (17%), Latin America 
(13%), Eastern Europe (12%), Middle East and Africa (4%) and Australasia
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(2%), with large growth predicted in the smaller markets over the coming 
years.
The global population is increasing and with improvements in nutrition and 
health care so too is the age of populations. Concomitant to an ageing 
population is an increase in the number of non-communicable diseases 
which is the cause of more than 36 million deaths around the world each 
year, more than 80% of these deaths are due to cardiovascular diseases, 
cancers, diabetes and respiratory diseases (United Nations 2012). The 
economic impact of such chronic diseases has been estimated by the World 
Health Organisation (World Health Organization 2006) which predicts the 
greatest burden will be on the low and middle income countries. The 
estimated accumulated loss of national income between 2005 and 2015 is 
$3.4 billion in the United Kingdom, whilst China, India and Russia have 
estimated national losses of $53.3 billion, $23 billion and $29.8 billion, 
respectively. One factor associated with chronic non-communicable disease 
is an unhealthy diet; some governments have already introduced taxes on 
unhealthy foods whilst others are considering this possibility (KPMG LLP 
2012).
The 2008/2009 UK National Dietary Nutrition Survey (NDNS) (Food 
Standards Agency 2010) reported that adults were consuming on average 
21 g of chocolate confectionery per day and the 2010 Family Food survey 
(Department for Environment 2011) reported an average contribution to 
energy intake from confectionery (including chocolate) of 4% per person per 
day. In 2010 confectionery as a whole contributed 15% of the total non-milk 
extrinsic sugars (NMES) consumed per person per day from household 
purchases and 13% from foods purchased outside the home (Department
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for Environment 2011); the current UK reference nutrient intake (RNI) 
recommends that NMES should not provide more than 11% of the daily 
energy intake (Food Standards Agency 2006). Considering potential taxes 
on unhealthy foods and the increasing global popularity of chocolate there 
appears to be scope for manufacturers to invest in research and 
development to manufacture products with functional health benefits.
1.2.2 Epidemiological evidence for beneficial effects
During the last 5 years there have been numerous reviews considering the 
role of cocoa in specific health issues in addition to a small number of 
epidemiological studies. The majority of published work during this time is 
human and non-human intervention trials particularly focusing on the effect 
of cocoa products or chemical components of cocoa individually. The 
majority of work relates to cardiovascular disease (CVD) with hypotheses 
typically that consumption of cocoa or Intake of specific components of 
cocoa are able to lower risk or improve biomarkers of disease. Discussion in 
this section predominantly considers the literature pertaining to CVD but is 
inclusive of other areas of study with all human intervention trials 
summarised in table format (Table 1.1). _
The risk of death from stroke, coronary heart disease (CHD) and CVD 
amongst participants of the Iowa Women’s Health Study (IWHS) was lower 
in women who consumed chocolate relative to those who consumed no 
chocolate (Mink et al. 2007). Similarly data taken from the United States 
National Heart, Lung and Blood Institute Family Heart Study (Djousse et al. 
2011) suggests that compared with no intake, participants with a greater 
frequency of chocolate intake have a reduced odds of CHD prevalence, the
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lowest in consumers of 5 or more servings per week. However by contrast, 
a study of women participating in the Swedish Mammography Cohort 
(Mostofsky et al. 2010) demonstrated that the beneficial effect of chocolate 
consumption on risk of heart failure was reversed as intake exceeded 2 
servings per week. It is relevant to note at this point that serving size is not 
stated in the aforementioned studies, although the authors of the Swedish 
investigation do suggest an average portion size somewhere between 19 
and 30 g. An inverse association between chocolate consumption up to 7.5 
g per day and risk of CVD among German adults participating in the 
European Prospective Investigation into Cancer was reported (Buijsse et al.
2010). In the latter study and that of the IWHS, the association appeared 
most compelling for stroke. Evaluation of data taken from The Stockholm 
Heart Epidemiology Program (Janszky et al. 2009) of individuals who have 
experienced a first acute myocardial infarction, show that the risk of cardiac 
mortality is lowest in those who consume a 50 g portion of chocolate at least 
twice per week and the risk of a non-fatal stroke was shown to be lowest in 
those consuming up to one portion per week.
From this small collection of epidemiological studies it can be surmised that 
the consumption of 50-100 g per week of chocolate may reduce the risk of 
cardiovascular disease, in particular stroke. What is not established in any 
of these investigations is the type of chocolate consumed. The type of 
chocolate, i.e. dark, milk or white, and the addition of other ingredients such 
as fruit or nuts, is an important factor in the overall analysis of evidence. 
Dark chocolate typically contains more non-fat cocoa solids (NFCS) than 
milk chocolate, and white chocolate contains no NFCS. As the percentage 
of NFCS content increases, the percentage content of sugar decreases
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(U.S. Department of Agriculture 2011). Furthermore milk and white 
chocolate also contain milk powder that is not present in dark chocolate. 
One study investigating the effects of additional ingredients demonstrated 
that the lipid profile and inflammation biomarker concentration was improved 
following consumption of a cocoa product with the addition of hazelnuts, 
phytosterols and soluble fibre. The cocoa product without added ingredients 
had no significant effect (Sola et al. 2012).
Some epidemiological studies have investigated more specific interactions 
by focusing on particular components of cocoa. The primary focus has been 
flavonoids and in relation to cocoa, particularly the flavan-3-ol and 
proanthocyanidin sub-classes of polyphenols. An evaluation of incident 
hypertension, biomarkers of inflammation and endothelial dysfunction in 
relation to flavonoid intake of participants in the Nurses’ Health Study (NHS) 
I and II, and the Health Professionals Follow-Up Study (HPFS) (Cassidy et 
al. 2011, Landberg et al. 2011) did not find any relationship with flavan-3-ol 
or proanthocyanidin intake. However, at the highest daily intake of catechin 
and epicatechin, the primary flavan-3-ol constituents of cocoa, there was a 
significantly lower risk of incident hypertension. In contrast, a significant 
reduction in the risk of CVD has been reported with increased intake of 
flavanols and proanthocyanidins (McCullough et al. 2012). The reduction 
was not linear and, similar to other epidemiological evidence, reversed in the 
highest intake groups.*
r*
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1.2.3 Mechanisms of biological effects
1.2.3.1 Endothelial cell dysfunction
Endothelial cell dysfunction is an indicator of cardiovascular disease that has 
been widely studied in vivo and in vitro. Many of the human intervention 
trials described in this chapter involve quantification of products secreted by 
the endothelium such as nitric oxide, or expression of inflammatory response 
proteins such as interleukin-6 (IL-6). One study recently reported that nitric 
oxide (NO) production by platelets isolated from healthy subjects increased 
following 3 weeks daily consumption of dark chocolate (Nanetti et al. 2012). 
Systolic blood pressure (SBP) in spontaneously hypertensive rats (SHR) 
was reduced and considered to be a consequence of increased nitric oxide 
production following an acute dose of CocoanOX (a polyphenol-rich cocoa 
powder); the effect was prevented in the presence of an endothelial nitric 
oxide synthase (eNOS) inhibitor (M. Quinones et al. 2011). The same 
authors investigated the long-term effect of CocoanOX supplementation and 
observed attenuated development of hypertension in SHR with the effect 
being greatest in animals given the lowest dose (Quinones et al. 2010). 
Another study of SHR whose diets were supplemented with soluble cocoa 
fibre exhibited lower SBP and DBP during the treatment period. Throughout 
a 4 week post-treatment period when the test treatment had been 
discontinued SBP increased equivalent to control and DBP increased 
beyond that of control animals (Sanchez etal. 2010).
SHR administered 200 and 400 mg kg'1 doses of CocoanoX exhibited higher 
plasma angiotensin converting enzyme (ACE) activity at the end of the 
intervention period, plasma concentration of angiotensin II was also raised.
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The latter remaining elevated after treatment ended. Although this may be 
suggestive of a negative consequence, the authors discussed the possibility 
that inhibition of ACE leads to an increase in its plasma concentration 
without reducing efficacy of the inhibitor. The same study measured 
relaxation of pre-contracted intact aorta rings extracted from control animals
induced by incubation with CocoanOX. Relaxation was reduced in the
%
presence of N^-nitro-L-arginine methyl ester (L-NAME) but not indomethacin 
implying that dilation was a result of eNOS activity rather than prostaglandin- 
I synthase (Mar Quinones et at. 2011). Similar effects have been reported 
using pre-contracted renal arteries isolated from wild-type (WT) and 
atherosclerotic mice (ATX) (Gendron etal. 2010). Catechin treatment in WT 
mice during months 9 to 12 improved dilation at 12 months compared with 
the untreated group, however this effect was not replicated in ATX mice. 
Incubation with NG-nitro L-arginine (L-NNA) attenuated dilation in untreated 
WT mice but animals exposed to 3 months catechin treatment were 
unaffected, suggesting that eNOS was not inhibited in catechin treated cells 
or that addition of indomethacin to the incubation did not further affect this 
result.
In vitro studies using human umbilical vein endothelial cells (HUVEC) are 
widely used as a model to study endothelial function. HUVEC cells 
incubated with (-)-epicatechin for 2 hours had significantly increased nitrite 
levels up to 1 pM of (-)-epicatechin however beyond this, up to 10 pM, the 
nitrite concentration did not differ from control (Brossette et al. 2011). 
Similarly the greatest augmentation of nitric oxide produced by human 
coronary artery endothelial cells (HCAES) was reported following a 10 
minute incubation with 1 pM (-)-epicatechin (Ramirez-Sanchez et al. 2010).
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Following a 24 hour incubation with (-)-epicatechin Brossette et al (2011) 
observed no significant change in endothelial nitric oxide synthase (eNOS) 
mRNA expression nor any variation in its stability. It may be that increased 
production of nitric oxide is attributable to an interaction with the 
phosphatidylinositol 3-kinase (PI3K) pathway which is involved in controlling 
phosphorylation of the activation residues Ser1177 and Ser633. Treatment 
of HCAES with epicatechin increased phosphorylation of these serine 
residues and reduced phosphorylation of Thr495. In addition epicatechin 
treatment appeared to induce activation of eNOS through uncoupling from 
caveolin-1 (Cav-1) which it is bound to at the cytosolic side of the cell 
membrane in its inactive form, and binding with calmodulin (CaM) to 
stimulate solubilisation of the active enzyme. Further analysis suggested 
that this effect was mediated via interaction with phospholipase C. Whilst 
these conditions were dependent on the presence of calcium, the same 
authors have also demonstrated that epicatechin is able to stimulate NO 
production induced by phosphorylation of serine residues and activation of 
eNOS without uncoupling from Cav-1 in calcium-free conditions (Ramirez- 
Sanchez et al. 2011).
Similarly enhanced phosphorylation of non-specific serine/threonine protein 
kinase (Akt), an enzyme involved in the PI3K pathway, was measured in 
mice subjected to ischemia-reperfusion injury following 10 days of 
supplementation with 1 mg kg'1 body weight (-)-epicatechin; infarct size was 
reduced. Co-supplementation with the opioid antagonist’s naloxone or 
naltrindole eliminated the effect on Akt phosphorylation and infarct size. The 
results suggest that the protection conveyed by epicatechin was dependent 
on interaction with opioid receptors in the heart (Panneerselvam etal. 2010).
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Endothelium secretion of endothelin-1 (ET-1) is associated with vascular 
constriction and therefore negative cardiovascular consequences. Bovine 
aortic endothelial cells (BAEC) treated with a procyanidin-rich extract of 
cocoa produced less ET-1 than control cells; the response was dose- 
dependent (Caton et al. 2010). Procyanidin-rich extracts of other fruits 
elicited similar results and the trimer to pentamer fractions of cranberry 
extract were shown to downregulate expression of ET-1 mRNA and 
upregulate Kruppel-like factor 2 (KLF2) mRNA, a transcription factor that 
mediates the synthesis of ET-1. Garcia-Conesa et a l (2009) demonstrated a 
similar reduction in ET-1 synthesis in HUVEC treated with a procyanidin-rich 
fraction of apple (Garcia-Conesa etal. 2009).
Increasing nitric oxide concentration in vivo is generally considered a 
positive consequence due to its functions of vasodilation (Figure 1.3) and 
inhibition of platelet aggregation. It is possible that reported increases in 
flow-mediated dilation (FMD) and reduction of blood pressure following 
cocoa consumption (Table 1.1) is due to an increase in the production of 
nitric oxide stimulated by epicatechin (Figure 1.41. Chronic intake may have 
a long-term protective effect in the event of CVD, although in vitro and non­
human in vivo results are not necessarily transferable to humans and 
consumption of cocoa products will contribute to energy and macronutrient 
intake that may be considered unhealthy.
1.2.3.2 Inflammation
Serum concentration of C-reactive protein (CRP) in a cohort of healthy 
Italian adults participating in the Moli-sani Project was lower amongst 
consumers of less than 3 x 20 g servings per week of dark chocolate (di
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Giuseppe et al. 2008); this effect was not observed in consumers of 3 or 
more servings per week. A higher CRP concentration is associated with a 
higher risk of CHD therefore it can be inferred from this study that moderate 
consumers of dark chocolate have a lower risk of CHD than non- and high- 
consumers. Of the human intervention trials published since 2007 in which 
the serum CRP concentration is quantified following a chronic cocoa 
supplementation, the overall effect Is inconclusive. In healthy subjects 
significant reductions in CRP following intervention have been observed 
(Hamed et al. 2008, Tzounis et al. 2011), whereas in subjects suffering from 
hypertension, hypercholesterolemia or type-2 diabetes there have been no 
significant changes observed (Grassi etal. 2008, Mellor etal. 2010, Sarria et 
al. 2012). By contrast, in a study of diabetic mice whose diets were 
supplemented with epicatechin significantly lower CRP levels were reported 
compared with diabetic mice whose diets were not supplemented (Si et al.
2011). Although serum CRP concentration is indicative of CVD it is yet to be 
determined whether high serum concentration contributes to the 
development of disease or whether it is a consequence of the disease. The 
level of intake of cocoa products or individual components, and whether any 
ability to lower CRP levels improves prognosis in patients or reduces risk in 
a healthy population, is yet to be determined.
1.2.3.3 Oxidative stress and dyslipidemia
Daily oral supplementation of 1 mg kg'1 epicatechin for 10 days prior to 
ischemia-reperfusion injury, in rats, reduced infarct size and oxidized 
glutathione/reduced glutathione ratio (GSSH/GSH) at 48 hours post-injury 
(Yamazaki et al. 2008). Infarct size remained significantly smaller at 3
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weeks post-injury. A further study by the same authors performed on 
animals exposed to permanent coronary occlusion (POC) yielded very 
similar results of infarct size, they also hypothesized that exposure to 
epicatechin prior to POC may elicit an increase of Akt phosphorylation
i
however no significant changes were observed (Yamazaki et al. 2010). 
Dyslipidemia is a major risk factor of CVD that has prompted an abundance 
of investigations, not least in relation to cocoa consumption. Many of the 
intervention trials described in Table 1.1 have reported increased HDL 
cholesterol levels and improved total cholesterol/HDL cholesterol ratio 
following cocoa intervention. A soluble cocoa fibre product fed to rats 
consuming a high cholesterol diet attenuated the negative consequences of 
the diet. The cholesterol-rich diet raised total- and LDL cholesterol 
concentration, and malondialdehyde (MDA) concentration of serum but 
these levels were significantly reduced in the group supplemented with the 
cocoa fibre product. In contrast the cholesterol-rich diet caused a reduction 
in HDL cholesterol concentration that was also improved by supplementation 
with the cocoa fibre product (Ramos et al. 2008, Bravo et al. 2008). A 
similar study of rats fed a high cholesterol diet with and without the addition 
of cocoa procyanidins reported that rats fed the cholesterol-rich diet 
experienced significantly higher plasma total cholesterol than rats fed a 
normal diet. This increase was significantly attenuated by the addition of 0.5 
or 1.0% cocoa procyanidins to the high cholesterol diet. Furthermore rats 
consuming the high cholesterol diet ail exhibited significantly more 
cholesterol and triglycerides in the liver than rats fed the normal diet. At the 
highest supplementation of cocoa procyanidins this increase was 
significantly less (Osakabe and Yamagishi 2009).
I
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Obese-diabetic rats fed a diet supplemented with cocoa extract for 4 weeks 
demonstrated improved levels of plasma total cholesterol that was similar to 
that of non-diabetic rats consuming a normal diet. An improvement of similar 
magnitude was also noted for plasma triglycerides and LDL cholesterol. 
There were no significant changes in plasma HDL cholesterol concentration 
(Jalil et al. 2009). Diabetic mice treated with epicatechin for 15 weeks 
exhibited similar total- and LDL cholesterol levels to non-diabetic mice at the 
end of the study period that were significantly lower than untreated diabetic 
mice. Longevity of the epicatechin-supplemented mice was also improved; 
the number of mice surviving until the end of the study period was 
significantly greater than diabetic mice without supplementation, and not 
different from control mice. Markers of inflammation in the serum of 
epicatechin-supplemented diabetic mice were also affected by the treatment. 
Compared with non-treated diabetic mice, insulin-like growth factor-1 (IGF- 
1), CRP-1, interleukin-1 p (¡L-1P) and glutathione were either returned to 
control levels or reduced significantly. Interestingly, although there were no 
significant differences of superoxide dismutase (SOD) activity between 
control and diabetic mice, activity was significantly greater in the treated 
diabetic group (Si etal. 2011).
Investigations using the Zucker fatty rat model of obesity and metabolic 
syndrome demonstrated that supplementation of the diet with 5% soluble 
cocoa fibre resulted in a significant reduction of plasma MDA concentration 
such that levels were no longer significantly different from lean control rats. 
Zucker fatty rats fed a standard diet exhibited significantly higher levels of 
tumour necrosis factor-a (TNF-a) compared with the lean control animals but 
this was reduced in animals that consumed the 5% soluble cocoa fibre diet.
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It is important to note that this reduction was not statistically significant 
however levels in the supplemented group were not significantly different 
from either fatty or lean rats. Fatty animals fed the 5% soluble cocoa fibre 
supplemented diet had significantly higher levels of plasma adiponectin
t
compared with fatty rats and lean rats, which had similar levels (Sanchez et 
al. 2011). The same authors investigated the effect of a soluble cocoa fibre 
on development of hypertension in SHR and reported reduced MDA plasma 
concentration (Sanchez et af. 2010). A similar reduction in plasma MDA 
concentration was observed when SHR were treated with 100, 200 and 400 
mg kg'1 doses of CocoanOX; the effect was reversed by the end of a 4 week 
post-treatment period (Mar Quinones et al. 2011).
1.2.3.4 Conclusion
Cardiovascular diseases are responsible for more deaths globally than any 
other cause (World Health Organization 2011) and are the focus of much 
research, not least in relation to cocoa. The main focus of such research 
has been to identify associations between intake and disease, and to elicit 
mechanisms by which onset of disease can be delayed or prevented, or 
where treatment of cardiovascular events can be facilitated. Many of the 
human intervention studies described in Table 1.1 have involved intervention 
treatments that have demonstrated improvements in markers of disease risk 
factors such as total/HDL cholesterol ratio and FMD. Nitric oxide synthesis 
is possibly the most investigated endothelial function in relation to cocoa 
over the last 5 years with many authors reporting increases in NO 
concentration of plasma. At this time the predominant mechanistic 
hypothesis is that cocoa, or a component such as epicatechin, stimulates
'W>
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eNOS activity. Although this doesn’t appear to be the only mechanism that 
is affected, certainly increasing NO synthesis may be one reason why FMD 
and blood pressure are improved following intervention treatments.
Intervention Control Study design Outcomes Ref.
1 Cu deficient patients 
supplemented with 10- 
40 g cocoa powder per 
day until improvement 
observed
None Serum trace metal 
concentration monitored s 
24 months post-enteral 
tube insertion in 23 
patients (78.8 ± 10.4 
years)
1 serum [Cu] and 
neutrophil count
(Nishiwaki 
et al. 2011)
2 One cup of espresso 
coffee and 30 g DC 
(separate occasions)
None 50 term pregnant women 
without complicated 
gestation (31.8 ± 5.05 
years)
f  fetal HR 
accelerations and 
variability
(Buscicchio 
et al. 2012)
3 15 g pp-rich DC per day 
for 8 weeks
15 g macronutrient 
matched low-pp 
chocolate (3.9 mg ECE
g-1)
Double-blind, randomised 
cross-over; 10 subjects 
diagnosed with CFS (6 
females, 4 males) (52 ± 8 
years)
Improved symptoms 
of CFS
(Sathyapala 
n et al. 
2010)
4 HF beverage Macronutrient-matched 
LF beverage
Cross-over; 10 healthy 
females (18-65 years)
f  cutaneous blood 
flow
(Neukam et 
al. 2007)
. 5 20 g HF chocolate per 
day for 12 weeks
20 g LF chocolate (<30 
mg flavanols)
Double-blind, randomised; 
30 healthy subjects (22 
females, 8 males) (42.7 ± 
10 years)
|  minimal erythema 
dose
(Williams et 
al. 2009)
6 37 g DC and 237 mL 
cocoa beverage per day 
for 6 weeks
Low-pp bar and 
beverage containing 
0.20 mg g~1 and 40.87 
mg g_1 total 
proanthocyanidins, 
respectively
Double-blind, randomised; 
101 healthy subjects (60 
females, 41 males) (£60 
years)
|  pulse rate at 
midpoint and end-of- 
treatment
(Crews et 
al. 2008)
1.2.4 H
um
an intervention trials
Intervention Control Study design Outcomes Ref.
7 Flavanol-rich cocoa 
beverage per day for 1 
week
Flavanol-poor cocoa 
beverage (36 mg 
flavanols per day)
Double-blind, randomised; 
21 healthy subjects (10 
females, 11 males) (72.2 ± 
6 years)
t  cerebral blood flow 
in response to acute 
dose of cocoa 
beverage
(Sorond et 
al. 2008)
8 Cocoa beverage 
containing either 520 
mg or 994 mg cocoa 
flavanols
Macronutrient-matched 
cocoa beverage 
containing 46 mg cocoa 
flavanols
Double-blind, cross-over; 
30 healthy subjects (17 
females, 13 males) (21.9 ± 
SE 0.61 years)
Improved cognitive 
performance and 
reduced mental 
fatigue
(Scholey et 
al. 2010)
9 35 g DC 35 g white chocolate Cross-over; 30 subjects (22 
females, 8 males) (18-25 
years)
Improved contrast 
sensitivity, motion 
integration threshold,
(Field et al. 
2011)
Visual spatial working
memory, and reaction 01
time
10
11
20 g chocolate 
beverage
containing MF or HF 
content per day for 30
days_______________
Mashed potato powder 
(1 g kg-1 BW) 
supplemented with 
cocoa butter (1 g k g 1 
BW)______________ _
20 g chocolate Double-blind, randomised; f  posterior parietal (Camfield ef
beverage LF content 63 subjects (52.30 ± 7.49 activity, synaptic al. 2012)
years) excitation and neural
information 
processing speed
Mashed potato powder Randomised, cross-over; Plasma [TAG] and (Tholstrup et 
(1 g k g 1 BW) 10 healthy females (38.2 ± [IL-6] were altered (no al. 2011)
supplemented with olive 10.7 years) significant difference
oil (1 g kg-1 BW) between the meals)
Intervention Control Study design Outcomes Ref.
12 Cocoa beverage twice 
per day for 12 weeks
Cocoa-free beverage Randomised; 25 healthy 
males (38 ±  SE 1 years)
i  LDL susceptibility to (Baba et al. 
oxidation and urinary 2007b) 
[dityrosine]; f  HDL 
cholesterol
13 Low-, medium-, or high- 
pp cocoa beverage 
twice per day for 4  
weeks
Nutrient matched 
beverage (trace 
amounts of cocoa pp)
Double-blind; 160 normo- 
and mildly
hypercholesterolemic 
subjects (91 females, 69 
males) (20-70 years)
i  [Apo BJ in M CP and 
HCP groups; |  
oxidised LDL (kU L*1 
plasma) in all groups
(Baba et at. 
2007a)
14 40 g DC Macronutrient matched, 
flavonoid-free chocolate
Double-blind, randomised; 
22 heart transplant 
recipients (4 females, 18 
males)
t  Coronary artery 
diameter and %  
change of 
endothelial- 
dependent 
vasomotion; J, [8-iso- 
PGF2a] and platelet 
adherence
(Flammer et 
al. 2007)
15 22 g DC supplemented Macro- and Double-blind, cross-over, i  Serum total- and (Allen et al.
with 1.1 g canola sterol 
esters twice per day for 
4 weeks
micronutrient matched 
DC without the addition 
of plant sterols
49 subjects (32 females, 17 
males) (24-70 years) with 
elevated cholesterol (5.20- 
7.28 mmol L-1)
LDL cholesterol; i  
SBPand DBP 
(combined 
intervention and 
control results)
2008)
16 MF or HF beverage Macro- and 
micronutrient matched 
LF beverage
Double-blind, randomised, 
cross-over; 10 type-2 
diabetic subjects (2 
. females, 8 males) (64.7 ±  
9.9 years)
t  FMD (Balzer et al. 
2008)
Intervention Control Study design Outcomes Ref.
17 Flavanol containing 
beverage 3 times per 
day for 30 days
Macro- and 
micronutrient matched 
LF beverage
Double-blind, randomised; 
41 type-2 diabetic subjects 
(29 females, 12 males) 
(intervention, 63.1 ±  8.3 
years; control, 64.4 ±  8.6 
years)
T FMD (Balzer et al. 
2008)
18 HF beverage twice per 
day for 12 weeks with 
and without 45 min 
physical activity 3 days 
per week
Macro- and 
micronutrient matched 
LF beverage with and 
without physical activity
Double-blind, randomised; 
49 overweight and obese 
subjects (32 females, 17 
males) (40-50 years)
t  FMD (combined 
exercise and non- 
exercise results); |  
insulin resistance, 
DBP and MAP 
(flavanol treatment 
nested in time)
(Davison et 
al. 2008)
19 Phase 1: Acute 
consumption of 74 g DC
Phase 2 :2  cups of 
either sugar-containing 
cocoa beverage or 
sugar-free cocoa 
beverage
Phase 1: 74 g cocoa- 
free chocolate
Phase 2 :2  cups of 
sugar-containing cocoa- 
free beverage
Single-blind, randomised, 
cross-over; 45 healthy 
subjects (35 females, 10 
males) (52.8 ± 1 1 .0  years)
T FMD; iS B P and  
DBP; greatest FMD  
improvement 
following sugar-free 
cocoa beverage.
(Faridi et al. 
2008)
20 100 g flavanol-rich DC 
per day for 15 days
100 g flavanol-free white 
chocolate per day
Double-blind, cross-over; 
19 hypertensive, 
prediabetic subjects (8 
females, 11 males) (44.8 ±  
8.0 years)
4, Insulin resistance 
and t insulin 
sensitivity; J, clinical 
SBP and DBP, and 
ambulatory BP; f  
FMD and j. serum  
total- and LDL 
cholesterol
(Grassi et al. 
2003)
Intervention Control Study design Outcomes Ref.
21 100 g DC per day for 1 
week
None 28 healthy subjects (19 
females, 9 males) (42 ±12  
years)
|  platelet activated '  
GP llb/llla 
expression; J, LDL 
cholesterol; î  HDL 
cholesterol, i  C- 
reactive protein 
(females only)
(Hamed et 
at. 2008)
22 Cocoa beverage twice 
per day for 2 weeks
Macro- and 
micronutrient matched 
LF beverage
Double-blind, randomised, 
cross-over; 20 
hypertensive subjects (12 
females, 8 males) (51 ± SE 
1.5 years)
T insulin-stimulated 
brachial artery 
diameter
(Muniyappa 
et at. 2008)
23 20 g cocoa powder in 
250 mL skimmed milk 
twice per day for 4 
weeks
250 mL skimmed milk 
without cocoa powder
'i
Randomised, cross-over; 
42 high-risk of CVD 
subjects (23 females, 19 
males) (69.7 ±11.5 years)
î  HDL cholesterol; J. 
expression of 
adhesion molecules 
on the surface of 
monocytes and
(Monagas et 
ai. 2009, 
Khan et al. 
2010)
concentration of 
circulating soluble 
adhesion molecules
24 HF cocoa beverage 
followed by 10 min 
cycling
Macronutrient matched Double-blind, randomised, |  FMD; |  AUC for (Berry et at.
LF cocoa beverage cross-over; 21 healthy DBPandM APin 2010)
followed by cycling overweight/obese subjects response to exercise
(8 females, 13 males) (54.9 
± SE 2.2 years)
Intervention Control Study desiqn Outcomes Ref.
25 Cocoa beverage 
containing 33, 372, 712, 
or 1052 mg total 
flavanols per day for 6 
weeks
None Double-blind, randomised; 
52 mildly hypertensive 
subjects (20 females, 32 
males) (42-74 years)
j, 24 h ambulatory 
MAP, SBP and DBP 
(1052 mg); 1 
Overnight ambulatory 
SBP, DBP and HR
(Davison et 
al. 2010)
26 6 g or 25 g DC per day 
for 3 months
None Single-blind, randomised; 
91 cardiovascular high-risk
i  24 h, day- and 
night-time MAP, SBP
(Desch et al. 
2010)
patients (20 females, 71 
males) (57-74 years)
and DBP (6 g); 1 24 h 
and daytime MAP  
and SBP (25 q)
27 HF cocoa beverage Nutrient matched LF Double-blind, randomised, t  FMD (both (Heiss et al.
twice per day for 30 
days
cocoa beverage cross-over; 16 coronary 
artery disease (CAD) 
patients (3 females, 13 
males) (64 ± 3 years)
conditions), FMD  
post-intervention was 
higher than post­
control; T % of CACs; 
J, plasma [nitrite]; f 
SBP
2010)
28 15 g DC 3 times per day Macronutrient matched Double-blind, randomised, t  Serum [HDL (Mellor et al.
for 8 weeks cocoa solids-free 
chocolate
cross-over; 12 type-2 
diabetic subjects (5
cholesterol]; J. total 
cholesterol:HDL
2010)
females, 7 males) (42-71 
years)
cholesterol ratio
29 Dairy based cocoa 
beverage containing 
either natural-dose 
(NTC) or high-dose 
(TEC) theobromine 
once per day for 3
Unspecified dairy based 
placebo beverage
Double-blind, randomised, 
cross-over; 42 pre-/stage 1 
hypertensive, healthy 
subjects (10 females, 32 
males) (62 ±  4.5 years)
T 24 h DBP (NTC); T 
24 h SBP, daytime 
DBP, 24 h, day- and 
night-time HR (TEC); 
|  central SBP, HR  
and stroke volume
(van den 
Bogaard et 
al. 2010)
weeks (TEC)
30
31
32
Dairy-based high-fat 
liquid meal plus HF 
cocoa powder
In terven tion_________
40 g DC twice per day 
for 2 weeks followed by 
1.5 h cycling
40 g DC
Macronutrient matched 
dairy-based high-fat 
liquid meal containing 
LF cocoa powder
C ontro l_________________
Double-blind, randomised, 
cross-over; 18 healthy 
subjects (16 females, 2 
males) (25.2 ±  2 .5  years)
S tu d y  d e s ig n ______________
30.4 g bar of sugar- and Single-blind, randomised; 
fat-matched cocoa 20 healthy males (22 ±  4
liquor-free chocolate years)
followed by cycling
40 g milk chocolate Single-blind, randomised,
cross-over; 20 healthy 
subjects (13 females, 7
\  males) (33 ±11  years) and
20 smokers (13 females, 7 
males) (33 ±11  years)
f  serum [triglycerides] (Westphal 
and [free fatty acids] and Luley 
(both conditions); |  2011)
FMD (both conditions, 
higher following
intervention)______________________
t  Plasma [F2- (Allgrove et
isoprostane] post- a/. 2011)
exercise (both
conditions, lower
following
intervention); |
oxidised LDL pre- and
post-exercise____________________
l  Serum sNOx2-dp, (Loffredo et
urinary isoprostane a/. 2011,
excretion and platelet Camevale et
ROS, sNOx2-dp and a/. 2012)
8-iso-PGF2a (healthy
subjects); f  FMD,
serum [NOx] and
platelet NOx
production (smokers);
l  serum sNOx2-dp,
urinary isoprostane
excretion and platelet
ROS, sNOx2-dp and
8-iso-PGF2a
(smokers)
O u tc o m e s ______________R ef.__________
wo
Intervention Control Study design Outcomes Ref.
33 Cocoa beverage 
containing either 2,5, 
13 or 26 g of cocoa
Macronutrient matched 
beverage without cocoa 
powder
Double-blind, randomised; 
23 healthy subjects (14 
females, 9 males) (63 ± SE 
2 years)
Dose-dependent 
greater change in 
FMD (5, 13 and 26 
g); t  SBP(2 and 26 
g); t  DBP (2,13 and 
26 g); |  MAP (2,13 
and 26 g); j, [glucose] 
(0, 2 and 5 g)
(Monahan et 
al. 2011)
34 Sugar-free cocoa 
beverage or a sugar- 
sweetened cocoa 
beverage twice per day 
for 6 weeks
Cocoa-free sugar- 
sweetened beverage
Double-blind, randomised, 
cross-over; 39 overweight, 
healthy subjects (33 
females, 6 males) (41-63 
years)
t  FMD (both 
conditions)
(Njike et at. 
2011)
35 75 g DC None 16 healthy subjects (6 
females, 10 males) (20-45 
years)
i  Angiotensin­
converting enzyme 
activity
(Persson et 
al. 2011)
36 13.5 g flavonoid- Macronutrient matched
enriched chocolate placebo chocolate
twice per day for 1 year
Double-blind, randomised; 
93 postmenopausal, type-2 
diabetic patients (51-74 
years)
|  Plasma [insulin] and (Curtis et al. 
insulin resistance; |  2012)
insulin sensitivity; |
[LDL cholesterol]; f  
CHD risk (both 
conditions, less 
following intervention)
Intervention Control Study design Outcomes Ref.
37 100 g DC followed by 
2.5 h of cycling
Macronutrient matched 
cocoa solids-free bar 
(71 g) followed by 
cycling
Single-blind, randomised, 
cross-over; 14 healthy male 
subjects (22 ±  1 years)
t  Plasma total 
antioxidant status 
(both conditions); |  
[insulin] pre-exercise 
and 1 h post­
exercise; i  plasma 
[glucose] post­
exercise (both 
conditions)
(Davison et 
at. 2012)
38 100 g high-antioxidant 
dark chocolate (HADC) 
or 100 g DC
None
>
Double-blind, randomised, 
cross-over; 15 healthy 
subjects (9 females, 6 
males) (30 ±  5 years)
t  Plasma FRAP (both 
interventions); HADC  
FRAP remained 
higher at 4 and 5 h; |  
urinary HADC FRAP 
up to 12 h; T ; 
[triacylglycerol] (both 
interventions); f  [thiol] 
at 2- and 4 h (both 
interventions)
(Lettieri- 
Barbato et 
at. 2012)
39 50 g DC per day for 3 
weeks
None 50 healthy subjects (25 
females, 25 males) (28-45 
years)
t [HDL cholesterol] 
and [triglyceride] and 
]. LDL cholesterol 
(females only); i  lipid 
peroxidation, 
conjugated diene and 
hydroperoxide 
content of HDL and 
LDL; t  platelet 
production of NO; j. 
peroxyn ¡trite
(Nanetti et 
at. 2012)
Intervention Control Study design Outcomes Ref.
40 Cocoa products: (B)
cocoa + hazelnuts, (C) 
cocoa + hazelnuts + 
phytosterols, (D) cocoa 
+ hazelnuts + 
phytosterols + soluble 
fibre per day for 4 
weeks
(A) Cocoa Double-blind, randomised; 
113 pre/stage-1 
hypertensive and 
hypercholesterolemic 
subjects (67 females, 46 
males) (43-65 years)
J, [Total-] and [LDL 
cholesterol] and 
[Apo B] and Apo 
B:Apo A ratio (C) 
and (D); J, hsCRP 
and oxidised LDL (D)
(Sola et at. 
2012)
41 DC and cocoa
beverage once per day 
for 3 months
None 5 type-2 diabetic patients 
with stage II and III heart 
failure (47-71 years)
t  [HDL cholesterol]; 
enhanced 
expression of 
markers of 
mitochondrial 
structure in skeletal 
muscle
(Taub et al. 
2012)
Table 1.1 Summary of intervention studies using cocoa published between 2007 and 2012. Only outcomes 
with a statistical significance of a maximum p<0.05 are reported. Mean ± standard deviation unless 
otherwise stated. Abbreviations used in the table: increase; J. decrease; DC, dark chocolate; HR, heart 
rate; pp. Polyphenol; CFS, chronic fatigue syndrome; HF, high flavanol; LF, low flavanol; MF, medium 
flavanol; BW, body weight; TAG, triacylglycerol; IL-6, interleukin 6; LDL, low-density lipoprotein; HDL, high- 
density lipoprotein; Apo B, apolipoprotein B; 8-iso-PGF2a, 8-iso-prostaglandin F2a; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; FMD, flow mediated dilation; MAP, mean arterial pressure; GP, 
glycoprotein; CVD, cardiovascular disease; AUC, area under curve; CACs, circulating angiogenic cells; 
sNOx2-dp, soluble NOx2 derived peptide; • ROS, reactive oxygen species; FRAP, ferric reducing ability of 
Dlasma: NO. nitric oxide.
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Nitric Oxide
Nitric Oxide-
Figure 1.3 Nitric oxide stimulated vasodilation
3 5
Peroxynitrite Nitric Oxide
Superoxide
_ X
/O
NADPH Oxidase7
Figure 1.4 Potential mechanisms by which epicatechin increases nitric oxide 
concentration
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1.3 Carbohydrate metabolism
1.3.1 Sucrose hydrolysis
Sucrose is a disaccharide, MW 342.3, composed of glucose and fructose 
monosaccharides (Figure 1.5). Hydrolysis of sucrose is an acid catalysed 
reactions that liberates a-D-glucose and 3-D fructose with no mutarotation 
reported (Zagalak and Curtius 1975). The authors of this study investigated 
enzyme catalysed acid hydrolysis of sucrose and revealed that cleavage of 
the monosaccharide units occurs between the anomeric carbon of glucose 
and the adjoining oxygen atom; experiments using H2180  confirmed the 
incorporation of 180  into liberated a-D-glucose but not 3-D-fructose. The use 
of 2H20  demonstrated that protonation of each monosaccharide upon 
release from sucrose was not from water present in the reaction mix.
Enzyme hydrolysis of sucrose in humans is exclusively catalysed by sucrase 
(EC 3.2.1.48) although it also exhibits activity for maltose, a disaccharide 
comprised of two glucose units. Sucrase is located at the luminal surface of 
enterocytes, both crypt cells and microvillus cells express the enzyme in its 
mature and precursor form (Beaulieu et al. 1989). Sucrase is anchored to 
the epithelial cell membrane via another a-glucosidase enzyme, isomaltase 
(EC 3.2.1.10), that is responsible for the hydrolysis of maltose and 
isomaltose. The two subunits of sucrase and isomaltase are initially 
synthesised in the rough endoplasmic reticulum (RER) as a single 
polypeptide chain of 1827 amino acid residues with a MW in the region of 
220,000-280,000 Daltons (Da) (Conklin et al. 1975). The exact molecular 
weight measured varies depending on the method of solubilisation, either 
papain or Triton-X-100 (Brunner et al. 1979). The protein is then transported
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to the Golgi apparatus where N- and O-linked glycosylation takes place; 
transfer from the RER to the Golgi apparatus takes 2-3 hours (Beaulieu et al. 
1989). The glycosylated precursor protein is transported to the basolateral 
epithelial membrane then inserted into the lipid bilayer with the N ^ -term inal 
of isomaltase remaining in the cytosol. A hydrophobic region containing 31 
amino acids acts as the membrane anchor and the mainly hydrophilic amino 
acids are exposed to the luminal cavity (Semenza 1986). Exposure of the 
precursor to the lumen permits cleavage of the two subunits by pancreatic 
protease enzymes with the subunits remaining associated in the sucrase- 
isomaltase (SI) complex (Hauri et al. 1979).
The active site of sucrase displays activity towards hydrolysis of a 1-2 and 
a1-4 glycosidic bonds. Human lysosomal a-glucosidase shares a highly 
conserved catalytic site with human and rabbit isomaltase, and rabbit 
sucrase (Hermans et al. 1991, Chantret et al. 1992). A study of the 
interaction between human lysosomal or yeast a-glucosidase and the 
inhibitor conduritol B epoxide (CBE) revealed that the (3-carboxyl group of 
aspartic acid at the active site was essential for hydrogen bond formation 
with CBE and that proton donation was likely to be from an aspartic acid 
residue (Hermans et al. 1991, Okuyama et al. 2001). In support of these 
findings, structural studies using the inhibitors kotalanol and Man2GlcNAc2, 
an asparagine-linked N-acetylated oligosaccharide, have revealed hydrogen 
bond formation between aspartic acid residues and saccharide hydroxyl 
groups, with aspartic acid residues also identified as catalytic nucleophiles. 
Stabilisation of the enzyme-inhibitor complex was proposed to involve 
additional hydrophobic interactions with leucine, tryptophan, phenylalanine, 
valine and tyrosine (Sim et al. 2010).
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1.3.1.1 Modification of sucrase activity
1.3.1.1.1 Diet and disease
The activity of Si may be enhanced or diminished in different disease states 
or through diet. A diet high in sucrose or medium-chain triacylglycerols 
resulted in significantly increased SI mRNA levels and increased activity in 
rats compared with animals fed a low-starch, high long-chain triacylglyerol 
diet (Yasutake etal. 1995). Intrajejunal administration of fructose or sucrose 
solution, but not glucose, compared with sugar-free solution, similarly 
enhanced SI activity and mRNA levels in rats (Kishi et al. 1999). A high- 
carbohydrate, low-fat diet fed to mice similarly enhanced the activity and 
mRNA levels of SI compared with animals fed a low-carbohydrate, high-fat 
diet (Honma et al. 2007). The authors reported the increase to be associated 
with enhanced acetylation of histone H3 and H4 on the promoter and 
transcription regions of the SI gene. Increased SI activity has also been 
reported in streptozotocin-induced diabetic rats due to a reduced rate of 
enzyme degradation (Olsen and Korsmo 1977). A more recent study 
demonstrated that increased SI mRNA levels, protein expression and 
enzyme activity were reduced to levels equivalent to those in non-diabetic 
rats, with insulin treatment (Liu etal. 2011). The authors treated Caco-2 cells 
with insulin and observed reduced SI mRNA levels and activity that was 
associated with a reduction in the level of caudal type homeobox 2 (CDX2) 
mRNA. Inhibition of the mitogen-activated protein kinase (MAPK)-dependent 
pathway, via which CDX2 is expressed, returned CDX2 mRNA levels, and SI 
mRNA levels and activity to a level equivalent to control cells not treated with 
insulin. Hepatocyte nuclear factor-1a (HNF-1a), another transcriptional
-**
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protein, is also implicated in the regulation of SI expression. Decreased 
expression and activity of SI in Caco-2 cells cultured with high concentration 
glucose media, was reversed when glucose concentration was lowered; 
HNF-1a mRNA was similarly affected by glucose concentration (Gu et al. 
2007).
Congenital sucrase-isomaltase deficiency (CSID) is an autosomal recessive 
disease of the human small intestine that results in abdominal pain and 
diarrhoea following ingestion of sugar. The pathogenesis of CSID has been 
mostly attributed to a mutation of the SI gene that encodes the precursor 
enzyme protein (Uhrich et al. 2012). Subsequent synthesis of the protein in 
the RER leads to the substitution of specific amino acids in the single 
polypeptide chain. Various amino acid alterations have been noted in 
biopsies obtained from patients suffering with CSID a small number of which 
appear more frequently. Consequently substituted amino acid residues lead 
to incorrect folding of the protein, insufficient transportation from either the 
RER or the Golgi apparatus, and cleavage of the hydrophobic membrane 
domain from the precursor protein within the RER ultimately preventing 
anchorage in the apical membrane of the epithelial cell (Jacob et al. 2000, 
Ritz etal. 2003, Keiser etal. 2006).
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Figure 1.5 Structure of the disaccharide sucrose composed of a-D-glucose 
and (3-D-fructose
1.3.2 Glucose transport
Glucose absorption from the lumen of the small intestine is controlled by two 
distinct protein carriers located at the apical membrane, SGLT1 and GLUT2, 
and one at the basolateral membrane, GLUT2. The primary glucose carrier, 
SGLT1, is a protein composed of 664 amino acid residues of which 14 
helical regions span the apical membrane (Hediger et al. 1989, Turk et al. 
1994, Turk et al. 1996). Activity of the carrier is dependent on the binding of 
sodium ions and maintenance of a negative electrochemical gradient within 
the cell. This gradient is a result of basolateral efflux of 3 sodium ions by the 
sodium-potassium pump and influx of fewer sodium ions via the glucose 
carrier protein. Affinity of this secondary active cotransporter for glucose is 
high as demonstrated by a low Michaelis-constant, ~5 mM (Scow et al. 
2011), which represents the ratio of dissociation to formation of the 
transporter-substrate complex. Even at low luminal concentrations SGLT1 
continues to transport glucose against a concentration gradient. Structural
i
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evaluations have demonstrated that the number of sodium ions bound to the 
transporter affects the capacity for glucose binding and that cation-n: 
interactions are involved in binding two sodium ions to the transporter which 
induces a conformational change that permits glucose binding (Jiang et al. 
2012). Investigations using the SGLT1 inhibitor phloridzin and glucose 
stereoisomers implicate the C-terminal loop 13 and tryptophan residues in 
formation of the transporter-substrate complex (Raja et al. 2003, Raja et al. 
2004, Kumar et al. 2007, Tyagi et al. 2007, Wimmer et al. 2009). In order to 
release sodium and glucose into the cytosol the transporter must undergo a 
reorientation from outward to inward facing (Sala-Rabanal et al. 2012). This 
conformational change is a result of a sequence of altered electrical charges 
(Longpre et al. 2012). Reorientation weakens the bond between the 
transporter and one of the sodium ions which confers a disruption to the 
hydrogen bonds that maintain the transporter-glucose complex thereby 
releasing glucose into the cell. It has been proposed that only one sodium 
ion is released into the cell and that the second remains bound to the 
transporter and returns to the extracellular facing orientation. 
Sodium-independent passive diffusion of glucose is facilitated by the GLUT2 
protein carrier. Located in the basolateral membrane GLUT2 allows 
transport of glucose and fructose out of the cell into the hepatic portal vein. 
Relatively recently this transporter has also been detected in the apical 
membrane where it is believed to assist SGLT1 uptake of glucose in the 
presence of a high glucose concentration in the intestinal lumen (Zheng et 
al. 2009, Chaudhry et al. 2012). The secondary structure of GLUT2 is similar 
to that of SGLT1. It is a protein comprised of 554 amino acids that span the 
cell membrane across 12 regions with both the C- and A/-terminal cytosol
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facing (Mueckler 1994, Olson and Pessin 1996). Passive diffusion of glucose 
is proposed to involve hydrogen bond formation of glucose at carbon atoms 
1, 3 and 4 with carbon-6 involved in a hydrophobic association with the 
transporter (Colville et al. 1993); transmembrane regions 9 to 12 have been 
considered essential for transporter-glucose affinity (Wu et al. 1998). In 
contrast to SGLT1, GLUT2 is a low affinity-high capacity carrier of glucose, 
Km = ~20 mM, that does not show saturated kinetics with increasing 
concentration of substrate (Scow et al. 2011, Zheng et al. 2012). 
Translocation of GLUT2 to the apical membrane occurs rapidly within 
minutes of cells sensing the presence of a high luminal concentration of 
glucose. The mechanism for apical GLUT2 translocation is proposed to 
involve two separate pathways that cooperate to enhance activity of protein 
kinase C isoform pil (PCKpil) (EC 2.7.11.13). Cotransport of sodium ions 
into the cell leads to depolarisation of the cell membrane which activates the 
calcium channel Cav1.3 permitting a flux of calcium ions into the cell; this is 
maximal at glucose concentrations that saturate SGLT1. The increased 
influx of calcium alters the cytoskeletal structure and increases PCKpil 
affinity for phosphatidylserine. Similarly at SGLT1 saturating concentrations 
of glucose, apical sweet taste receptors are activated and internalised by the 
cell; the alpha subunits of these receptors is cleaved and released into the 
cytosol. The remaining beta and gamma subunits activate phospholipase C 
isoform pil (PLCpIl) (EC 3.1.4.11) which catalyses the removal of a 
diacylglycérol from phosphatidyl inositol-bisphosphate. The presence of 
diacylglycérol fully activates PKCpil which leads to translocation of GLUT2 
to the apical membrane (Scow et al. 2011). Caco-2 cells co-incubated with
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PKC inhibitors or activator demonstrate reduced and elevated glucose 
uptake, respectively (Zheng etal. 2012).
1.3.2.1 Modification of transporter activity
1.3.2.1.1 Diet and disease
In healthy subjects the plasma increase in glucose concentration following a 
meal stimulates the release of insulin from pancreatic beta cells. Insulin 
receptors on muscle cells and adipocytes bind to the plasma insulin 
subsequently resulting in the insertion of glucose transporter GLUT4 into the 
cell membrane to facilitate glucose uptake, thereby lowering plasma glucose 
concentration. Insulin receptors at the apical membrane of epithelial cells 
similarly bind to insulin in the lumen and induce a reduction of GLUT2 
translocation to the apical membrane that lowers glucose absorption from 
the small intestine (Tobin et al. 2008). In the diabetic disease state, glucose 
uptake into adipocytes and muscle cells is impaired due to resistance to the 
action of insulin or through lack of insulin release from pancreatic beta cells. 
In response to both situations, enhanced insertion of GLUT4 into the plasma 
membrane of adipocytes and muscle cells is not stimulated and plasma 
glucose concentration remains elevated. At the intestinal level, GLUT2 
internalisation is not promoted therefore apical GLUT2 levels remain high 
and glucose uptake continues to be facilitated (Tobin et al. 2008). 
Streptozotocln-induced diabetic rats exhibit enhanced expression of GLUT2 
in enterocytes that is reversed with insulin treatment (Burant et al. 1994, 
Corpe et al. 1996). Increased levels of GLUT2 in the small intestine of 
human subjects with type-2 diabetes has also been reported (Dyer et al. 
2002).
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1.4 Objectives
The objective of this project was to investigate the interaction between dark 
chocolate flavanols and sugars, including the metabolic fate of each, and to 
identify potential mechanisms by which interaction may occur.
)
Chapter 2 Materials and methods
2.1 Chemicals
All chemical reagents were purchased from Sigma-Aldrich, Dorset UK, and 
all water is ultrapure with a resistivity of 18.2 MQ-cm at 25°C supplied using 
the Millipore Milli-Q Integral system, unless otherwise stated.
2.1.1 Reagent preparation
Transport buffer solution was prepared according to the Hanks' Balanced 
Salt solution (H6648) formulation without the addition of D-glucose. Briefly, 
0.4 g L"1 potassium chloride (P5405), 0.06 g L'1 potassium phosphate 
(P0662), 0.05 g L'1 sodium phosphate dibasic (S9763), 0.35 g L‘1 sodium 
bicarbonate (S5761), 8 g L'1 sodium chloride (S5886), supplemented with 
0.27 g L‘1 calcium chloride dihydrate (C7902) and 0.018 g L'1 ascorbic acid 
(A4544) were dissolved in water and the solution adjusted to pH 7.4 at 37°C 
before being sterile filtered (Corning® 430049).
2.1.1.1 Dark chocolate extract preparation
A flavanol-rich dark chocolate extract was prepared as recently described 
(Robbins e ta l2012). Nestlé Noir Intense 70% cocoa solids was ground to a 
powder and the fat removed by treatment with hexane. A volume (45 ml_) of 
hexane (Fisher Scientific, H/0406/PB17) was added to 5 g of powder and the 
suspension sonicated at 50°C for 5 min before being centrifuged at 3,000 
rpm for 5 min. The hexane was decanted to waste and the process repeated 
twice more; residual hexane was evaporated overnight in a fume cupboard. 
A flavanol-rich extract was prepared from the fat-free powder; 10 mL of 
extraction solution containing acetone (Fisher Scientific, A/0606/17), water
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and acetic acid (Fisher Scientific, A/0360/PB15) (70:29.5:0.5) was added to 
the required quantity of powder and the suspension sonicated at 50°C for 5 
min followed by centrifugation at 3,000 rpm for 5 min. The supernatant was 
collected and passed through a strong-cation exchange solid phase 
extraction cartridge (52686) and filtered through a polytetrafluoroethylene 
(PTFE) membrane syringe filter, 17 mm, 0.2 pm (Chromacol, 17-SF-02(T)). 
The filtrate was evaporated to dry under vacuum then reconstituted in 20 mL 
of test or control solution and corrected to pH 7.4 at 37°C.
2.1.1.1.1 HPLC-FLD protocol
The flavanol profile, monomer to decamer, of dark chocolate extract was 
analysed using an Agilent 1200 series HPLC with fluorescence detection, as 
recently described (Robbins et al. 2012). A Phenomenex Develosil Diol 100 
A 5 pm column, 250 x 4.6 mm, plus Phenomenex cyano guard column, 4.x 3 
mm, was maintained at 35°C in a thermostatted column oven. The mobile 
phase consisted of solvent A) 2% acetic acid in acetonitrile (Fisher Scientific, 
A/0626/17) (98:2 v/v), and B) 2% acetic acid in aqueous methanol (Fisher 
Scientific, M/4058/17) (95:3:2 v/v/v/). The flow rate was maintained at 1.0 mL 
min'1 throughout the duration of the analytical run. The mobile phase 
gradient of solvent B in solvent A was as follows: 0 min, 7% B; 3 min, 7% B; 
60 min, 37.6% B; 63 min, 100%; 70 min 100% B; 76 min, 7% B; 81 min, 7%
B. Fluorescence detection was performed with excitation at 230 nm and 
emission at 321 nm. The photomultiplier level was set to 10. Standard 
epicatechin was used to prepare a calibration curve of fluorescence as a 
function of epicatechin concentration. Linear regression analysis, with the y- 
intercept fixed at zero, was conducted to obtain the gradient and adjusted R-
i
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square value of the curve. The concentration of flavanols dimer to decamer 
was calculated using the epicatechin calibration curve with a relative 
response factor applied to each fraction. The flavanol content (mg 100g'1) of 
fresh weight dark chocolate was calculated firstly by converting the 
concentration (mg mL'1) to the content (mg g '1) of defatted dark chocolate. A 
correction factor was applied to account for the dilution factor and fat content 
of the dark chocolate.
2.1.1.2 In  vitro  epicatechin transport and methyiation
Sugar solutions containing 100 mM sucrose (S9378), glucose (Fisher 
Scientific, G/0450/60) or fructose (47740) were prepared in transport buffer 
solution and corrected to pH 7.4 at 37°C. Each sugar solution was 
subsequently used to prepare test solutions containing 250 pM epicatechin. 
Briefly, 2 mg epicatechin was dissolved in a mixture containing 10 pL 
dimethyl sulfoxide plus 990 pL sugar solution, or transport buffer for the 
experimental control. The suspension was sonicated at 37°C for 30 min then 
vortexed to ensure complete dissolution. A volume (725 pL) of epicatechin 
solution was diluted to 20 mL using the corresponding solution then 
corrected to pH 7.4 at 37°C.
2.1.1.3 Dark chocolate extract inhibits sucrose hydrolysis in the Caco> 
2 cell model
A 20 mM sucrose solution was prepared. Briefly, 684 mg of sucrose (S9378) 
was dissolved in 100 mL of transport buffer solution and then corrected to 
pH 7.4 at 37°C.
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2.1.1.3.1 Pure compounds
Pure compounds were weighed and initially dissolved in 1 mL of a 1% 
solution of DMSO (60153) in transport buffer solution or 20 mM sucrose 
solution (v/v). Aliquots were diluted to 20 mL using transport buffer solution 
or 20 mM sucrose solution to obtain final concentrations as described below.
Compound Weight
(mg)
Aliquot
(pL)
Final Concentration 
(pM)
Flavanol monomers 3 970 500
2 581 200
1 580 100
1 290 50
1 116 20
Procyanidin B2 3 385 100
(Extrasynthese, 0984) 3 193 50
Acarbose (A8980) 3 860 200
2 645 100
1 645 50
a(-)-Epicatechin (Extrasynthese, 0977 S), (+)-Epicatechin (Nacalia Tesque, 
02573-34), (-)-Catechin (C0567), (+)-Catechin (Extrasynthese, 0976 S).
2.1.1.3.2 Ethyl acetate extract of dark chocolate extract
A volume (0.75 mL) of ethyl acetate (Fisher Scientific, E/0906/17) was 
added to the dry extract; the suspension was vortexed to mix and 
centrifuged at 17,000 x g for 5 minutes. The supernatant was removed and 
evaporated to dry. To the remaining pellet the ethyl acetate extraction 
procedure was repeated and the supernatant evaporated to dry. Each ethyl 
acetate fraction was reconstituted in 20 mL of sucrose solution and then 
correct to pH 7.4 at 37°C.
2.1.1.4 Glucose transport inhibition by a flavanol-rich dark chocolate 
extract
A stock solution of 10 mM glucose was prepared. Briefly, 180 mg of glucose 
(Fisher Scientific, G/0450/60) was dissolved in 100 mL of transport buffer 
solution and 50 mL serial dilutions ranging from 0.25-7 mM prepared in 
transport buffer solution. A 20 mL aliquot of each concentration was taken to 
which 9 pL of 0.1 pCi pL'1 [14C]-glucose was added to a final radioactivity 
concentration of 0.045 pCi mL'1 and then corrected to pH 7.4 at 37°C.
2.1.1.4.1 Pure compound preparation
Pure compounds were weighed and initially dissolved in 1 mL of a 1% 
solution of DMSO (60153) in transport buffer solution (v/v). Aliquots were 
diluted to 20 mL to obtain final concentrations as described below. A volume 
(9 pL) of 0.1 pCi pL'1 [14C]-glucose was added to each 20 mL solution to 
obtain a final radioactivity concentration of 0.045 pCi mL'1, and then 
corrected to pH 7.4 at 37°C.
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Compound Weight
(mg)
Aliquot
(pL)
Final Concentration 
(mM)
(-)-Epicatechin 
(Extrasynthese, 0977 S)
2 581 0.2
(-)-Epicatechin 6 969 1
(+)-Epicatechin (Nacalai Tesque, 02573- 
34)
2 581 0.2
(-)-Catechin (C0567) 2 581 0.2
(+)-Catechin 
(Extrasynthese, 0976 S)
2 581 0.2
Procyanidin B2 
(Extrasynthese, 0984)
3 780 0.2
Caffeine (C0750) 1 971 0.25
Theobromine (T4500) 10 605 1.68
2.1.1.4.2 Solid phase extraction of flavanol fractions
There are no commercially available standards of flavanols with a degree of 
polymerisation greater than trimer. In order to obtain and investigate the 
effect of flavanol polymers larger than dimer, a solid phase extraction (SPE) 
procedure was developed based on the HPLC-FLD method used to quantify 
the compounds. Using a vacuum manifold, vacuum 0.2 bar, Supelclean™ 
LC-Diol tubes (57016) were pre-conditioned with 2 mL of acetonitrile. Dried 
dark chocolate extract was reconstituted in water and 2 mL of the aqueous 
extract was loaded into the SPE tube. To prevent dilution of the collected 
sample, the initial 2 mL of aqueous extract was eluted to waste. A further 1 
mL of aqueous extract was loaded into the SPE tube and collected in a 
centrifuge tube. The SPE material was washed twice with 1 mL per wash of 
water; each of these washes was collected separately in a centrifuge tube.
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Analytes that remained adsorbed to the SPE material were eluted with two 
washes, 1 mL each wash, of a predominantly organic solvent. The elution 
solvent contained 85% acetonitrile/acetic acid (98:2 v/v) and 15% 
methanol/water/acetic acid (95:3:2 v/v/v). The elution samples were 
collected separately in centrifuge tubes. Each sample was evaporated to dry 
then reconstituted in 0.5 mL acetone/water/acetic acid (70:29.5:0.5 v/v/v) for 
HPLC-FLD analysis.
2.2 Cell culture
The human colon adenocarcinoma cell line, Caco-2 (HTB-37™), was 
obtained from the American Type Culture Collection (ATCC®) at passage 18 
(LGC Standards, Middlesex UK) and propagated in 25 cm2 (Corning® 
430639) and 75 cm2 (Corning® 430641) polystyrene culture flasks using 
Eagle’s Minimum Essential Medium (EMEM). Media containing 1g L'1 D- 
glucose (30-2003, LGC Standards, Middlesex UK) supplemented with 15% 
(v/v) fetal bovine serum (F7524), 19.6 mL L'1 L-glutamine (200 mM; G7513), 
10 mL L'1 penicillin-streptomycin (10,000 U mL'1-10 mg mL'1; P0781), 10 mL 
L'1 MEM non-essential amino acid solution (100x; M7145) and 1 mL L‘1 
amphotericin B (250 pg mL'1; A2942). The incubation temperature was 
maintained at 37°C with an atmosphere of 95% air and 5% carbon dioxide 
(CO2). At 2 or 3 day intervals growth media was replenished and at 80% 
confluence cells were detached from the flask surface using 0.25% trypsin- 
EDTA solution (T4049). For experiments cells were cultured in 24 mm 
Transwell® plates on a 4.67 cm2, 0.4 pm pore polycarbonate membrane 
insert (Corning® 3412) at a density of 6.43 x 104 cells cm'2. Growth media 
contained 10% fetal bovine serum (v/v) in EMEM supplemented as
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described previously, incubation conditions remained unchanged. 
Experiments were performed between 21 and 23 days after seeding on 
Transwell® membrane inserts.
2.2.1 Validation of ceil membrane integrity
The integrity of the Caco-2 monolayer in each Transwell® insert was 
confirmed by measuring the trans-epithelial electrical resistance (TEER) of 
the cells using a Millicell ERS-2 Electrical Resistance System (Millipore, 
Watford UK). TEER value is indicative of the monolayer condition, a low 
value implying less well formed tight junctions between the cells which may 
increase the paracellular transport of a compound across the membrane. 
Readings were taken at three positions per insert with the mean ± SEM 
being calculated for each well. The mean resistance of a blank insert, i.e. 
with no cells, was subtracted from the mean of each Transwell® insert 
containing cells to provide the resistance of the cell monolayer.
2.2.2 Assay protocol
Initially cells were washed to remove traces of cell culture media in a 
process that involved aspiration of media from apical and basolateral 
compartments and replacement with 2 mL of pre-warmed transport buffer. 
The solution was immediately aspirated and replaced with a further 2 mL of 
transport buffer before being returned to the incubator for 30 min at 37°C, 
5% CO2 to facilitate tight junction formation between cells. Following 
incubation trans-epithelial electrical resistance (TEER) was measured. The 
transport buffer was aspirated and replaced with a further 2 mL of transport 
buffer in the basolateral compartment and 2 mL of control or test solution in 
the apical compartment. Transwell® plates were returned to the incubator,
'M r
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for up to 55 minutes (refer to section 2.3.2, 2.3.3 and 2.3.4 for the specific 
duration of each assay) at 37°C, 5% CO2.
Upon removal from the incubator the trans-epithelial electrical resistance 
was measured in each insert before collection of apical and basolateral 
samples. Cells were washed with the addition of 2 mL of transport buffer in 
each compartment to ensure collection of all analytes. Cells were then 
detached from the membrane using 1 mL of 1 M sodium hydroxide (71686) 
solution per insert, and placing the Transwell® plate on a rotating shaker for 
30-40 min. Upon collection of the detached cells the solution was neutralised 
by the addition of 1 mL of 1 M hydrochloric acid (Fisher Scientific, 
H/1200/PB17) solution. All samples were stored at -20°C until required for 
analysis.
2.3 Analytical methods
2.3.1 Validation
Protocol validation was based upon the international Union of Pure and 
Applied Chemistry (IUPAC) harmonised guidelines for single-laboratory 
validation of methods of analysis (Thompson et al. 2002).
2.3.2 In vitro  epicatechin transport and methylation
All pure compound epicatechin is the 2R, 3R enantiomer (Extrasynthese, 
0977 S). One Transwell® plate was allocated per experimental condition to 
provide six replicates. Two passages of cells, passage 43 and 50, were 
utilised in the investigation of epicatechin transport and methylation. The cell 
culture assay duration was 60 minutes.
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2.3.2.1 HPLC-DAD-MS2 Protocol
2.3.2.1.1 Parameters
An Agilent 1200 series Rapid Resolution System equipped with a 
Phenomenex Kinetex® C18 2.1 x 150 mm column was employed for the 
liquid chromatographic separation*of analytes. The stationary phase was 
fitted in a thermostatted column compartment maintained at 35 ± 0.15°C. 
The mobile phase consisted of solvent A: 0.2% formic acid in water (v/v) and 
solvent B: 0.2% formic acid in LCMS grade acetonitrile (v/v) (Fisher 
Scientific, A/0638/17). The solvent flow was maintained at 0.3 mL min'1 
throughout the following gradient schedule of solvent B, briefly: 0 min, 5%; 
5.8 min, 5%; 35 min, 30%; 37.4 min, 95%; 41 min, 95%; 44.6 min, 5%; and
53.1 min, 5%. The diode array detector was set to measure signal intensity 
at 220 nm and 280 nm each with a bandwidth of 8 nm. Mass spectrometric 
detection of analytes was performed using the Agilent 6410 Triple 
Quadrupole LC/MS system. In negative electrospray ionisation mode the 
instrument parameters were as follows: gas temperature and flow 350°C, 11 
L min'1; nebuliser gas pressure 30 psi; capillary voltage, -4000 V; and delta 
EMV 400 V. The analytical method run time was divided into 4 segments; 
the first being a window of 0 to 2 min whereby flow to the mass 
spectrometer was diverted to waste so as to reduce the transfer of salts 
which may otherwise interfere with analyte detection and quantification by 
causing increased background noise and suppression of ionisation. The 
remaining time segments, along with analytical parameters for compound 
quantification and qualification are shown in Table 2.1.
$
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Multiple reaction monitoring extraction from total ion counts and peak area 
integration for each compound was performed using Agilent MassHunter 
Workstation Software version B.03.01.
2.3.2.1.2 Linearity, precision and limit of quantification
Initially six calibration standard solutions were prepared in the range of 0-50 
pM and analysed in triplicate. Briefly, 1 mg of epicatechin was dissolved in a 
1 % solution of dimethyl sulfoxide (DMSO) (60153) in water (v/v). Serial 
dilutions were prepared using water to closely match the sample matrix. For 
each concentration the mean peak area ± standard error of the mean (SEM) 
(n=3) was plotted against concentration; linear regression analysis was 
performed to calculate the adjusted R-square value and gradient of the 
calibration curve. The relative standard deviation (RSD) of replicate peak 
areas was calculated for each concentration to assess precision of the 
analysis at each concentration. Limit of detection and limit of quantification 
was defined as 6x and 10x respectively, the mean of replicate zero 
concentration solutions.
2.3.2.1.3 Sample preparation for HPLC-DAD-MS2 analysis
Samples were vortexed to ensure homogeneity then centrifuged at 17,000 x 
g for 5 min at room temperature to remove cellular matter. Supernatant was 
collected into a 1.8 mL cryogenic vial for storage at -20°C, and 1 mL passed 
through a polytetrafluoroethylene (PTFE) membrane syringe filter, 17 mm, 
0.2 pm (Chromacol, 17-SF-02(T)) pre-conditioned with 1 mL methanol 
(Fisher Scientific, M/4058/17) followed by 1 mL water. A volume of filtered 
sample (180 pL) was added to an amber micro-vial along with 20 pL of 16.4
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pM taxifolin (Extrasynthese, 1036), final concentration 1.6 pM, chosen as a 
suitable internal standard for the relative identification of analytes.
Time
segment
Retention
time
(min)
Compound Precursor
ion
(nVz)
Quantification Qualification
Product
ion
(m/z)
Fragmerrtor
voltage
(V)
Collision
energy
(V)
Product
ion
(m/z)
Fragmentor
voltage
(V)
Collision
energy
(V)
2 13.0 Ca tech in 289.0 244.8 120 8 202.9 120 15
3 17.4 Epicatechin 289.0 245.0 120 8 203.0 120 15
4 21.6 3’-0-metfiyt-
epicatechin
303.1 136.8 110 12 165.0 110 10
4 23.4 4’-0-methyl-
epicatechin
303.1 1368 110 12 165.0 110 12
4 225 Taxifolin 303.1 284.9 110 15 124.9 110 2
Table 2.1: Mass spectrometry parameters for quantification and qualification of epicatechin, methylated epicatechin metabolites 
and taxifolin
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2.3.3 Dark chocolate extract inhibits sucrose hydrolysis in the 
Caco-2 cell model
Cells between passage 25 and 49 were utilised in the investigation of 
sucrose hydrolysis. A minimum of three replicates was allocated per 
experimental condition. The cell culture assay duration was 20 minutes
2.3.3.1 Glucose oxidase/peroxidase assay
The rate of sucrose hydrolysis was initially quantified by determination of 
glucose concentration In the sample and dividing this by the incubation time. 
The initial method for measuring glucose concentration was the glucose 
oxidase/peroxidase assay in which glucose oxidation to gluconic acid and 
hydrogen peroxide is catalysed by glucose oxidase/peroxidase from 
Aspergillus niger (EC 1.1.3.4) (49180). In the presence of hydrogen 
peroxide, horseradish peroxidase (EC 1.11.1.7) (P8125) catalyses the 
oxidation of o-dianisidine (D9154) to form a brown colour, addition of 
sulphuric acid (Fisher Scientific, S/9160/PB17) to the reaction mix changes 
the wavelength of absorbance and thus a colour change to pink is observed. 
The absorbance of the solution was measured at 540 nm. The Caco-2 cell 
assay protocol was developed based on Michaelis-Menten kinetic analysis 
of sucrose hydrolysis using this method. Initial inhibition assays using a 
cocoa powder extract provided by Nestlé revealed an inhibitory effect on 
enzymes of the glucose oxidase/peroxidase assay. To overcome  ^ this 
problem a solid phase extraction procedure using hydrophilic-lipophilic 
balanced reversed-phase cartridges (Waters, 186003849) was investigated, 
however this proved unsuccessful. An alternative method using universally 
radiolabelled [14C]-sucrose and liquid scintillation counting was proposed as 
. <•*»
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a more suitable method. This also had the benefit of allowing distinction 
between glucose produced from sucrose hydrolysis and residual glucose 
from the cell culture media which may cause inaccurate determinations of 
glucose concentration.
2.3.3.1.1 Linearity, precision, limit of detection and limit of quantification
Six standard calibration solutions were prepared in the range of 0-80 pg mL'1 
and analysed in triplicate. The concentration of each calibration solution was 
plotted against the mean absorbance at 540 nm ± standard error of the 
mean (SEM) (n=3). Linear regression analysis was performed, with the y- 
intercept fixed at zero, to calculate the gradient and adjusted R-square value 
of the calibration curve. The relative standard deviation (RSD) of replicate 
absorbance values was calculated for each concentration to assess 
precision of the analytical method. Limit of detection and limit of 
quantification, as defined by The Food and Drug Administration Validation of 
Analytical Procedures, were calculated as shown in Equation 2.1 and 
Equation 2.2.
Limit o f  detection =
3.3<r
m. .  . r , r . . 10 a
Limit o f quantification =
Equation 2.1 
Equation 2.2
Where a = standard deviation of blank samples and m = gradient of the 
calibration curve.
2.3.3.1.2 Sample preparation for glucose oxidase/peroxidase assay
Samples were centrifuged at 17,000 x g  for 5 minutes to remove cell debris 
and 0.06 mL of the supernatant added to a microplate well. To commence
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the assay, 0.12 mL of assay reagent containing 12.5 units mL'1 of glucose 
oxidase/peroxidase, 2.5 purpurogallin units mL'1 of peroxidase and 2.5 pg 
mL'1 o-dianisidine, was added to the microplate well containing cell culture 
sample and incubated for 30 min at 37°C. The reaction was stopped by 
addition of 0.12 mL of 6 M sulphuric acid. The absorbance of each well was 
measured at 540 nm using a microplate reader.
2.3.3.1.3 Calculations
The absorbance of each sample was initially corrected against a blank and 
the concentration of glucose calculated from the linear regression equation 
determined for the absorbance calibration curve. The molar concentration 
was converted to rate of product formed per minute by division of the total 
molar concentration of glucose by the incubation time. The rate of product 
formation was equated to the rate of sucrose hydrolysis. The kinetic 
properties of sucrose hydrolysis were measured using the Michaelis-Menten 
model. A plot of rate of sucrose hydrolysis as a function of initial sucrose 
concentration was prepared and nonlinear regression analysis based on the 
Michaelis-Menten equation performed (Equation 2.3). Rearrangement of the 
equation permitted the maximum velocity (Vmax) and Michaelis constant (Km) 
to be determined (Equation 2.4 and Equation 2.5V
i f  ..... VmaxlS] 
0 *M +  IS]
Equation 2.3
„ v0(KM +  [S ])
Vmax -  [Sj
Equation 2.4
, ,  K n a x t^ l rr1
k M — 1/ "  “M)
Equation 2.5
2.3.3.2 Liquid scintillation counting
Liquid scintillation counting was performed using a Packard 1600 TR Liquid 
Scintillation Analyser. The carbon-14 isotope emits high energy beta 
radiation and has a half-life of 5730 years which promotes sample stability 
allowing repeated sample analysis. Use of a liquid scintillation cocktail 
(National Diagnostics/Fisher Scientific, SCN-220-110F) containing an 
energy-collecting solvent and a phosphor facilitates the measurement of 
radiation emissions, referred to as disintegrations. One disintegration per 
second (DPS) equates to 1 Becquerel (Bq), the standard international unit of 
radioactivity, and can be converted to the commonly used unit of Curie (Ci). 
The radioactive component emits a beta particle, the energy from which is 
ultimately absorbed by the phosphor. The phosphor becomes excited from 
the absorption of energy causing it to emit light energy that is detected by 
the scintillation counting equipment. Each phosphor emits one photon but 
multiple phosphors may be excited by the emission of one beta particle 
creating a distinct intensity of light that is measured as a pulse. The pulses 
are expressed as the number of counts per minute (CPM) which can be 
converted to the number of disintegrations per minute (DPM) based on the 
efficiency of energy transfer of the liquid scintillation cocktail and 
subsequently converted to units of radioactivity. In the current investigation 
the protocol for liquid scintillation counting used a minimum ratio of scintillant 
to sample volume of 1: 10 to ensure sufficient energy transfer and therefore 
permit the equation of one count per minute to one disintegration per minute. 
Counts were converted to units of Curie based on the relation of 1 Curie 
being equal to 2.2 x 1012 disintegrations per minute. Counting efficiency of 
the equipment and background radiation was corrected for. The counts per
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minute determined for a carbon-14 calibration solution, relative to its 
specified value was calculated, and the correction factor applied to the 
counts per min for each calibration solution. The counts per minute of a 
background calibration solution were then subtracted from the counts per 
minute measured for each sample.
Because the [14C]-sucrose (Perkin-Elmer, NEC100X050UC) was universally 
labelled the basolateral radioactivity measured was a combination of glucose 
and fructose liberated during sucrose hydrolysis; apical radioactivity was the 
sum of sucrose, glucose and fructose. Because of this glucose and fructose 
could not be quantified in the apical compartment. Initial analysis using the 
glucose oxidase/peroxidase method had demonstrated that relatively only a 
small amount of glucose was detected in the basolateral compartment, the 
majority was present in the apical compartment. To overcome this issue a 
high pressure liquid chromatography (HPLC) separation with 
electrochemical detection was developed to quantify mono- and 
disaccharides. After development of the HPLC-IPAD method the presence of 
sucrose in the basolateral compartment of Transwell® plates was observed 
rendering the use of [14C]-sucrose ineffective for quantification of sucrose 
hydrolysis.
Concentration of glucose and fructose was not quantified using this method 
therefore a calibration curve was not produced.
2.3.3.2.1 Sample preparation for liquid scintillation counting
Samples were vortexed to ensure homogeneity then a volume, 0.25 mL for 
apical samples and sample blanks, and 0.5 mL for basolateral and cell 
samples, was added to liquid scintillation vials containing 5 mL of scintillant.
. •>»
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Light emission was counted for 10 min per vial and the number of counts per 
minute calculated by the equipment software.
2.3.3.2.2 Calculations
Radioactivity in the basolateral compartment of Transwell® plates was 
converted from counts per minute to Curie and expressed as a percentage 
of the total (apical + basolateral + cellular) radioactivity in the well.
2.3.3.3 HPLC-Integrated Pulsed Amperometrlc Detection (IPAD)
Carbohydrate separation is based on the principle of anion exchange 
chromatography. In water at 25°C the dissociation constants of glucose and 
fructose are >12; a strong sodium hydroxide gradient, pH>12, causes 
ionisation of the sugars and permits separation of glucose, fructose and 
sucrose. Electrochemical detection employs the use of three electrodes, a 
gold working electrode, a combined pH-silver/silver chloride reference 
electrode and a titanium counter electrode. Application of a repeating 
sequence of potentials across the working and reference electrodes causes 
oxidation of the gold electrode. The titanium counter electrode receives the 
flow of electrons to ensure the potential applied across the working and 
reference electrodes remains unaffected by current flowing from the gold 
electrode. Anionic sugar molecules are attracted to the oxidised gold 
electrode and a transfer of electrons results in the detection of current. The 
current is integrated over time which gives a measure of charge that is 
expressed in units of Coulombs (C).
Separation of mono- and disaccharides was achieved using a Dionex 
CarboPac PA20 column (3 x 150 mm), with Dionex CarboPac PA20 guard 
column (3 x 30 mm), fitted into a thermostatted column compartment on a
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Dionex LC system with autosampler (AS50), gradient pump (GS50), and 
electrochemical detector (ED50), controlled by Chromeleon 6 software. 
Sonicated solvents A) water, and B) 200 mM sodium hydroxide (71686) 
were stored under nitrogen gas for the duration of use and replaced with 
fresn solutions at least once per week. Solvent flow rate was maintained at 
0.4 m l min'1 throughout the following gradient schedule of solvent B in 
solvent A: 0 min, 30%; 10 min, 50%; 17 min, 30%; 27 min, 30%. The 
repeating sequence of potentials was as follows: 0.00 s, 0.05 V; 0.20 s, 0.05 
V; 0.40 s, 0.05 V; 0.41 s, 0.75 V; 0.60 s, 0.75 V; 0.61 s, -0.15 V; 1.00 s, - 
0.15V; integration of current over time began at 0.20 s and ended at 0.40 s. 
The electrode cleaning step from 0.41 s to 1.00 s firstly ensured full 
oxidation of analytes at the gold electrode with the application of a high 
positive potential, then repulsion of all analytes upon application of a 
negative potential. The autosampler temperature was maintained at 10°C 
and the column oven at 30°C.
2.3.3.3.1 Linearity, precision, limit of detection and limit o f quantification
Ten standard calibration solutions were prepared in the range of 0-500 pM 
and analysed in triplicate. The molar concentration of each calibration 
solution was plotted against the mean peak area, expressed in units of 
nC*min, ± standard error of the mean (SEM) (n=3). Linear regression 
analysis was performed, with the y-intercept fixed at zero, to calculate the 
gradient and adjusted R-square value of the calibration curve. The relative 
standard deviation (RSD) of replicate calibration solutions was calculated for 
each concentration to assess precision of the analytical method. Limit of
■ ■ * 4 ,
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detection and quantification were calculated as shown in Equation 2.1 and 
Equation 2.2.
2.3.3.3.2 Sample preparation for HPLC-IPAD
Samples were centrifuged at 17,000 x g for 5 minutes to remove cell debris. 
Supernatant was passed through a 1.7 mm, 0.2 pm PTFE filter pre­
conditioned with 1 mL methanol (Fisher Scientific, M/4056/17) followed by 1 
ml_ water. A volume of filtered sample (180 pL) was added to a 
polypropylene HPLC vial along with 20 pL of 1 mM fucose (F2252) used as 
an internal standard.
2.3.3.3.3 Calculations
The concentration of each glucose and fructose was calculated from the 
linear regression equation determined from the peak area calibration curve 
for each monosaccharide. The sum of apical and basolateral molar 
concentration for each monosaccharide was calculated and corrected 
against the appropriate sample blank. To account for any potential loss of 
glucose and fructose through cellular glycolysis the mean monosaccharide 
concentration was derived from the individual total concentrations of glucose 
and fructose. The rate of product formation was equated to the rate of 
sucrose hydrolysis and was calculated by dividing the total molar 
concentration by incubation time.
2.3.4 Glucose transport inhibition by a flavanol-rich dark 
chocolate extract
All glucose used in the investigation was the D- isomer. Cells between 
passage 33 and 50 were utilised in the investigation of [14C]-glucose
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transport. One Transwell® plate was allocated per experimental condition to 
provide six replicates. The cell culture assay duration was 30 minutes.
2.3.4.1 Liquid Scintillation Counting
Liquid scintillation counting was performed using a Packard 1600 TR Liquid 
Scintillation Analyser. A universally labelled [14C]-glucose isotope (Perkin- 
Elmer, NEC042V250UC) was used in the measurement of apical to 
basolateral glucose transport and cellular uptake. To prevent residual 
glucose from the cell culture media interfering with determination of 
basolateral and cellular glucose concentration, each solution was 
supplemented with a fixed volume of radiolabelled glucose containing a 
specific radioactivity. The benefits of this were two-fold: firstly glucose 
analysis was precise and sensitive, and secondly minimal pre-analytical 
sample preparation was required due to lack of interference from other 
compounds in the sample matrix.
The carbon-14 isotope emits high energy beta radiation and has a half-life of 
5730 years which promotes sample stability allowing repeated sample 
analysis. Use of a liquid scintillation cocktail containing an energy-collecting 
solvent and a phosphor facilitates the measurement of radiation emissions, 
referred to as disintegrations. One disintegration per second (DPS) equates 
to 1 Becquerel (Bq), the standard international unit of radioactivity, and can 
be converted to the commonly used unit of Curie (Ci).
The radioactive component emits a beta particle, the energy from which is 
ultimately absorbed by the phosphor. The absorption of energy excites the 
phosphor causing it to emit light energy that is detected by the scintillation 
counting equipment. Each phosphor emits one photon but multiple
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phosphors may be excited by the emission of one beta particle creating a 
distinct intensity of light that is measured as a pulse. The pulses are 
expressed as the number of counts per minute (CPM) which can be 
converted to the number of disintegrations per minute (DPM) based on the 
efficiency of energy transfer of the liquid scintillation cocktail and 
subsequently converted to units of radioactivity. In the current investigation 
the protocol for liquid scintillation counting used a minimum ratio of scintillant 
to sample of 10:1 (v/v) to ensure sufficient energy transfer and therefore 
permit the equation of one count per minute to one disintegration per minute. 
Counts were converted to units of Curie based on the relation of 1 Curie 
being equal to 2.2 x 1012 disintegrations per minute. Counting efficiency of 
the equipment and background radiation was corrected for. The counts per 
minute determined for a carbon-14 calibration solution, relative to its 
specified value was calculated, and the correction factor applied to the 
counts per min for each calibration solution. The counts per minute of a 
background calibration solution were then subtracted from the counts per 
minute measured for each sample.
2.3.4.1.1 Linearity, precision and limit o f quantification
Ten standard calibration solutions were prepared in the range of 0-0.014 pCi 
(0-30,000 CPM) and analysed in triplicate. Briefly, 2 pL of 0.1 pCi pL'1 [14C]- 
glucose stock solution was diluted to 2 mL (0.1 pCi mL'1) and serial dilutions 
prepared using transport buffer solution. Based on the specific activity of the 
stock solution (319 pCi pmol'1) the molar content of each calibration solution 
was calculated and plotted against the mean number of counts per minute ± 
standard error of the mean (SEM) (n=3). Linear regression analysis was
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performed with the y-intercept fixed at zero to calculate the gradient and 
adjusted R-square value of the calibration curve. The relative standard 
deviation (RSD) of replicate counts per minute was calculated for each 
calibration solution to assess precision of the analysis at each molar amount. 
The limit of quantification was defined as the concentration equivalent to 10x 
the standard deviation of background corrected blank samples (Currie 
1968).
2.3.4.1.2 Sample preparation for liquid scintillation counting 
Refer to section 2.3.3.2.1, page 62.
2.3.4.1.3 Calculations
Each sample was corrected for background radiation and the content of [U- 
14C]-glucose calculated from the linear regression equation determined for 
the calibration curve. The content was converted to concentration per 
millilitre and, based on the ratio of radiolabelled glucose to non-radiolabelled 
glucose in the corresponding transport solution, the concentration per 
millilitre of non-radiolabelled glucose was calculated. Total glucose 
concentration per millilitre was calculated as the sum of radiolabelled and 
non-radiolabelled glucose, then converted to the concentration per litre. The 
rate of apical to basolateral transport and cellular uptake (pM min'1) was 
calculated from the total glucose concentration in either the basolateral 
samples or cellular samples, respectively, divided by total incubation time. 
The kinetic properties of apical to basolateral glucose transport and cellular 
uptake were measured using the Michaelis-Menten model. A plot of 
transport rate as a function of initial glucose concentration was prepared and 
nonlinear regression analysis based on the Michaelis-Menten equation was
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performed (Equation 2.3). Rearrangement of the equation permitted the 
maximum velocity (Vmax) and Michaelis constant (KM) to be determined 
(Equation 2.4 and Equation 2.5).
2.4 Statistical analysis
All statistical analysis of data was performed using IBM 
SPSS Statistics 19. Levene’s homogeneity of variances was initially 
executed to calculate whether data variation within each group was 
significant. Where significant variations were measured a non-parametric 
test to determine significant differences between groups was applied. If data 
variations were not significant a parametric test was utilised. Data are 
expressed as mean values ± standard error of the mean (SEM), and 
differences were considered statistically significant when p<0.05, unless
otherwise stated.
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Chapter 3 In  v itro  epicatechin transport and méthylation
3.1 Abstract
The investigation of epicatechin transport and méthylation presented here 
was carried out to determine whether transport of pure epicatechin across 
the Caco-2 cell monolayer was significantly affected by co-incubation with 
sucrose, glucose or fructose; and whether transport of epicatechin from a 
flavanol-rich dark chocolate extract was significantly different from that of the 
individual compound. The results of this study reveal that whilst epicatechin 
transport is not significantly affected by the presence of higher molecular 
weight oligomers and polymers in a dark chocolate extract, O-methylation of 
epicatechin is significantly attenuated. The presence of sucrose significantly 
improved epicatechin transport but did not elicit a significant effect on the 
formation of 3’- and 4’-0-methy!ated metabolites. Conversely co-incubation 
with glucose and fructose did not significantly affect epicatechin absorption 
but did significantly reduce the synthesis of 3’-0-methylated metabolites. 
The role of paracellular permeability in epicatechin transport and the 
potential for competitive, inhibition of catechol-O-methyltransferase by 
oligomeric flavanols and by glycolytic enzymes requiring the magnesium 
divalent cation is discussed.
.
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3.2 Introduction
There are several reports in the literature of eplcatechin bioavailability 
studies undertaken in humans and animals and absorption studies in cell 
culture models using flavanol-rich foods, beverages, plant extracts and the 
pure compound. Effects of the food matrix on gastrointestinal absorption and 
metabolism of epicatechin from cocoa in human and animal subjects has 
been investigated with particular attention to the carbohydrate and protein 
content, both of which are of significance to confectionary and beverages 
containing cocoa flavanols. The physical form in which the cocoa is ingested 
appears to significantly affect the pharmacokinetic properties of epicatechin 
with maximum concentration (Cmax) of serum epicatechin greater in human 
subjects following ingestion of a cocoa beverage compared with a dark 
chocolate bar containing an equivalent amount of total flavanols (Neilson et 
al. 2009). Although this could be a consequence of the different cocoa butter 
content, and therefore fat content, of the bars and beverages. The ability of 
carbohydrates to enhance epicatechin absorption has been proposed but 
the evidence is inconclusive. Carbohydrate content of a meal and plasma 
flavanol area under the curve (AUC) was reported following an investigation 
of volunteers consuming either table sugar, bread or grapefruit juice 
immediately before consumption of a sugar-free flavanol-rich cocoa 
beverage (Schramm et al. 2003). Each test meal significantly increased 
plasma flavanol (epicatechin + catechin) 0-8 hour AUC relative to 
consumption of the cocoa beverage only. Table sugar and bread also 
increased the Cmax. Augmented plasma epicatechin Cmax and AUC following 
consumption of a dark chocolate bar containing sucrose compared with an
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equivalent bar containing maltitol has also been reported (Rodriguez-Mateos 
et al. 2012). However the authors noted that the perceived enhancement 
induced by sucrose may be a consequence of reduced epicatechin 
absorption brought about by the presence of maltitol. A sugar-free flavanol 
equivalent control would be required to confirm the result.
Neilson et al (2009) speculated that the presence of sucrose may enhance 
epicatechin bioavailability. This was based on the highest Cmax following 
consumption of a high-sucrose confectionary bar compared with a low- 
sucrose equivalent, and a sucrose-containing beverage compared with 
sucrose-free beverage. However neither of these results was significant. 
Furthermore non-significant results were reported using a rat model to 
compare the effect of sucrose and milk-protein compared with a reference 
dark chocolate on epicatechin pharmacokinetics (Neilson et al. 2010).
These studies focus on the effect of sucrose on intestinal absorption of free 
epicatechin however it has been reported that following consumption of dark 
chocolate epicatechin in its free form is not detected in the plasma of human 
subjects (Actis-Goretta et al. 2012). The presence of free epicatechin in the 
plasma of human subjects following cocoa intake is controversial. In addition 
to the intervention studies discussed here others, including those based on 
animal models, have quantified free epicatechin along with methylated and 
non-methylated conjugates in the plasma of subjects (Baba et al. 2000b, 
Baba et al. 2000a, Baba et al. 2001a). Epicatechin and its metabolite 
concentrations in the plasma and urine of rats was examined following 
ingestion of increasing doses of pure epicatechin. The results were 
compared with concentrations following almost identical doses of 
epicatechin administered in a cocoa powder (Baba et al. 2001a). The
authors reported significantly lower plasma concentrations of methylated and 
non-methylated epicatechin conjugates post-ingestion of the cocoa powder 
compared with the pure compound. Conversely, free epicatechin 
concentration in plasma was significantly higher following cocoa powder 
treatment compared with the pure compound. Analysis of free epicatechin 
and its metabolite concentrations in urine revealed no significant differences 
between the two treatments suggesting an attenuated rate of epicatechin 
absorption from the gut lumen and/or metabolism within the intestinal 
epithelial cells.
The observation that free epicatechin concentration is higher and metabolite 
bioavailability is lower from cocoa than from the pure compound may be 
explained by the presence of higher molecular weight flavanols in the cocoa. 
Perfusion studies of rat small intestine with mixtures of flavanol oligomers 
have resulted in the detection of low levels of the B2 dimer when co­
incubated with either a procyanidin tetramer or B5 dimer (Spencer et al. 
2001, Appeldoorn et al. 2009b). Methylated dimer has also been detected 
along with free epicatechin following incubation of rat small intestine with a 
mix of B2 and B5 dimers (Spencer et al. 2001); although the detection of 
free epicatechin following incubation of flavanol oligomers has been 
contested (Donovan etal. 2002, Ottaviani etal. 2012).
Detection of methylated dimer but not methylated epicatechin suggested 
inhibition of the enzyme catechol-O-methyltransferase (COMT) within the 
cells. Dose-dependent reduction of COMT activity with epicatechin as the 
substrate, in the presence of increasing concentration of dimers was 
observed. Concurrently dose-dependent formation of O-methylated B2 and 
B5 dimers was noted at concentrations up to 300 pM of dimers. Above this
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concentration methylation of both dimers decreased indicating that inhibition 
of COMT activity £300 pM is competitive whereas >300 pM inhibition 
becomes non-competitive. Epicatechin and quercetin have been reported to 
inhibit the activity of human liver cytosolic COMT using 4-hydroxyestradiol as 
substrate, both flavonoids demonstrated a mixed mechanism of inhibition 
with non-competitive inhibition occurring at high concentrations of each 
(Nagai et al. 2004). The authors hypothesised that non-competitive inhibition 
is in part due to the presence of many COMT substrates that increases the 
formation of S-adenosyl-L-homocysteine (SAH) from S-adenosyl-L- 
methionine (SAM), SAH itself being a non-competitive inhibitor of COMT. In 
addition increased utilisation of SAM would reduce its availability as a methyl 
group donor.
Based on in vivo observations the objective of the investigation described in 
this chapter was to determine whether incubation of a flavanol-rich dark 
chocolate extract and the saccharides sucrose, glucose and fructose were 
able to modify in vitro epicatechin absorption and methylation using Caco-2 
cells as a model of the human small intestine.
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3.3 Results
3.3.1 HPLC-DAD-MS2 Validation
3.3.1.1 Linearity, precision and limit of detection and quantification
Epicatechin calibration solutions in the range 0-50 pM were analysed in 
triplicate and the mean peak area ± standard error of the mean (SEM) plot 
against concentration (Figure 3.1). Triplicate zero concentration epicatechin 
solutions generated small ion counts of which the peak areas were 
integrated. The signal to noise ratio of these peaks was calculated to be less 
than 10; subsequently the values were substituted for zero and for linear 
regression analysis the y-axis intercept was set to zero. An adjusted R- 
square value of 1.0 was calculated suggesting good proportionality of 
concentration with peak area.
The relative standard deviation was calculated for each of the five 
concentrations ranging from 1-50 pM; because the zero concentration peak 
areas had been corrected to zero the mean and standard deviation was 
calculated as zero. For all other concentrations relative standard deviation 
ranged from 10-20 %, becoming smaller with increasing concentration; 
precision of the protocol was considered acceptable.
The limit of detection was defined as the smallest peak area that was 
significantly different from the mean peak area of replicate zero 
concentration solutions (p<0.05). This equated to a concentration of 113 nM. 
The limit of quantification was calculated as the concentration at which the 
peak area was 10x that of the mean peak area of replicate zero 
concentration solutions. This equated to 188 nM.
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Concentration of epicatechin and methylated metabolites were calculated by 
rearrangement (Equation 3.2) of the linear regression equation obtained 
from the epicatechin calibration curve (Equation 3.1). The concentrations of 
methylated metabolites were calculated as epicatechin equivalents 
assuming a relative response factor of 1.0.
y  = mx + c Equation 3.1
(y -  c) Equation 3.2
x = ---------m
[Epicatechin] (pM)
Figure 3.1 Epicatechin calibration curve. Mean ± SEM (n=3); gradient = 
1475, adjusted R-square = 1.0.
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3.3.2 Epicatechin transport study
3.3.2.1 Caco-2 cell monolayer validation
Monolayer permeability is of importance when investigating the transport of 
a compound across the cell membrane. Blank corrected TEER values below 
300 ohms may be demonstrative of less well formed tight junctions between 
the cells. Only cells with TEER values £300 ohms were used in the 
investigation presented here (Table 3.1).
For each cell culture assay performed the TEER values were compared to 
determine whether a significant difference existed between the conditions 
investigated. In the assay that investigated the effect of a flavanol-rich dark 
chocolate extract there was no significant difference in TEER values 
between the two groups consequently it was considered that any significant 
differences in basolateral epicatechin concentration could be reasonably 
considered a result of the condition being tested. In the experiment to test 
the effect of sucrose, glucose and fructose on epicatechin transport and 
methylation the mean TEER of control cells (250 pM epicatechin) was 
significantly lower (p<0.05) than the mean TEER of cells used in the test 
conditions of sucrose, glucose and fructose. Partial correlation analysis 
controlling for condition showed no significant correlation between 
basolateral epicatechin concentration and TEER value (Figure 3.2). To avoid 
this problem replicates should have been distributed throughout the 
Transwell® plates rather than allocating one plate per condition.
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Condition TEER (Ohms)
250 pM Epicatechin 416± 12
Dark chocolate extract containing 241 pM epicatechin 455 ± 21
250 pM Epicatechin 291 ± 12a
250 pM Epicatechin + 100 mM sucrose 333 ± 8b
250 pM Epicatechin + 100 mM glucose 342 ± 10b
250 pM Epicatechin + 100 mM fructose • 326 ± 6b
Table 3.1 Blank corrected trans-epithelial electrical resistance (TEER) 
measured before commencement of each assay. Mean ± SEM (n=6) for 
each condition. Different superscript letters represent a significant difference, 
p<0.05.
Trans-epithelial electrical resistance (Ohms)
Figure 3.2 Basolateral concentration of epicatechin after the 60 minute 
incubation, in the absence and presence of 100 mM sucrose, glucose or 
fructose, as a function of mean ± SEM (n=3) trans-epithelial electrical 
resistance per Transwell® insert measured before commencement of the 
assay.
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3.3.2.2 Epicatechin transport and méthylation
3.3.2.2.1 Effect of dark chocolate extract
Transport of epicatechin through a Caco-2 cell monolayer was assessed in 
the absence and presence of a flavanol-rich dark chocolate extract. Table
3.2 shows the flavanol content of Nestlé NOIR Intense 70% cocoa solids 
and the extract used in the cell culture assay. A HPLC-FLD chromatogram 
representative of dark chocolate extract containing flavanol monomers to 
decamer is presented in Figure 3.3. Caco-2 cells were incubated for 60 min 
with either a flavanol-rich cocoa extract containing 241 pM epicatechin or 
250 pM epicatechin standard referred to as the control. TEER values 
measured after the 60 minute incubation revealed a significant reduction 
compared with the resistance measured before commencement of the assay 
(Figure 3.4A1. The mean TEER of cells incubated with the flavanol-rich dark 
chocolate extract were also significantly lower than the mean control cell 
resistance post-incubation. The mean TEER did not fall below 300 Ohms in 
either condition investigated indicating that the monolayer maintained an 
acceptable level of integrity. The concentration of epicatechin in the 
basolateral compartment and 3’- and 4’-0-methylated epicatechin in the 
apical and basolateral compartments was calculated from the epicatechin 
calibration curve and corrected to account for the limit of quantification 
(LOQ). Concentrations below the LOQ were considered to be zero. 
Following incubation with the flavanol-rich dark chocolate extract epicatechin 
concentration in the basolateral compartment was not significantly different 
from the control (Figure 3.4B) however the total concentration of 3’-0 - 
methylated epicatechin (sum of apical and basolateral concentrations) was
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significantly lower than the control (Figure 3.5A). Basolateral concentration 
of 3’-0-methyl epicatechin was not significantly different from the control and 
neither was the total or basolateral concentration of 4’-Omethyl epicatechin 
(Figure 3.5B).
Degree of Polymerisation Content
mg 100 g'1 FW Dark 
Chocolate
pg mL'1 Dark 
Chocolate Extract
Monomer 68.7 116.7
Dimer 43.2 73.5
Trimer 11.0 18.6
Tetramer 6.8 11.7
Pentamer 2.6 4.6
Hexamer 1.2 2.1
Heptamer 0.6 1.3
Octamer 0.3 0.6
Nonamer 0.2 0.4
Decamer 0.2 0 .2
Table 3.2 Flavanol content of the dark chocolate extract used to investigate 
epicatechin transport and méthylation by Caco-2 cells. Values represent the 
mean of two replicates and are expressed as the quantity (mg) per 100 g 
fresh weight (FW) of Nestlé NOIR Intense 70% cocoa solids dark chocolate 
and the amount present in the extract that was incubated with cells.
Figure 3.3 HPLC-FLD chromatogram of dark chocolate extract containing 
64.3 mg of flavanol monomers 100 g '1 fresh weight of dark chocolate. Peak 
numbering equates to the degree of polymerisation with 1 = monomer, 2 = 
dimer etc.
8 2
250 pM Epicatechin DC Extract 241 pM EC
B
Figure 3.4 A) Blank corrected trans-epithelial electrical resistance (TEER) of 
Caco-2 monolayers measured before and after the 60 min incubation. Mean 
± SEM (n=6 ). Different letters represent significant differences, p<0.05. B) 
Epicatechin concentration in the basolateral compartment of Transwell® 
plates post-incubation with 250 pM standard epicatechin (EC) or a flavanol- 
rich dark chocolate (DC) extract containing 241 pM EC. Mean ± SEM (n=6 ).
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□  Apical
I Apical
Figure 3.5 A) Concentration of 3’-0-methyl epicatechin, and B) 4'-C>-methyl 
epicatechin in the apical and basolateral compartments of Transwell® plates 
after the 60 min incubation with 250 pM standard epicatechin (EC) or a 
flavanol-rich dark chocolate (DC) extract containing 241 pM EC. Mean ± 
SEM (n=6 ). Asterisk denotes a significant difference in the total 
concentration (sum of apical and basolateral concentrations) compared with 
250 pM epicatechin, **p<0.01.
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3.3.2.2.2 Effect of sucrose, glucose and fructose
Epicatechin transport through the Caco-2 cell monolayer and methylation by 
cells was assessed In the absence (control) and presence of 100 mM 
sucrose, glucose, and fructose. TEER of the cell monolayer following 
incubation with 100 mM sucrose, glucose or fructose significantly diminished 
compared with the corresponding measurements taken before 
commencement of the 60 minute incubation (Figure 3.6A). The TEER of the 
control cells did not significantly change and the post-incubation TEER of 
cells incubated in the presence of 100 mM glucose or fructose was not 
significantly different from the post-incubation control cells TEER. Incubation 
of cells with 100 mM sucrose did significantly lower the TEER compared with 
post-incubation TEER of the control cells. A significant correlation was 
established between basolatera! epicatechin concentration and TEER 
measurements taken post-incubation (Figure 3.7).
The concentration of epicatechin in the basolateral compartment was 
significantly higher in the presence of 100 mM sucrose compared with the 
control (Figure 3.6B). Glucose and fructose did not significantly affect the 
basolateral epicatechin concentration.
Analysis of both apical and basolateral solutions revealed that only in control 
cells was 3’-0-methylated epicatechin metabolites effluxed across the 
basolateral membrane; 4 ’-0-methylated epicatechin metabolites were only 
effluxed across the apical membrane in control and sucrose-incubated cells 
(Figure 3.8A and B). Co-incubation with glucose or fructose significantly 
reduced the total and apical concentration of 3’-0-methyl epicatechin, but 
not the basolateral concentration, compared with the control; sucrose did not
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elicit a significant effect. There was no significant change in 4’-0-methylation 
of epicatechin across any of the conditions tested.
Figure 3.6 A) Blank corrected trans-epithelial electrical resistance of Caco-2 
monolayers measured before and after the 60 min incubation in the absence 
(control) and presence of 100 mM sucrose, glucose or fructose. Mean ± 
SEM (n=6). Different letters represent significant differences, p<0.05. B) 
Epicatechin concentration in the basolateral compartment of Transwell® 
plates post-incubation. Mean ± SEM (n=6). Asterisk denotes a significant 
difference from the control, *p<0.05.
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Figure 3.7 Basolateral concentration of epicatechin after the 60 minute 
incubation as a function of mean ± SEM (n=3) trans-epithelial electrical 
resistance per Transwell® insert measured post-incubation. Partial 
correlation analysis controlling for condition revealed a significant correlation 
between basolateral epicatechin concentration and TEER, p<0.001.
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B
Figure 3.8 A) Concentration of 3’-O-methyl epicatechin, and B) 4’-0-methyl 
epicatechin in the apical and basolateral compartments of Transwell® plates 
after the 60 min incubation in the absence (control) and presence of 1 0 0  mM 
sucrose, glucose or fructose. Mean ± SEM (n=6 ). Asterisk denotes a 
significant difference in the total concentration (sum of apical and basolateral 
concentrations) compared with the control, **p<0 .0 1 .
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3.4 Discussion
3.4.1 Effect of dark chocolate extract
The trans-epithelial electrical resistance of cells post-incubation was 
significantly lower than before commencement of the assay. Whilst there 
was no significant difference in pre-incubation TEER between the conditions 
investigated, the post-incubation TEER was significantly different but 
remained £300 Ohms. The cell monolayer was considered to be sufficiently 
intact that paracellular permeability was not affected. Incubation of Caco-2 
cells with the flavanol-rich dark chocolate extract containing 241 pM 
epicatechin did not significantly affect epicatechin transport compared with 
transport of 250 pM standard epicatechin. Formation of 3'-0-methylated 
epicatechin metabolites was significantly diminished in the presence of dark 
chocolate extract relative to standard epicatechin; this is in agreement with a 
study of rats in which total 3’-0-methylated epicatechin metabolites were 
significantly lower post-consumption of cocoa powder compared with 
ingestion of standard epicatechin (Baba et al. 2001a).
The predominant flavanol in the dark chocolate extract was epicatechin 
however a substantial quantity of dimers and trimers was also present. 
Tetrameric flavanols have been shown to enhance the cellular absorption of 
dimers (Appeldoorn et a i 2009b) which are reported to competitively inhibit 
the activity of catechol-O-methyltransferase reducing the formation of 
methylated epicatechin metabolites at concentrations relevant to this study 
(Spencer et al. 2001). It is postulated that the attenuation of 3'-0-methylated 
epicatechin observed in the present investigation may be a consequence of
cellular uptake of dimeric flavanols that compete with epicatechin for 
methylation by COMT.
3.4.2 Effect of sucrose, glucose and fructose
Incubation of cells with 100 mM sucrose, glucose or fructose significantly 
reduced the post-incubation TEER of the monolayer relative to pre­
incubation TEER. Co-incubation with sucrose, but not glucose or fructose, 
significantly reduced the TEER relative to the control. In each test condition 
the value fell below 300 Ohms which indicates loss of monolayer integrity 
and potential for increased paracellular transport of solutes. The paracellular 
route has a net negative charge which results in a differential rate of solute 
permeability in the order from fastest to lowest cationic > neutral > anionic 
(Amidon et al. 1999). In addition to this principle the rate of permeability is 
also regulated by the molecular weight and radius of the solute, such that 
smaller molecules permeate faster than larger ones. The authors 
demonstrated that disruption of the cell monolayer of Madin-Darby canine- 
kidney (MDCK) cells increased paracellular transport of sucrose and 
mannitol with sucrose permeability being more greatly affected than 
mannitol. The pore radius of an integral MDCK monolayer was calculated as
6.1 A; by comparison the radius of mannitol and sucrose is 4.1 and 5.6 A, 
respectively. The disrupted monolayer, pore size 11.0 A, was considered to 
become relatively less inhibiting to the larger molecule. The pore radius of 
Caco-2 cells is almost double that of MDCK cells however the permeability 
coefficient of mannitol is not significantly different between the two cell 
models. This is considered to be a function of other physical characteristics
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of the cells including cell height and width, length of tight junctions and width 
of lateral space.
Incubation of Caco-2 cells with 100 mM sucrose, but not glucose or fructose, 
significantly increased the apical to basolateral transport of epicatechin. 
Concomitantly the TEER of cells incubated in the presence of sucrose 
significantly diminished compared with the control. It is probable that 
increased basolateral epicatechin concentration was a result of a 
significantly disrupted cell monolayer which allowed greater paracellular 
permeation. The absence of a significant change in basolateral epicatechin 
concentration following incubation with glucose or fructose, even though the 
monolayer resistance diminished below 300 Ohms, is believed to be a result 
of there being no significant difference between the post-incubation TEER of 
cells incubated with glucose and fructose compared with control cells.
In Caco-2 cells activation of the sodium-dependent glucose transporter, 
SGLT1, has been reported to increase tight junction permeability (Turner 
and Black 2000). The presence of sucrose in the diet of mice significantly 
increased SGLT1 activity compared with a carbohydrate-free diet or diet 
containing maltose (Weiss et al. 1998, Lam et al. 2002). Weiss et al {1998) 
also demonstrated that sucrose a-glucosldase activity increased parallel with 
SGLT1 activity. Whilst it would be expected that the presence of glucose 
would induce activation of SGLT1, it has been reported that sucrose and 
fructose, but not glucose, enhances the activity of sucrose a-glucosidase 
(EC 3.2.1.48) in rats (Kishi et al. 1999). It could be postulated that incubation 
of Caco-2 cells with sucrose, but not glucose or fructose, induces SGLT1 
activity that leads to increased tight junction pore size as determined by
■ r*
reduced electrical resistance of the cell monolayer, and therefore increased 
paracellular permeability of epicatechin.
The presence of glucose or fructose, but not sucrose, elicited a significant 
reduction in 3’-0-methylation of epicatechin. The méthylation of epicatechin 
is an enzyme catalysed reaction in which a methyl group is transferred from 
S-adenosyl-methionine to the substrate. It is a requirement of the enzyme 
activity for the presence of a divalent metal cation; this is usually magnesium 
(II). The metal cation ensures that the substrate binds to the enzyme- 
cofactor complex in the correct orientation to permit methyl group transfer; 
changing the metal ion affects the enzyme activity. In the present cell culture 
study magnesium is not present in the transport solution; the only divalent 
cation present is calcium (II). It has been reported that substituting calcium 
(II) for magnesium (II) produces a significant inhibition of the enzyme. 
Because the calcium (II) ion is larger than the magnesium (II) ion this 
prohibits the correct cofactor-substrate alignment within the enzymes active 
site (Sparta and Alexandrova 2012). The control transport solution is 
formulated using the same protocol therefore is it likely that magnesium (II) 
stored within the cells permits continued COMT activity. The inhibition of 
enzyme activity in the presence of glucose or fructose may be due to 
competition for magnesium (II) from other enzymes within the cell. Glucose 
is the primary substrate in the glycolytic pathway, it is initially phosphorylated 
by hexokinase (EC 2.7.1.1), an enzyme requiring magnesium (II) for its 
activity, to produce glucose-6-phosphate. The pathway continues with 
conversion to fructose-6-phosphate catalysed by glucose-6-phosphate 
isomerase (EC 5.3.1.9) and further phosphorylation to form fructose-1, 6- 
bisphosphate by 6-phosphofructokinase (EC 2.7.1.11), an enzyme that also
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requires magnesium (II). It is probable that sucrose does not elicit a similar 
reduction of epicatechin méthylation due to the relatively low levels of 
glucose and fructose liberated from enzymatic sucrose hydrolysis; the 
concentration of each monosaccharide produced may remain too low to 
exhibit an inhibitory effect of COMT.
Schramm et al (2003) demonstrated a positive association between 
carbohydrate content of a meal and plasma epicatechin area under the 
curve. Other studies have proposed similar associations but with less 
convincing results (Neilson et al. 2009, Rodriguez-Mateos et al. 2012). It 
may be that other components of the formulations are responsible for the 
effects observed or that lack of significant differences is due to the dose 
administered. The doses administered to subjects in the human studies 
described previously to determine the effect of food components on 
epicatechin bioavailability are shown in Table 3.3. In the Caco-2 study 
presented here the concentration of epicatechin and sucrose applied to cells 
was 250 pM and 100 mM, respectively. Assuming 500 mL of gastric fluid this 
would be the equivalent to a serving of approximately 53 g and 71 g of 
Nestlé NOIR Intense dark chocolate containing 70% cocoa solids to achieve 
the same epicatechin and sucrose concentrations.
• ¥ *
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Reference Sucrose Flavanol monomer
(9) (mM) (mg) (MM)
Schramm et a/ (2003) 35 204 100 689
Neilson et a/(2009) 15 88 36 248
Rodriguez-Mateos et al (2012) 10 58 75 517
Table 3.3 Sucrose and flavanol monomer content per serving based on 65 
kg body weight and equivalent concentration assuming 500 mL gastric fluid 
given to human subjects to investigate the effect of sucrose on epicatechin 
bioavailability.
3.5 Conclusion
In the Caco-2 cell model the apical to basolateral transport of epicatechin is 
not affected by the presence of higher molecular weight flavanols in a dark 
chocolate extract or monosaccharides glucose and fructose. Sucrose does 
significantly enhance epicatechin transport, possibly via its potential to 
increase paracellular permeability through stimulation of SGLT1 activity. The 
formation of 3’-0-methylated epicatechin is significantly attenuated in the 
presence of a dark chocolate extract and glucose or fructose. It is 
hypothesised that the effect of dark chocolate extract is attributable to the 
presence of dimeric flavanols in the dark chocolate extract which compete 
with epicatechin for methylation. The effect of glucose and fructose is 
proposed to be a consequence of glycolysis enzymes competing with COMT 
for magnesium (II) cations that are necessary for activity. Prospective 
studies in which the effect of sucrose on SGLT1 activity and TEER of Caco- 
2 cells are required to confirm the hypothesis presented here. Co-incubation 
of epicatechin with commercially available dimeric flavanol standards should 
be performed in Caco-2 cells to confirm whether epicatechin transport and 
COMT activity is significantly affected by the presence of dimeric flavanols.
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Chapter 4 Dark chocolate extract inhibits sucrose hydrolysis 
in the Caco-2 cell model
4.1 Abstract
The rate of sucrose hydrolysis in Caco-2 cells was investigated in the 
presence of flavanol-rich dark chocolate and individual flavanol constituents 
of dark chocolate. Enantiomers of each catechin stereoisomer and 
acarbose, used as a positive control, were also assessed. Acarbose dose- 
dependently reduced the rate of hydrolysis. Dark chocolate extract 
containing 322 pM flavanol monomers and 500 pM (-)-epicatechin 
significantly decreased the rate of hydrolysis by 59% and 31% respectively. 
This suggests that the epicatechin content of dark chocolate is partly 
responsible with potential synergistic effects from other flavanol components 
contributing to the difference. All individual flavanol monomers and dimer 
investigated significantly enhanced the rate of sucrose hydrolysis at a 
concentration of 50 pM. With the exception of (+)-epicatechin, all other 
concentrations investigated did not affect the rate of sucrose hydrolysis. It is 
hypothesised that sucrase-flavanol binding may occur at two distinct 
locations; one that is not the active site, could alter the tertiary structure of 
the enzyme exposing more catalytic residues, thereby enhancing sucrose 
hydrolysis at moderate concentrations; and two at the more accessible 
active site, flavanol binding would elicit an inhibitory effect that becomes 
more prominent with increasing concentration of inhibitor.
4.2 Introduction
The effects of plant extracts and the individual phenolic components on 
carbohydrate metabolising enzymes present in the small intestine have been 
extensively investigated during the last decade (Kim et al. 2000, Hansawasdi 
etal. 2001, Matsui etal. 2001, Matsui etal. 2002, Ramachandra etal. 2005, 
McDougall et al. 2005, Barrenetxe et al. 2006, Iwai et al. 2006, He et al.
2007, Gupta et al. 2007, Ani and Naidu 2008, Kumarappan and Mandaol
2008, Adisakwattana and Chanathong 2011, Pereira et al. 2011, El- 
Beshbishy and Bahashwan 2012). Primarily these studies have focused on 
inhibition of enzymes belonging to the hydrolase family -  a-amylase (EC 
3.2.1.1), a-glucosidase (maltase) (EC 3.2.1.20), and sucrose a-glucosidase 
(sucrase) (EC 3.2.1.48). Common features of these enzymes are the 
catalytic residues of aspartic and glutamic acid that, each contains an acidic 
side chain (Nichols et al. 2003, Lo Piparo et al. 2008). At physiological pH 
the ionised a-carboxyl group of each amino acid is able to participate in 
hydrogen bond formation with the hydroxyl groups of phenolic compounds. 
Many investigations have observed that more hydroxyl groups present in the 
molecule generally equates to stronger inhibition of the enzyme compared 
with similar structures containing fewer hydroxyl groups. This was 
demonstrated by a study of monomeric flavanols and condensed tannins 
typically present in tea. The most effective inhibition of maltase and sucrase 
was performed by those compounds esterified to gallic acid, such as 
theaflavin-3-O-gallate, epigallocatechin gallate and epicatechin gallate 
(Matsui etal. 2007, Kamiyama etal. 2010). A summary of the concentrations
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required to reduce activity of the enzymes by 50% (IC50) reported by Matsui 
et al (2007) is shown in Table 4.1.
The stereochemical configuration of hydroxyl groups was also found to be of 
importance to the efficacy of inhibition. The 3’ hydroxyl group of theaflavin-3- 
O  gallate rotated in the 'R  configuration inhibits maltase more potently than 
the 'S’ configuration. Similarly the HR  configuration of the C-ring hydroxyl 
group of both catechin and epicatechin inhibited maltase more than the ‘S  
isomer (Matsui et a i 2007).
The number of hydroxyl groups present on the B-ring of flavonols affects the 
inhibitory capacity towards sucrase, maltase and a-amylase. The order of 
inhibition from strongest to weakest was reported to match the number of 
hydroxyl groups from most to fewest in a study of guava leaf constituents, 
with myricetin > quercetin > kaempferol (Wang et a i 2010). Apigenin, a 
flavone containing one B-ring hydroxyl group but no C-ring hydroxyl, 
exhibited only slight inhibition (IC50 >30 mM), suggesting that hydroxylation 
of the C-ring is also important.
A double bond between carbon-2 and carbon-3 of the C-ring forms a 
conjugated system with delocalised electrons throughout the A- and C-rings, 
the presence of which has also been implicated in the ability of a flavonoid to 
inhibit glucohydrolase enzymes. Lo Piparo et al (2008) assessed the 
interaction between a variety of flavonoids and amino add residues at the 
active site of human salivary a-amylase. They found the conjugated system 
was able to form n-n bonds with the aromatic side chains of tryptophan and 
tyrosine. Luteolin and quercetin, a flavone and flavonol containing the 
conjugated AC ring system and presenting identical structures except for the 
presence of a carbon-3 hydroxyl group in quercetin, exhibit similar IC50
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values, 18.4 pM and 21.4 pM respectively. Catechin and epicatechin, 
flavanols that do not possess the conjugated system were unable to achieve 
50% inhibition of a-amylase at concentrations up to 100 pM.
The flavanols catechin and epicatechin are also only weak inhibitors of 
sucrase and maltase, refer to Table 4.1. and supported by the observations 
of Kamiyama et a /(2010). Concentrations required to reduce enzyme activity 
to 50% are not physiologically easy to achieve. For example, one of the 
best sources of (-)-epicatechin is dark chocolate that contains approximately 
70 mg 100 g'1 fresh weight (Neveu et al. 2010). Assuming 500 mL of gastric 
liquid this equates to approximately 480 pM. Any benefits arising from 
inhibition of carbohydrate hydrolysis would likely be offset by the high sugar 
and fat intake from consuming 200 g of dark chocolate. As previously 
discussed the gallateci flavanols seem to be more effective inhibitors of a- 
glucosidase enzymes at physiologically relevant concentrations, which may 
explain the medicinal use of green tea as an anti-diabetic treatment in some
cultures.
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Maltase IC50 
(pM)
Sucrase IC50 
(pM)
(-)-Epicatechin (2R, 3R) 770 1080
(+)-Epicatechin (2S, 3S) 1320 Not measured
(-)-Catechin (2S, 3R) 1890 Not measured
(+)-Catechin (2R, 3S) 4320 Not measured
Epigallocatechin : 1260 921
Epicatechin gallate 53 172
Epigallocatechin gallate 40 169
Theaflavin 500 >10,000
Theaflavln-3-O-gallate (3 ’R) 10 1024
Theaflavin-3-O-gallate (3’S) 83 Not measured
Table 4.1 Concentration of flavanols required to inhibit the activity of maltase 
(EC 3.2.1.20) and sucrase (EC 3.2.1.48) by 50% (IC50) taken from Matsui et 
al (2007).
Plant extracts containing relatively high concentrations of polymerised 
flavanols such as grape seed extract have been assayed to determine the 
efficacy of a-glucosidase inhibition and protein binding. Sucrase activity in 
the Caco-2 cell model was reduced by 61% in the presence of 0.3 g L'1 pre­
digested grape seed extract containing approximately 54% flavanols with a 
degree of polymerisation greater than dimer (Laurent et al. 2007). The 
protein binding capacity of flavanols, ranging from monomer to hexamer 
extracted from grape seed, was assessed by fluorescence quenching of 
tryptophan residues in bovine serum albumin and a-amylase (Soares et al. 
2007). Flavanols with a higher molecular weight (MW) exerted greater 
quenching capacity of a-amylase tryptophan residues than the smaller 
molecules, and flavanols with a gallate moiety were more effective than non-
i
gallated compounds. Tannic acid, a large phenolic compound with MW 
1701.2, exerted the strongest fluorescence quenching capacity.
Tannic acid has been described to inhibit human salivary a-amylase by a 
mixed mode (Kandra et al. 2004) and similarly Inhibits sucrase by mixed- 
type at physiological pH 7.2 (Gupta et al. 2010). The authors reported that 
binding of the phenolic compound altered the tertiary structure of the 
enzyme such that tryptophan residues in the active site became more 
exposed to the hydrophilic environment.
Synergistic effects between individual compounds and extracts have also 
been reported. Mulberry extract combined with either roselle, 
chrysanthemum or butterfly pea extract enhanced maltase inhibition 
compared with mulberry extract alone. Similarly, roselle extract combined 
with either chrysanthemum, mulberry, bael or butterfly pea extract increased 
a-amylase inhibition compared with roselle extract alone (Adisakwattana et 
al. 2012). The combined pure compounds quercetin and myricetin, hyperin 
and avicularin, kaempferol and quercetin increased sucrase and maltase 
inhibition compared with the compounds assayed individually; a-amylase 
was not affected (Wang etal. 2010).
The aim of this investigation was to determine whether flavanol-rich dark 
chocolate extract and individual flavanol components were able to inhibit the 
hydrolysis of sucrose in the Caco-2 cell model.
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4.3 Results
4.3.1 Analytical protocol validation
4.3.1.1 Linearity, precision, limit of detection and limit of quantification
4.3.1.1.1 Glucose oxidase/peroxidase assay
Calibration solutions in the range 0-80 pg mL'1 were assayed using the 
glucose oxidase/peroxidase method and a calibration curve of absorbance 
at 540 nm as a function of glucose concentration prepared. The linear 
regression equation was obtained, with the y-intercept fixed at zero the 
gradient = 0.014 and the adjusted R-square = 0.99, suggesting good 
proportionality of absorbance and concentration
Figure 4.1V The relative standard deviation of absorbance was calculated for 
each concentration of glucose, and ranged from 2.2 to 12.7% indicating that 
precision of the method was acceptable. The limit of detection was 
calculated as 1.9 pg mL'1 and the limit of quantification as 5.7 pg mL'1.
Figure 4.1 Glucose oxidase/peroxidase assay calibration curve; gradient = 
0.014, adjusted R-square = 0.99. Mean ± standard error of the mean (n=3).
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The rate of sucrose hydrolysis in Caco-2 cells co-incubated with a cocoa 
powder extract provided by Nestlé, was investigated using the glucose 
oxidase/peroxidase method to determine glucose concentration in the 
sample. At this point it was observed that the cocoa powder extract inhibited 
the activity of enzymes in the glucose/oxidase assay. To overcome 
interference a solid phase extraction procedure, using hydrophilic-lipophilic 
balanced cartridges, was trialled to assess whether the interfering 
compounds could be removed from the sample. Whilst the extraction 
improved glucose measurement in the presence of cocoa powder, some 
glucose was retained by the adsorbent (RguæJL2). In addition this process 
was labour intensive and time-consuming such that alternative methods of 
glucose analysis were investigated.
Figure 4.2 Absorbance of glucose calibration solutions, determined using the 
glucose oxidase/peroxidase method, following incubation in the absence and 
presence of a cocoa powder extract, with (+ SPE) and without (No SPE) 
solid phase extraction. Mean ± SEM (n=3).
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4.3.1.1.2 HPLC-IPAD
Data analysis was performed over a 15 month period with a 3 month break 
between December 2010 and March 2011. At the beginning of each 
analytical period calibration solutions in the range 0-500 pM were analysed 
to ensure accurate data analysis and compare equipment function. 
Calibration curves of peak area as a function of glucose or fructose 
concentration were prepared (Figure 4.3A and Bl  The linear regression 
equation was obtained with the y-intercept fixed at zero the gradient for 
glucose and fructose were calculated as 0.19 and 0.16, respectively, and the 
adjusted R-square was 1.0 for each, suggesting good proportionality of peak 
area and concentration (Figure 4.3A and B1. The relative standard deviation 
(RSD) of peak area was calculated for each concentration of glucose and 
fructose, and ranged from 0.7 to 11.2% and 0.8 to 8.7%, respectively. The 
limit of detection and limit of quantification were calculated as 0.02 pM and 
0.06 pM for glucose and 0.01 pM and 0.04 pM for fructose.
Precision of the analytical method at the beginning of the second analytical 
period, determined by calculation of RSD, remained acceptable although 
there was a loss of sensitivity reflected in lower gradients and higher limits of 
detection (LOD) and quantification (LOQ). Glucose: gradient = 0.14, LOD = 
0.44 pM, and LOQ = 1.32 pM; fructose: gradient = 0.12, LOD = 0.05 pM, 
and LOQ = 0.14 pM.
Figure 4.4 represents a typical chromatogram of 200 pM calibration solution 
containing fucose, glucose, fructose and sucrose. Fucose was used as an 
internal standard. Figure 4.5 demonstrates the presence of sucrose in a 
basolateral cell culture sample.
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Figure 4.3 A) Glucose, and B) fructose HPLC-IPAD calibration curves. A) 
Gradient = 0.19, adjusted R-square = 1.0. B) Gradient = 0.16, adjusted R- 
square = 1.0. Mean ± standard error of the mean (n=3).
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Figure 4.4 HPLC-IPAD chromatogram representing peaks of fucose, 
glucose, fructose and sucrose, from left to right. Concentration of each = 200 
pM.
Figure 4.5 HPLC-IPAD chromatogram demonstrating the presence of 
sucrose in a basolateral cell culture sample. Fucose was added as the 
internal standard.
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4.3.2 Cell culture
4.3.2.1 Validation of cell membrane integrity
Trans-epithelial electrical resistance (TEER) was measured before the 20 
min incubation and corrected to account for resistance of the polycarbonate 
membrane to provide a measure of the cell monolayer resistance. Mean 
TEER varied from 130 to 464 (Table 4.2). The rate of sucrose hydrolysis 
significantly correlated with TEER even when the assay condition was 
controlled for, p<0.01 (Figure 4.6). An association between TEER and cell 
passage number was considered but no significant correlation existed, 
whereas the rate of sucrose hydrolysis and passage number did correlate 
significantly, p<0.001 (Figure 4.7V However, controlling for the condition and 
passage number did not alleviate the significant correlation between TEER 
and rate of sucrose hydrolysis, p<0.01. During 2010, after the first period of 
cell culture assays whilst a new batch of cells was being prepared for the 
second period of cell culture assays, cell clumping was observed in culture 
flasks. It was proposed that high glucose concentration in the media may be 
a contributing factor to cells forming clumps in which rather than remaining 
as a monolayer they began to stack on top of one another. The 
concentration of glucose in the culture media was reduced from 25 mM to 5 
mM which resulted in a general lowering of TEER of the cell monolayer. 
TEER and rate of sucrose hydrolysis significantly correlated with media 
glucose concentration, p<0.001 (Figure 4.8A and B1. Controlling for the 
assay condition, passage number and media glucose concentration 
removed any significant correlation between the rate of sucrose hydrolysis 
and TEER. In assays where the TEER of the test condition differed
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significantly from the control condition partial correlation analysis, controlling 
for the condition, was performed and confirmed there was no association 
between TEER and the rate of hydrolysis, p>0.05.
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Condition TEER (Ohms)
Control Test
200 pM Acarbose 195 236**
100 pM Acarbose 209 310**
50 pM Acarbose 319 385***
DCa extract 322 pM epicatechin 213 254**
DC extract 141 pM epicatechin 443 403
DC extract ethyl acetate fraction 65 pM epicatechin 443 463
DC extract ethyl acetate fraction <1 pM epicatechin 443 437
500 pM (-)-Epicatechin 334 332
200 pM (-)-Epicatechin 195 285**
200 pM (-)-Epicatechin 130 177
200 pM (-)-Epicatechin 392 423*
100 pM (-)-Epicatechin 160 187
100 pM (-)-Epicatechin 209 424***
50 pM (-)-Epicatechin 319 415***
20 pM (-)-Epicatechin 392 434**
200 pM (+)-Epicatechin 195 289**
200 pM (+)-Epicatechin 392 . 417
100 pM (+)-Epicatechin 209 405***
50 pM (+)-Epicatechin 319 402**
20 (+)-Epicatechin 392 424*
200 pM (+)-Catechin 337 447***
100 pM (+)-Catechin 209 363**
50 pM (+)-Catechin 319 403***
20 pM (+)-Catechin 337 464***
200 pM (-)-Catechin 337 409*
100 pM (-)-Catechin 209 367**
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Condition TEER (Ohms)
Control Test
50 pM (-)-Catechin 319 405**
20 pM (-)-Catechin 337 447**
100 pM Procyanidin B2 209 319**
50 pM Procyanidin B2 319 401**
Table 4.2 Blank-corrected Caco-2 cell monolayer trans-epithelial electrical 
resistance (TEER) for each assay condition investigated. Mean ± SEM. 
Abbreviation: DC, dark chocolate. Asterisk denotes a significant difference 
from the control, *p<0.05, **p<0.01 and ***p<0.001.
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Figure 4.6 Rate of sucrose hydrolysis plotted against mean ± SEM trans 
epithelial electrical resistance (n=163).
Figure 4.7 Rate of sucrose hydrolysis as a function of cell passage number.
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Figure 4.8 A) Trans-epithelial electrical resistance, and B) rate of sucrose 
hydrolysis as a function of glucose concentration in the cell culture media.
- * *
111
4.3.3 Sucrose hydrolysis study
4.3.3.1 Kinetic investigation
The kinetic properties of sucrose hydrolysis were determined using the 
glucose oxidase/peroxidase assay to measure glucose concentration. To 
establish the most appropriate sucrose concentration the kinetic properties 
were assessed using the Michaelis-Menten model. Assays of 1-120 mM 
sucrose revealed a typical hyperbolic growth curve when rate of hydrolysis 
was plotted against sucrose concentration (Figure 4.91. The maximum rate 
of hydrolysis (Vmax) = 20.5 nmol min'1, and Michaelis constant (KM) = 19.3 
mM, was calculated from nonlinear regression analysis using the Michaelis- 
Menten function and rearrangement of the Michaelis-Menten equation. 
Subsequent assays were performed using 20 mM sucrose as this was within 
the linear range of the curve signifying that the enzyme was not saturated.
Figure 4.9 Plot of rate of hydrolysis against sucrose concentration with 
Michaelis-Menten nonlinear regression analysis. Mean ± SEM (n=3).
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4.3.3.2 Inhibition investigation
The effect of dark chocolate extract and flavanol monomers and dimers on 
sucrose hydrolysis was investigated with the rate of sucrose hydrolysis 
calculated based on the concentration of mean glucose and fructose 
concentrations in the samples. Acarbose, an anti-diabetic prescription drug 
which inhibits the activity of carbohydrate hydrolysing enzymes, was used as 
a positive control. The total flavanol profile of monomers to decamers for the 
dark chocolate extracts and ethyl acetate fractions used in this investigation 
are displayed in Table 4.3. The mean concentration of glucose and fructose 
in each dark chocolate extract and ethyl acetate fraction is also presented. 
Acarbose dose-dependently inhibited the rate of sucrose hydrolysis up to 
93%, p<0.001 (Table 4.41. Dark chocolate extract containing 322 pM 
flavanol monomers significantly reduced the rate of sucrose hydrolysis by 
59% (p<0.01). Dark chocolate extract containing 141 pM flavanol monomers 
and ethyl acetate fractions containing £65 pM flavanol monomers had no 
significant effect (Figure 4.10). Inhibition of sucrose hydrolysis in the 
presence of (-)-epicatechin was only significant at the highest concentration 
investigated (500 pM) = 31% inhibition, p<0.001 (Figure 4.11V A 10-fold 
lower concentration of (-)-epicatechin (50 pM) significantly enhanced 
sucrose hydrolysis by 56%, p<0.01. All other concentrations of (-)- 
epicatechin investigated did not elicit a significant effect. The (+)-epicatechin 
enantiomer also significantly enhanced sucrose hydrolysis, by 60%, at 
concentrations of 50 and 100 pM, p<0.05 and p<0.01 respectively (Figure 
4.13A). Other concentrations of (+)-epicatechin investigated, 20 and 200 pM, 
did not significantly affect the rate of sucrose hydrolysis. The (+) and (-)- 
catechin enantiomers demonstrated significant enhancement of sucrose
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hydrolysis at a concentration of 50 pM, increasing it by 51% (p<0.05) and 
64% (p<0.01), respectively (Figure 4.12A and B). Similarly, procyanidin B2 
significantly enhanced sucrose hydrolysis by 26% at a concentration of 50 
pM, p<0.05. All other concentration of (+)-catechin, (-)-catechin and 
procyanidin B2 did not produce a significant moderation of sucrose 
hydrolysis in Caco-2 cells.
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Total flavanol content of dark chocolate extract3 and ethyl 
acetate fractions0 (mg) / Monosaccharide concentration (pM) 
Degree o f --------------------------------------------------------------------------------------------------------
polymerisation Flavanol m onom ers (jjM ) 
322s 141a 65* <1b
Monomer 3.09 1.36 0.63 0.01
Dimer 1.95 0.14 0.06 0.03
Trimer 0.49 0.04 0.02 0.01
Tetramer 0.31 0.02 0.01 0.0
Pentamer 0.12 0.01 0 0
Hexamer 0.05 0 0 0
Heptamer 0.03 0 0 0
Octamer 0.02 0 0 0
Nonamer 0.01 0 0 0
Decamer 0.01 0 0 0
Monosaccharide 377 120 4 0
Table 4.3 Total flavanol content (mg) and monosaccharide concentration 
(pM) of dark chocolate extract3 and ethyl acetate fractions'3 used to 
investigate the effect on sucrose hydrolysis in Caco-2 cells.
Condition Rate of hydrolysis 
(nmol min'1)
Control T est
A% Statistical
analysis
Acarbose (pM)
50 3.42 1.19 ¿65 p<0.001
100 8.13 0.60 ¿93 p<0.001
200 3.32 0.24 ¿93 p<0.001
Table 4.4 Rate of hydrolysis for each concentration of acarbose investigated 
along with the corresponding control value, and percentage change relative 
to the control. Mean (n£3).
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Figure 4.10 Rate of sucrose hydrolysis as a percentage of control following 
incubation of Caco-2 cells with dark chocolate extract and ethyl acetate 
fractions containing 322, 141, 65 and <1 pM flavanol monomers. Horizontal 
line at 100% represents the control. Mean ± SEM (n=6). Asterisk denotes a 
significant difference from the control **p<0.01.
Figure 4.11 Rate of sucrose hydrolysis as a percentage of control following 
incubation of Caco-2 cells (-)-epicatechin ranging from 20-500 pM. 
Horizontal line at 100% represents the control. Mean ± SEM (n^3). Asterisk 
denotes a significant difference from the control; **p<0.01, ***p<0.001.
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Figure 4.12 Rate of sucrose hydrolysis as a percentage of control following 
incubation of Caco-2 cells with A) (+)-catechin and B) (-)-catechin. Horizontal 
line at 100% represents the control. Mean ± SEM (n>3). Asterisk denotes a 
rate of hydrolysis that is significantly different from the control; *p<0.05, 
**p<0.01.
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Figure 4.13 Rate of sucrose hydrolysis as a percentage of control following 
incubation of Caco-2 cells with A) (+)-epicatechin and B) procyanidin B2. 
Horizontal line at 100% represents the control. Mean ± SEM (n£3). Asterisk 
denotes a rate of hydrolysis that is significantly different from the control; 
*p<0.05, **p<0.01.
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4.4 Discussion
4.4.1 Cell culture validation
Validation of Caco-2 cell monolayer integrity highlighted the importance of 
establishing and maintaining a rugged cell culture protocol. Changes in 
glucose concentration, and potentially other nutrients, of the culture media 
significantly affected trans-epithelial electrical resistance (TEER) and the 
rate of sucrose hydrolysis. Overall diminishing rate of sucrose hydrolysis 
was associated with increasing cell passage number, which indicates that 
conducting experiments within a range that is as narrow as possible is 
essential for eliminating sources of error in the results. TEER has been 
reported to increase significantly with increasing cell passage number 
(BriskeAnderson et al. 1997), however in the investigation presented here 
this was not observed.
4.4.2 Analytical protocol validation
Interference of the glucose oxidase/peroxidase assay by polyphenols has 
been reported (Nishioka et al. 1998, Shaukat and Waqar 2011, Xu et al.
2012). Reduced glucose determination was associated with prevention of 
chromophore formation and hydrogen peroxide scavenging resulting in 
oxidation of the active component, epigallocatechin gallate (Shaukat and 
Waqar 2011). Investigations whereby glucose concentration has been 
quantified using the glucose oxidase/peroxidase assay in the presence of 
polyphenols require validation to confirm that the assay is not hindered by 
the presence of the polyphenolic component. In the event that this does
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occur, a suitable extraction procedure should be incorporated or an 
alternative method of glucose measurement developed.
4.4.3 Inhibition of sucrose hydrolysis
The greatest reduction of sucrose hydrolysis in Caco-2 cells was measured 
following incubation with 100 and 200 pM acarbose. Dark chocolate extract 
containing 322 pM flavanol monomers also significantly reduced the rate of 
sucrose hydrolysis. In order to determine whether the reduction was 
attributable to one specific flavanol monomer or dimer constituent of the 
extract the rate of sucrose hydrolysis was measured in the presence of (-)- 
epicatechin, (+)-catechin and procyanidin B2. Inhibition of sucrose hydrolysis 
was observed in the presence of 500 pM (-)-epicatechin, neither (+)-catechin 
or procyanidin B2 elicited a significant reduction. This supports the findings 
of Matsui et al (2007) and Kamiyama et al (2010) that report the necessity 
for a high concentration to achieve 50% inhibition of activity. These results 
suggest that inhibition of sucrose hydi olysis in the presence of dark 
chocolate extract containing 322 pM flavanol monomers may be partly 
attributable to the (-)-epicatechin component. It may be that a synergistic 
effect occurs between the different flavanol monomers, oligomers and 
polymers similar to the synergistic inhibition of sucrase reported for flavonols 
and flavonol glycosides (Wang etal. 2010).
Each of the flavanol monomers and B2 dimer enhanced the rate of sucrose 
hydrolysis at concentrations of 50 pM. Gupta et al (2010) proposed that 
binding of a phenolic compound such as tannic acid to a-amylase altered the 
tertiary structure such that tryptophan residues in the active site became 
more exposed to the hydrophilic environment. It may be that flavanol
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monomers and dimers are able to bind sucrase in two locations, one that 
induces a change in the structure of the enzyme exposing more of the 
catalytic residues subsequently enhancing activity, and the second at the 
active site causing inhibition of activity. This could explain how moderate 
concentrations appear to enhance enzyme activity and higher 
concentrations are inhibitory. At concentrations between, there is no 
apparent significant change due to the enhancement and inhibition 
counteracting one another. This supports previous evidence which shows 
that relatively high concentrations of non-gallated flavanol monomers are 
necessary to achieve 50% inhibition of enzyme activity (Matsui et at. 2007, 
Lo Piparo et at. 2008, Kamiyama etaf. 2010). In order to determine whether 
stereochemical configuration of the flavanol monomer affects the inhibitory 
capacity, higher concentrations of each enantiomer must be investigated. 
Enhancement of sucrase activity by each of the flavanol monomers and B2 
dimer does not significantly differ between the groups indicating that 
stereochemical configuration of the B-ring and of the C-ring hydroxyl group 
is not a contributing factor. Superficially the degree of polymerisation also 
appears to be inconsequential although further investigations using more 
polymerised flavanols are required to confirm this proposal.
Sustained augmentation of sucrase activity measured following incubation 
with 100 pM (+)-epicatechin may suggest that the 2S, 3S configuration 
restricts effective binding at the active site, thereby preventing a relative 
reduction of sucrose hydrolysis, as observed with the other flavanol 
monomers at this concentration.
Previous studies that have investigated the effect of phenolic compounds on 
a-glucosidase activity have suggested that the number of hydroxyl groups,
stereochemical configuration of the C-ring hydroxyl and conjugation of the 
AC-ring system is of importance to the inhibition of sucrase, maltase and a- 
amylase (Matsui et al, 2007, Wang étal, 2010(Lo Piparo étal. 2008). Based 
on the results of the investigation presented here it would be necessary to 
compare the inhibitory profile of flavanols with compounds that contain the 
conjugated AC-ring system and the same number of hydroxyl groups, for 
example epicatechin and quercetin. It would also be beneficial to compare 
the inhibitory capacity of epicatechin with epigallocatechin and epicatechin- 
3-O-gallate to investigate whether the addition of hydroxyl groups affect 
sucrase inhibition in the Caco-2 model.
Analysis of the kinetic properties of sucrase in the absence and presence of 
flavanols would suggest a method by which inhibition occurs. Further 
analysis of the protein structure-activity association may be confirmed using 
fluorescence quenching techniques or computational ligand docking 
software.
4.5 Conclusion
Sucrose hydrolysis in the Caco-2 cell model was reduced as a consequence 
of incubation with a flavanol-rich dark chocolate extract. The (-)-epicatechin 
content of the dark chocolate extract is considered to be partly responsible 
and a synergistic effect with other flavanol components is proposed to 
account for the difference of inhibitory capacity between the dark chocolate 
extract and individual compound. Multiple binding sites on the enzyme are 
hypothesised to be the reason for elevated sucrose hydrolysis at moderate 
concentrations of each flavanol monomer and dimer investigated. 
Prospective studies should include investigation of stereochemical
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configuration effects. Synergy between the flavanol components requires 
attention along with considering whether degree of polymerisation 
contributes to the overall effect. Kinetic analysis of sucrose hydrolysis in the 
Caco-2 cell model along with other structure-activity analytical methods may 
provide insight to the mechanism and binding properties of dark chocolate 
flavanols in relation to sucrase.
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Chapter 5 Glucose transport inhibition by a flavanol-rich 
dark chocolate extract
5.1 Abstract
Glucose transport across the Caco-2 cell monolayer was significantly 
reduced in the presence of a flavanol-rich dark chocolate extract containing 
35, 71, 142 and 322 pM epicatechin. Kinetic analysis revealed that the 
maximum rate of cellular uptake and apical to basolateral transport was 
significantly attenuated; this was dose-dependent for apical to basolateral 
transport. The concentration of glucose required to achieve half the 
maximum rate of apical to basolateral transport (Km) was significantly 
increased, independent of the dose investigated. Overall inhibition was of 
the mixed-type, with non-competitive inhibition being tentatively attributed to 
the apical sodium-dependent glucose transporter SGLT1 and competitive 
inhibition attributed to the basolateral glucose transporter GLUT2. Inhibition 
was not shown to be the result of individual flavanol monomer or B2 dimer 
components of the dark chocolate extract but is hypothesised to be a 
consequence of higher molecular weight flavanols or a synergistic effect 
between monomers and dimers. Caffeine, theobromine, procyanidin B2 and 
(+)-epicatechin increased the rate of cellular uptake but not apical to 
basolateral transport. The role of caffeine and theobromine as inhibitors of 
cyclic 3’, 5’-nucleotide phosphodiesterase and the potential for enhanced 
SGLT1 activity is considered and discussed in relation to the results 
presented here.
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5.2 Introduction
Cellular uptake of glucose is primarily a secondary active process performed 
by the high-affinity sodium-dependent transporter SGLT1, KM = 0.8 mM 
(Hediger and Rhoads 1994), that can transport glucose against its 
concentration gradient permitting uptake even when the concentration of 
glucose in the lumen is low. By contrast during post-prandial periods when 
the concentration of glucose in the lumen is high, glucose uptake is assisted 
by the sodium-independent hexose transport GLUT2 (Kellett and Brot- 
Laroche 2005). GLUT2 facilitates diffusion of glucose along its concentration 
gradient and although it has less affinity for glucose than its sodium- 
dependent counterpart, Km = 17 mM (Thorens 1996), it possesses a high 
capacity for glucose transport.
A number of in vitro and ex vivo studies have investigated the interaction of 
flavonoids with intestinal glucose transporters. The majority of these focus 
on the effects of flavonols, in particular quercetin and its glycosides. It is now 
widely accepted that flavonoid glycosides are either deglycosylated by 
lactase phloridzin hydrolase (LPH) located at the epithelial brush border 
allowing the aglycone to diffuse into the cell, or alternatively the glycoside is 
transported into the cell via the sodium-dependent glucose transporter 
SGLT1, before being deglycosylated by cytosolic (3-glucosidase. Entry of 
both the aglycone and glycoside has been established through detection of 
phase II metabolites of the aglycone.
Whilst quercetin-3-O-glucoside and 4-O-glucoside have been observed to 
competitively inhibit the sodium-dependent uptake of glucose (Ader et al. 
2001, Cermak et al. 2004), few studies report the ability of flavonoid
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aglycones to reduce SGLT1 activity. Of three investigations to report 
significant reduction in sodium-dependent glucose uptake by non- 
glycosylated flavonoids, only one reported inhibition with physiologically 
realistic concentrations. Significant reduction of sodium-dependent glucose 
uptake was observed in Caco-2 cells with 100 pM (+)-catechin, (-)- 
epicatechin, epigallocatechin, epicatechin gallate and epigallocatechin 
gallate (Johnston et al. 2005). Studies prior to this also demonstrated 
inhibition of sodium-dependent glucose transport by epicatechin gallate and 
epigallocatechin gallate although the concentrations required to elicit a 
similar reduction were much greater, up to 1 mM (Kobayashi et al. 2000, 
Hossain et al. 2002). Hossain et al (2002) also reported inhibition of sodium- 
dependent glucose transport by catechin, however the inhibition constant 
(K) was approximately 2.3 mM. The type of inhibition reported in these 
studies was contradictory; Kobayashi et al (2000) suggested competitive 
inhibition whereas Hossain et a /(2002) proposed non-competitive.
Reports of sodium-independent glucose transport inhibition by non- 
glycosylated flavonoids are more prominent. In Caco-2 cells and Xenopus 
Oocytes, quercetin was reported to attenuate glucose uptake at 
physiologically relevant concentrations (Johnston et al. 2005, Kwon et al. 
2007); the latter suggesting a non-competitive mode of inhibition. 
Epicatechin gallate and quercetin-3-O-glucoside were also reported to 
competitively inhibit sodium-independent glucose transport at a 
concentration of 100 pM each (Chen et al. 2007).
A more recent investigation of glucose uptake and transport across a Caco-2 
cell monolayer reported the dose-dependent inhibition of both sodium- 
dependent and independent transport in the presence of strawberry or apple
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extract; sodium independent inhibition was more potent as determined by 
the lower concentration required to achieve 50% inhibition (ICso)- Kinetic 
evaluation of the mechanism for transport inhibition indicated mixed-type for 
apical cellular uptake and non-competitive for transport across the 
basolateral membrane. Individual pure compounds were screened for 
inhibitory capacity, and quercetin-3-O-rhamnoside displayed the lowest IC5o 
for inhibition of apical and basolateral transport of those tested. (-)- 
Epicatechin elicited less than 50% inhibition at a concentration exceeding 
500 pM (Manzano and Williamson 2010).
The objective of the investigation presented here was to determine whether 
a flavanol-rich dark chocolate extract, and biologically active components of 
dark chocolate, were able to inhibit glucose uptake into Caco-2 cells and 
transport across the basolateral membrane.
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5.3 R esults
5.3.1 Liquid Scintillation Counting
5.3.1.1 Validation
5.3.1.1.1 Linearity, precision and limit of quantification
A calibration curve of radioactivity as a function of [U-14C]-glucose quantity 
was prepared and the linear regression equation obtained. With the y- 
intercept fixed at zero the gradient was calculated as 2441 and the adjusted 
R-square equal to 1.0, suggesting good proportionality of radioactivity and 
molar quantity (Figure 5.1V The relative standard deviation of radioactivity 
was calculated for each concentration of radiolabelled glucose, and ranged 
from 0.03 to 0.81% indicating that counting precision of the equipment was 
good. The limit of quantification was calculated as 0.02 pmol.
Figure 5.1 [U-14C]-Glucose calibration curve. Mean ± SEM (n=3); gradient = 
2441, adjusted R-square = 1.0.
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5.3.2 Cell culture
5.3.2.1 Validation of cell membrane integrity
Trans-epithelial electrical resistance (TEER) was measured before and after 
the 30 min incubation and corrected to account for resistance of the 
polycarbonate membrane to provide a measure of the cell monolayer 
resistance (Table 5.1). Inter-assay mean TEER measurements taken before 
commencement of the assay showed a large variation ranging from 160 to 
509 Ohms. Partial correlation analysis controlling for the assay condition 
confirmed that basolateral glucose concentration did not correlate with TEER 
measured pre- or post-incubation (Figure 5.2). Pre-incubation TEER value 
was significantly correlated with cell passage number (p<0.001) (Figure 5.31.
Condition TEER (Ohms)
Before After
1 mM Glucose 4231 14 326 19***
Dark chocolate extract 35 pM epicatechin 408±7 3451 10***
0.25 mM Glucose 282 1 11 25919
Dark chocolate extract 71 pM epicatechin 299 1 9 2891 14
0.5 mM Glucose ^ 322 112 2901 12
Dark chocolate extract 71 pM epicatechin 30316 3331 10*
1 mM Glucose 310115 2791 10
Dark chocolate extract 71 pM epicatechin 347 1 5 35617
2 mM Glucose 26916 25416
Dark chocolate extract 71 pM epicatechin 28215 29519
4 mM Glucose 32618 28317
Dark chocolate extract 71 pM epicatechin 321 15 , 3451 11**
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Condition TEER (Ohms)
Before After
7 mM Glucose 402 ± 12 353 ± 14*
Dark chocolate extract 71 pM epicatechin 423 ± 15 423 ± 8
0.25 mM Glucose 443 ± 22 268 ±19***
Dark chocolate extract 142 pM epicatechin 462 ± 17 331 ±13***
0.5 mM Glucose 451 ± 22 311 ±17***
Dark chocolate extract 142 pM epicatechin 497 ± 16 416 ±17**
1 mM Glucose 409 ±3 305 ± 10**
Dark chocolate extract 142 pM epicatechin 398 ± 12 400 ± 5
2 mM Glucose 386 ±14 384 ± 12
Dark chocolate extract 142 pM epicatechin 444 ± 10 404 ±13*
4 mM Glucose 425 ± 15 393 ± 20
Dark chocolate extract 142 pM epicatechin 424 ±6 450 ± 14
7 mM Glucose 509 ±8 322 ± 14
Dark chocolate extract 142 pM epicatechin 475 ± 20 337 ± 12
1 mM Glucose 272 ± 11 259 ± 12
Dark chocolate extract 322 pM epicatechin 254 ± 11 272 ±4
1 mM Glucose 160 ±7 184 ±8
200 pM (-)-Epicatechin 175± 15 187 ±5
200 pM (+)-Epicatechin 252 ± 16 246 ± 11
200 pM (-)-Catechin 276 ±8 265 ±9
1 mM Glucose 236 ± 10 232 ±11
200 pM (+)-Catechin 257 ±7 237 ±6
200 pM Procyanidin B2 313 ±22 273 ±4
1 mM (-)-Epicatechin 346 ±5 278 ± 6***
1 mM Glucose 323 ±7 275 ± 9**
250 pM Caffeine 366 ±6 321 ± 8**
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Condition TEER (Ohms)
Before After
1.68 mM Theobromine 355 ±10 285 ±8**
Table 5.1 Blank-corrected trans-epithellal electrical resistance (TEER) 
measured before and after each assay. Mean ± SEM (n=6) for each 
condition. Asterisk denotes significant difference from the corresponding pre­
incubation measurement, *p<0.05, **p<0.01 and ***p<0.001.
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Trans-epithelial electrical resistance (Ohms)
Figure 5.2 Basolateral concentration of glucose after the 30 min incubation 
in each assay replicate, as a function of mean ± SEM (n=3) trans-epithelial 
electrical resistance per Transwell® insert cell monolayer measured before 
commencement of the assay.
Figure 5.3 Pre-incubation trans-epithelial electrical resistance per 
Transwell® insert monolayer, mean ± SEM (n=3), as a function of cell 
passage number.
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5.3.2.2 [U-14C]-Glucose transport study
The effect of a flavanol-rich dark chocolate extract, containing between 35 to 
322 pM flavanol monomers (Table 5.2). on apical to basolateral transport 
and cellular uptake of glucose was investigated. Biologically active 
components of dark chocolate were also individually assayed to explore the 
possibility that they were able to moderate glucose uptake and transport at 
concentrations relevant to the dark chocolate extract.
Co-incubation of 1 mM glucose with dark chocolate extract dose- 
dependently attenuated the apical to basolateral transport and cellular 
uptake of glucose up to 75% and 68% respectively. Each preparation of dark 
chocolate extract significantly reduced the concentration of basolateral 
glucose, p<0.001 (Figure 5.4A). Dark chocolate extract containing 142 and 
322 pM epicatechin also significantly reduced the cellular concentration of 
glucose, p<0.001 (Figure 5.4B). Of the flavanol monomers and B2 dimer 
tested, none significantly affected the concentration of glucose measured in 
the basolateral compartment (Figure 5.5A); 200 pM of each (+)-epicatechin 
or procyanidin B2 significantly increased cellular glucose concentration by 
20% and 26% respectively (p<0.01) (Figure 5.5B). Caffeine (250 pM) and 
theobromine (1.68 mM) did not significantly affect the basolateral 
concentration of glucose (Figure 5.6A). By contrast the cellular concentration 
of glucose was significantly increased by 25% and 9% in the presence of 
caffeine (p<0.05) and theobromine (p<0.01) (Figure 5.6B).
The kinetic properties of glucose transport in the absence and presence of 
dark chocolate extract containing 71 pM and 142 pM epicatechin were 
investigated. Basolateral and cellular concentration of glucose following 
incubation with initial glucose concentrations ranging from 0.25 to 7 mM are
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displayed in Figure 5.7A and B. Both dark chocolate extract preparations 
significantly reduced the basolateral concentration of glucose at each 
substrate concentration investigated (p<0.01 or p<0.001). Cellular glucose 
concentration was significantly reduced at each substrate concentration 
investigated in the presence of dark chocolate extract containing 142 pM 
epicatechin (p<0.05 and p<0.001) and by dark chocolate extract containing 
71 pM epicatechin at substrate concentrations of 0.25, 4 and 7 mM (p<0.05 
and p<0.001). Graphical representation of apical to basolateral rate of 
transport and cellular uptake as a function of substrate concentration 
demonstrates typical Michaelis-Menten hyperbolic saturation curves in the 
absence and presence of dark chocolate extract (Figure 5.8A and B). 
Nonlinear regression analysis using the Michaelis-Menten equation 
performed on each data set revealed the maximum rate (Vmax) and Michaelis 
constant (KM) of apical to basolateral transport and cellular uptake of cells 
incubated in the presence of substrate only, and when co-incubated with 
each preparation of dark chocolate extract (Table 5.3). The rate of apical to 
basolateral glucose transport was significantly attenuated dose-dependently 
in the presence of dark chocolate extract (p<0 .01), this is indicative of non­
competitive inhibition. The Michaelis-constant was significantly augmented in 
the presence of dark chocolate extract (p<0.05 and p<0.01), independent of 
dose, indicating that transporter affinity for the substrate was reduced due to 
competitive-type inhibition. Together these kinetic parameters suggest that 
dark chocolate extract exerts a mixed-type inhibition of apical to basolateral 
glucose transport.
The rate of cellular glucose uptake was also significantly lower in the 
presence of dark chocolate extract (p<0 .01), dose-independent, suggesting
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non-competitive inhibition of cellular glucose uptake. The Michaelis constant 
significantly diminished in the presence of dark chocolate extract containing 
71 pM epicatechin implying that transporter affinity for the substrate was 
enhanced. Dark chocolate extract containing 142 pM epicatechin did not 
significantly affect the Michaelis constant relative to the control however in 
comparison to the dark chocolate extract containing 71 pM epicatechin it 
was significantly greater (p<0.01). Cellular glucose uptake appeared only to 
be inhibited in a non-competitive manner.
Defatted Dark Chocolate (g)
0.5 1 2 4.5
Total flavanol content (mg g-1 FW)a 
Transport solution concentration 
Flavanol monomers (pM)a 
Flavanol dimers (pM)a 
Caffeine (pM)b 
Theobromine (mM)b
0.7 1.4 2.7 6.1
35 71 142 322
11 22 45 102
62 124 248 563
0.7 1.3 2.7 6.1
Table 5.2 Total flavanol content (monomer to decamer) per gram of dark 
chocolate, fresh weight (FW), and concentration of flavanol monomers and 
dimers, caffeine and theobromine in the transport solution prepared using 
defatted dark chocolate. aBased on empirical measurement of flavanol 
content of an extract prepared using 1 g of defatted dark chocolate. 
Calculated from values reported in the USDA Nutrient Database (U.S. 
Department of Agriculture 2011).
DC Extract 322 pM EC
DC Extract 142 pM EC
DC Extract 71 pM EC
DC Extract 35 pM EC
Control
I _ 1 Apical 
I I Basolateral
[Glucose] (pM)
DC Extract 322 pM EC 
DC Extract 142 pM EC 
DC Extract 71 pM EC 
DC Extract 35 pM EC 
Control
Cellular [Glucose] (pM)
B
Figure 5.4 (A) Apical and basolateral, and (B) cellular concentration of 
glucose following a 30 min incubation of Caco-2 cells with 1 mM glucose in 
the absence (control) and presence of dark chocolate (DC) extract 
containing 35, 71, 142 or 322 pM epicatechin (EC). Control concentration 
equates to rate of apical to basolateral transport 5.9 ± 0.2 pM min'1 and rate 
of cellular uptake 0.41 ± 0.02 pM min'1. Mean ± SEM (n=£6). Asterisk 
denotes a significantly different basolateral or cellular concentration relative 
to the control, ***p<0.001.
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I | Apical
I I Basolateral
1 mM (-)-Epicatechin 
200 pM Procyamdin B2 
200 pM (+)-Catechin 
200 pM (-)-Catechin 
200 pM (+)-Epicatechin 
200 pM (-)-Epicatechin 
Control
[Glucose] (pM)
A
B
1 mM (-)-Epicatechin 
200 pM Procyanidin B2 
200 pM (+)-Catechin 
200 pM (-)-Catechin 
200 pM (+)-Epicatechin 
200 pM (-)-Epicatechin 
Control
Cellular [Glucose] (pM)
Figure 5.5 (A) Apical and basolateral, and (B) cellular concentration of 
glucose following a 30 min incubation of Caco-2 cells with 1 mM glucose in 
the absence (control) and presence of flavanol monomers and B2 dimer. 
Control concentration equates to rate of apical to basolateral transport 6.1 ± 
0.2 pM min'1 and rate of cellular uptake 0.36 ± 0.03 pM min'1. Mean ± SEM 
(n=£6). Asterisk denotes a significantly different cellular concentration 
relative to the control, **p<0.01.
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1.68 mM Theobromine
250 pM Caffeine
Control
B ApicalBasolateral
200 400 600
[Glucose] (pM)
800 1000
1.68 mM Theobromine
250 |jM Caffeine
Control
Cellular [Glucose] (^M)
a
Figure 5.6 (A) Apical and basolateral, and (B) cellular concentration of 
glucose following a 30 min incubation of Caco-2 cells with 1 mM glucose in 
the absence (control) and presence of caffeine and theobromine. Control 
concentration equates to rate of apical to basolateral transport 6.0 ±0.1 pM 
min'1 and rate of cellular uptake 0.29 ± 0.00 pM min'1. Mean ± SEM (n=6). 
Asterisk denotes a significantly different cellular concentration relative to the 
control, *p<0.05 and **p<0.01.
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[Glucose] (mM)
B
Figure 5.7 (A) Basolateral and (B) cellular concentration of glucose following 
a 30 min incubation of Caco-2 cells with 0.25-7 mM glucose in the absence 
(no extract) and presence of dark chocolate (DC) extract containing 71 or 
142 pM epicatechin (EC). Values are mean ± SEM (n=26). Asterisk denotes 
significant difference from the corresponding no extract value, *p<0.05,
**p <0 .01 , ***p <0 .001 .
♦ No Extract
Figure 5.8 Rate of (A) apical to basolateral transport and (B) cellular uptake 
of glucose following a 30 min incubation of Caco-2 cells with 0.25-7 mM 
glucose in the absence (no extract) and presence of dark chocolate (DC) 
extract containing 71 or 142 pM epicatechin (EC). Mean ± SEM (n=£6).
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Apical to Basolateral Cellular Uptake
Vmax KM Vmax KM
(pMmin-1) (mM) (pMmin-1) (mM)
No Extract 27.2 ± 0.9 3.5 ±0.3 1.3 (0.1) 2.2 (0.2)
DC Extract 
71 pM EC
21.3 ±0.7** 5.2 ± 0.3** 0.9 (0.04)** 1.3 (0.2)*
DC Extract 
142 pM EC
11.2 ± 0.3**t 4.6 ± 0.2* 1.0 (0.1)** 2.7 (0.3)t
Table 5.3 Michaelis-Menten kinetic properties of cellular uptake and apical to 
basolateral transport of glucose in the absence (no extract) and presence of 
dark chocolate (DC) extract containing 71 pM or 142 pM epicatechin (EC). 
Values are mean ± SEM (n£6) per condition. Asterisk denotes significant 
difference from the corresponding no extract value, *p<0.05 and **p<0.01 
and |  denotes significant difference from the corresponding DC extract 
containing 71 pM EC (p<0.01).
5.3.3 Solid phase extraction of flavanol fractions
Separation of dark chocolate extract fractions was achieved using a solid 
phase extraction (SPE) procedure based on the HPLC-FLD method of 
flavanol monomer to decamer quantification. Comparison of the whole 
extract not subjected to SPE l Figure 5.9) with the total flavanols obtained 
following SPE, calculated as the sum of each SPE step, displayed very 
similar concentrations indicating that most of the flavanols monomer to 
decamer were collected (Table 5.4). Monomers mainly eluted with the ‘initial’ 
pass of sample (Figure 5.10A) and the water wash phases. Dimers eluted 
equally across each phase except the final organic solvent elution step 
demonstrating no preference for aqueous or organic solvent. The larger 
compounds with a greater degree of polymerisation appeared to be retained 
by the sorbent material more strongly. Trimeric flavanols, in total, eluted
equally between the aqueous and organic solvents although a preference for 
the organic solvent was observed with the majority of the compound eluting 
with the first organic solvent elution step (Figure 5.1 OB). A small amount of 
tetramer and pentamer were collected in the aqueous wash phases however 
the majority of each was collected following the first organic solvent elution. 
The remaining compounds, hexamer to decamer, were eluted in the organic 
solvent elution only.
It was intended that the aqueous fractions combined, rich in flavanols 
monomer and dimer, and the fractions eluted with organic solvent, 
containing relatively few flavanol monomers and dimers but rich in trimers to 
decamers, would be used in the assay of glucose transport to determine 
whether either fraction replicated the effect of the whole dark chocolate. This 
would help to elucidate the main compounds responsible for inhibition of 
glucose transport. Due to lack of time remaining this assay was not 
performed but is recommended for future work in order to contribute to the 
understanding of glucose transport inhibition by dark chocolate extract.
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Concentration (pg mL'1)
Polymerisation A B C D E F G
Monomer 275.5 274.7 171.5 20.8 3.9 746.5 771.9
Dimer 35.1 42.5 30.9 39.9 4.0 152.6 145.5
Trimer 5.7 11.5 15.4 28.8 2.1 63.5 54.8
Tetramer 0.5 2.4 4.2 14.8 1.3 23.2 20.6
Pentamer 0.0 0.3 0.8 9.7 1.2 12.0 11.2
Hexamer 0.0 0.0 0.0 4.6 0.9 5.4 7.1
Heptamer 0.0 0.0 0.0 1.9 0.5 2.4 2.5
Octamer 0.0 0.0 0.0 0.7 0.2 1.0 1.1
Nonamer 0.0 0.0 0.0 0.3 0.1 0.4 0.5 •
Decamer 0.0 0.0 0.0 0.2 0.1 0.2 0.2
Table 5.4 Flavanols monomer to decamer determined by HPLC-FLD in 
fractions of dark chocolate extract separated by a solid phase extraction 
(SPE) procedure. A = initial collection of aqueous sample following SPE, B = 
first aqueous wash, C = second aqueous wash, D = first organic solvent 
elution, E = second organic solvent elution, F = total of all SPE steps A to E, 
and G = whole dark chocolate extract before SPE separation of fractions.
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Retention Time (min)
Figure 5.9 HPLC-FLD chromatogram of whole dark chocolate extract 
flavanols monomer to decamer before solid phase extraction separation of 
fractions. Peak numbers represent the degree of polymerisation; 1 = 
monomer, 2 = dimer, etc.
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Retention Time (min)
Figure 5.10 HPLC-FLD chromatogram of A) initial aqueous fraction collected 
following solid phase extraction, and B) the first organic solvent wash of 
sorbent retained compounds. Peak numbers represent the degree of 
polymerisation; 1 = monomer, 2 = dimer, etc.
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5.4 Discussion
Preparations of flavanol-rich dark chocolate extract containing 35, 71, 142 
and 322 pM epicatechin were shown to reduce basolateral glucose 
concentration in a dose-dependent manner. Cellular concentration of 
glucose was also dose-dependently reduced but only in the presence of dark 
chocolate extract containing 142 and 322 pM epicatechin. Glucose uptake 
into epithelial cells is predominantly governed by the sodium-dependent 
secondary active cotransporter SGLT1 and efflux from the basolateral 
membrane is maintained entirely by passive diffusion facilitated by the 
sodium-independent GLUT2. Kinetic analysis of apical to basolateral 
transport and rate of cellular uptake revealed that glucose transport and 
uptake reached saturation as substrate concentration increased; this is 
indicative of active transport. In the study presented here it is evident that 
the predominant mechanism of glucose transport is via the sodium- 
dependent cotransporter SGLT1.
The highest concentrations of epicatechin-containing dark chocolate extract, 
142 and 322 pM, significantly reduced the concentration of cellular glucose 
which could be considered responsible for the observed reduction in 
basolateral glucose concentration, however at the lowest concentrations of 
epicatechin-containing dark chocolate extract, 35 and 71 pM, the basolateral 
glucose concentration was significantly reduced without a corresponding 
reduction of cellular glucose concentration. If the cellular uptake of glucose 
remained constant a reduction in basolateral glucose concentration would be 
expected to create an accumulation of glucose within the cell. The absence 
of increased cellular glucose concentration may be a consequence of
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surplus glucose being either metabolised within the cell or effluxed from the 
apical membrane. Alternatively the results may indicate that apical glucose 
transport is also diminished but to a lesser extent than basolateral transport 
thereby negating any accumulation of glucose within the cell. Reduced 
cellular and basolateral concentration implies that apical uptake is affected 
still more to the point where a significant difference is observed. Inhibition of 
basolateral transport separate from that of apical transport demonstrates the 
ability of the inhibiting compound(s) to cross the apical cell membrane or 
permeate the tight junctions between cells to reach the basolateral 
membrane where the effect is elicited.
To assess whether inhibition of glucose transport was attributable to specific 
flavanol components of the dark chocolate extract, epicatechin was assayed 
at a concentration relevant to that in the dark chocolate extract. In this 
instance 200 pM, and 1 mM, (-)-epicatechin did not significantly affect 
glucose concentration in the cells or basolateral compartment. For ease of 
comparison the same concentration of (+)-catechin and procyanidin B2, a 
flavanol monomer and dimer present in dark chocolate, were also 
investigated. (+)-Catechin did not elicit a significant effect on glucose 
transport. In contrast the cellular concentration of glucose was significantly 
greater in the presence of procyanidin B2 relative to the control; basolateral 
concentration was unaffected. The enantiomers (+)-epicatechin and (-)- 
catechin were also investigated to determine whether the structural 
configuration of the flavanol monomer was able to exhibit a significant effect. 
200pM (-)-Catechin did not significantly moderate glucose transport however 
the same concentration of (+)-epicatechin significantly increased the cellular 
uptake of glucose without affecting basolateral efflux. From these results it
was apparent that individually flavanol monomers and B2 dimer were not 
responsible for the inhibitory effect induced by the dark chocolate extract, 
although a synergistic effect of flavanols in the dark chocolate extract could 
be responsible.
The methylated xanthine components of dark chocolate, caffeine and 
theobromine were also assayed at concentrations relevant to those 
expected in the dark chocolate extract. Both compounds significantly 
increased the cellular concentration of glucose without affecting the 
basolateral glucose concentration. Increased cellular uptake but not apical to 
basolateral transport of glucose following incubation in the presence of (+)- 
epicatechin, procyanidin B2, caffeine and theobromine is considered to be a 
consequence of enhanced apical glucose transporter activity without any 
significant change in the activity of basolateral glucose transport. It has been 
reported that the presence of caffeine significantly enhances intestinal 
glucose absorption in human subjects following ingestion of coffee (Johnston 
et al. 2003) and hypothesised that augmented carbohydrate oxidation during 
exercise is a consequence of a caffeine induced increase in glucose 
absorption (Yeo et al. 2005). Both caffeine and theobromine are inhibitors of 
the enzyme cyclic 3’, 5’-nucleotide phosphodiesterase (EC 3.1.4.17) that 
catalyses the hydrolysis of a phosphate ester on a 3', 5’-cyclic nucleoside 
monophosphate (Butcher and Sutherland 1962). Inhibition of this enzyme 
results in the intra-cellular increase of a substrate such as cyclic adenosine 
monophosphate (cAMP), which has been implicated in the stimulation of 
SGLT1 activity (Sharp and Debnam 1994). cAMP-dependent protein kinase 
(EC 2.7.11.11) catalyses the phosphorylation of proteins, such as SGLT1, by 
transferring a phosphate group from adenosine triphosphate (ATP). cAMP-
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activated protein kinase has been associated with enhancement of SGLT1 
activity through additional trafficking of the transporter to the apical 
membrane. The maximum rate of glucose transport was increased without 
alteration of transporter affinity for the substrate (Wright et al. 1997). 
Previous studies have reported flavonoid inhibition of phosphodiesterase 
activity with cAMP as the substrate (Beretz e t al. 1978, Ruckstuhl and 
Landry 1981) and stimulation of cAMP-dependent protein kinase (Eid et al. 
2010, Zygmunt et al. 2010). This offers a hypothesis for the observed 
increase in cellular glucose concentration in the presence of caffeine, 
theobromine, procyanidin B2 and (+)-epicatechin.
Analysis of the kinetic effects of dark chocolate extract revealed that the 
maximum rate of apical to basolateral transport was dose-dependently 
reduced parallel with an increase in the Michaelis constant, not dose- 
dependent, that is overall indicative of a mixed-type inhibition. The maximum 
rate of reaction (Vmax) is representative of the rate at which an enzyme- 
substrate complex dissociates to form the product dependent on the 
concentration of total enzyme present. Attenuation of the rate of reaction, or 
in this instance the rate of transport, signifies non-competitive inhibition. The 
Michaelis constant (KM) represents the ratio of enzyme-substrate complex 
dissociation, to enzyme and substrate or enzyme and product, relative to the 
formation of the enzyme-substrate complex. Increased Km is associated with 
decreased affinity of the enzyme, or in this instance transporter, for the 
substrate which is indicative of competitive inhibition.
Kinetic analysis of cellular glucose uptake demonstrated that dark chocolate 
extract significantly attenuated the maximum rate of transport, independent 
of dose, implying non-competitive inhibition. Dark chocolate extract
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containing 142 pM epicatechin did not significantly affect the Michaelis 
constant however the extract containing 71 pM epicatechin was responsible 
for a significant increase in the calculated KM that suggests enhancement of 
transporter affinity for the substrate.
Reduced Vmax of cellular uptake and apical to basolateral transport suggest 
that apical SGLT1 and basolateral GLUT2 are inhibited non-competitively. 
Increased Km of apical to basolateral transport but not cellular uptake 
suggests that competitive inhibition affects GLUT2 but not SGLT1. The 
ability to competitively inhibit GLUT2 indicates that the inhibitor is able to 
enter the cell and is therefore limited to the less polymerised flavanols. 
Inhibition of SGLT1 could be a consequence of flavanol-transporter bond 
formation at one of the extracellular or intracellular loops which alters the 
structural conformation of the protein. The lack of inhibition by the flavanol 
monomers and B2 dimer investigated, imply that flavanols with a greater 
degree of polymerisation are involved or that a synergistic effect occurs. 
Protein-flavanol interactions are more prolific with increasing molecular 
weight (Soares et al. 2007) however the ability to enter the cell and interact 
with intracellular loops is expected to be limited to compounds with a degree 
of polymerisation no larger than dimer (Spencer et al. 2001, Ottaviani et al. 
2012). The capacity to permeate the tight junctions and elicit an extracellular 
basolateral effect is probably limited to flavanols with a degree of 
polymerisation no greater than hexamer (Zumdick etal. 2012).
The observed increase in Km of cellular uptake is hypothesised to be a 
consequence of enhanced SGLT1 trafficking to the apical membrane elicited 
by the methyl xanthine content of the dark chocolate extract. Whilst it would 
be expected to observe an increase in cellular glucose concentration and
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therefore rate of transport, this effect may be negated by the presence of 
flavanols which non-competitively inhibited the activity of SGLT1. The 
proposed methyl xanthine induced effect may not be dose-dependent 
whereas dark chocolate extract induced reduction of cellular glucose 
concentration was dose-dependent. Dark chocolate extract containing 71 pM 
epicatechin may only inhibit cellular glucose uptake sufficiently to counteract 
the enhancement stimulated by caffeine and/or theobromine therefore there 
is no significant change in cellular glucose concentration. The addition of 
extra transporters that have the potential to increase glucose uptake are 
non-competitively inhibited, thus a reduced Vmax and increased Km is 
calculated. In the presence of dark chocolate containing 142 pM epicatechin 
SGLT1 is inhibited beyond the level of enhancement such that a significant 
reduction in cellular glucose concentration is observed. The Vmax remains 
attenuated whilst the Km is returned to a level similar to that of the control 
containing no dark chocolate extract.
5.5 C onclusion
Dark chocolate extract, but not individual flavanol monomers, B2 dimer and 
methyl xanthines, inhibit the cellular uptake and apical to basolateral 
transport of glucose. Non-competitive inhibition of both apical SGLT1 and 
basolateral GLUT2 along with competitive inhibition of GLUT2 is the 
proposed method of inhibition. Specific inhibitor/s remain unknown but are 
postulated to involve low molecular weight flavanols that are able to 
permeate the apical cell membrane where they interact with the intracellular 
active site of the protein carrier GLUT2. Inhibition of SGLT1 may involve low 
molecular weight flavanols that either enter the cell and form bonds with
intracellular regions of the protein or remain in the extracellular space where 
they similarly can interact with luminal facing regions of the protein. Larger 
molecular weight flavanols may also interact with the extracellular regions. 
Caffeine and theobromine are hypothesised to enhance cellular glucose 
concentration through inhibition of cyclic 3’, 5’-nucleotide phosphodiesterase 
which may increase the cellular concentration of cyclic adenosine 
monophosphate ultimately leading to additional SGLT1 trafficking to the 
apical membrane. This effect potentially conveys an enhancement of the 
SGLT1 Michaelis dissociation constant (KM) but is reversed by inhibition of 
the transporter.
Future studies should initially investigate inhibition of GLUT2 separately from 
SGLT1 as the kinetic properties of each transporter need to be determined 
separately. The potential for methyl xanthine inhibition of cyclic 3’, 5’- 
nucleotide phosphodiesterase and whether this does lead to enhancement 
of SGLT1 membrane insertion and activity in the Caco-2 cell model requires 
confirmation. The inhibitory effect of flavanols with a degree of 
polymerisation greater than dimer should also be investigated. Synergistic 
effects between the flavanol components of dark chocolate and antagonism 
of methyl xanthine effects require further consideration. Where possible, the 
flavanol binding sites of SGLT1 and GLUT2 should be elucidated.
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C hapter 6 S um m ary and fu tu re  perspectives
6.1 Epicatechin  transport
6.1.1 Effect of dark chocolate
Epicatechin present in dark chocolate extract was transported from the 
apical to basolateral membrane of the Caco-2 monolayer to the same extent 
as the individual compound. Transcellular transport of epicatechin was 
confirmed by the detection of O-methylated epicatechin in both apical and 
basolateral compartments following incubation of Caco-2 cells with standard 
epicatechin; the predominant form being 3’-0-methylated epicatechin. 
Incubation of cells with dark chocolate extract resulted in there being no O- 
methylated epicatechin detected in either apical or basolateral samples. 
Inhibition of epicatechin méthylation by flavanol dimers has been reported 
using epicatechin as the substrate (Spencer et al. 2001). Reduced formation 
of 3’-0-methyl epicatechin was linear at concentrations of dimer up to 300 
pM and increased dimer méthylation was noted. The concentration of 
flavanol dimers in the dark chocolate extract used in the investigation 
presented here was 76 pM. The absorption of flavanol dimers remains 
controversial, in vitro and animal models appear to more readily transport 
these compounds whereas availability in humans is less likely. This 
highlights the difficulty of extrapolating results obtained from animal and cell 
culture studies to humans.
In the study of epicatechin transport across the Caco-2 cell monolayer 
presented here, only free and methylated epicatechin were analysed, 
detection of free flavanol dimers in the basolateral compartment and 
methylated dimers along with conjugated metabolites of epicatechin would
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provide more insight as to the mechanisms that affected the metabolism of 
epicatechin present in the dark chocolate extract. In the absence of such 
analysis it is hypothesised that flavanol dimers present in the dark chocolate 
extract were taken up by the cell where they competitively inhibited 
méthylation of epicatechin. Studies of dimer absorption report very low 
concentrations permeating the epithelial membrane, which may have little 
significance in vivo. Similarly attenuating the rate at which epicatechin is 
metabolised by intestinal, kidney or hepatic cells doesn’t appear to affect 
total elimination in urine, thereby potentially restricting the impact this may 
have physiologically. Further investigations which address the bioactivity of 
metabolised forms of flavanol monomers and dimers may elucidate a 
physiological implication of these results.
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Figure 6.1 Illustration of proposed mechanism for dark chocolate extract 
inhibition of epicatechin méthylation in Caco-2 cells.
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6.1.2 Effect of sucrose, glucose and fructose
Sucrose enhanced the absorption of epicatechin in the Caco-2 cell model, 
which was attributed to stimulation of sodium-dependent glucose transporter 
activity at the apical membrane leading to increased tight junction pore size, 
determined by lower trans-epithelial electrical resistance; this resulted in 
greater paracellular permeability of epicatechin. A small number of human 
intervention studies have resulted in the speculation that sucrose may 
augment epicatechin bioavailability. Many investigations have focused on 
the bioactivity of epicatechin in its free form, with improvements in 
biomarkers of cardiovascular disease being its primary potential benefit. The 
mechanisms by which epicatechin may exert such influence include 
increased endothelial nitric oxide levels through inhibition of reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase which 
produces the superoxide radical that is able to form a complex with nitric 
oxide producing another radical, peroxynitrite. Endothelial nitric oxide may 
also be elevated through epicatechin inhibition of arginase, which competes 
with nitric oxide synthase for the substrate L-arginine. Stimulation of 
endothelial nitric oxide synthase activity by epicatechin induced 
phosphorylation of serine residues has also been proposed. Nitric oxide 
stimulates endothelial vasodilation and may be responsible for increased 
flow mediated dilation (FMD) observed in human intervention trials in which 
consumption of cocoa has resulted in greater FMD being measured.
Epicatechin has also been reported to improve biomarkers of CVD risk 
factors such as inflammation, oxidative stress and dyslipidemia. Reduction
of: C-reactive protein in diabetic mice supplemented with epicatechin, 
malondialdehyde concentration in rats supplemented with cocoa fibre, and 
total and LDL cholesterol levels of obese-diabetic rats supplemented with 
cocoa, have been reported.
Increasing bioavailability of epicatechin with formulations including sucrose 
may enhance such beneficial effects. However the impact of sucrose on 
biomarkers of disease must also be taken into consideration.
Glucose and fructose reduced the production of methylated epicatechin in 
the Caco-2 cell model although epicatechin transport was not affected. This 
suggested the inhibition of COMT activity. COMT inhibition in the presence 
of glucose or fructose is hypothesised to be a consequence of glycolytic 
enzymes competing with COMT for the magnesium cation cofactor required 
for activity in both pathways. Further investigations are required to determine 
whether, in the presence of magnesium (II) in the transport solution, glucose 
and fructose are able to inhibit COMT activity. It is possible that the inhibition 
observed in the epicatechin transport study presented here is unique to the 
specific conditions under which the assay was conducted, i.e. a lack of 
sufficient magnesium cations.
Sucrose Sucrose
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Figure 6.2 Illustration for the proposed mechanism by which sucrose may 
enhance epicatechin absorption in Caco-2 cells.
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Figure 6.3 Illustration of the proposed mechanism by which glucose and 
fructose inhibit the production of methylated epicatechin in Caco-2 cells.
6.2 S ucrose hydro lysis
Dark chocolate extract containing 322 pM epicatechin reduced the rate of 
sucrose hydrolysis in Caco-2 cells by 59%, this was partly attributable to the 
(-)-epicatechin content. Standard (-)-epicatechin also reduced the rate of 
sucrose hydrolysis but >500 pM would be required to achieve a 50% 
reduction in hydrolysis. This is consistent with previous studies that report 
IC50 concentrations >1 mM for inhibition of sucrase activity. Flavanol-protein 
interactions are greater as the molecular weight, and thus the degree of 
polymerisation, increases. Combined with the results of the study presented 
here, it is hypothesised that synergistic effects between flavanols in dark
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chocolate extract accounts for inhibition of sucrose hydrolysis in excess of 
that measured for (-)-epicatechin alone. Further investigation using 
commercially available standard compounds and/or those extracted by 
separation of flavanol fractions would confirm or refute this concept. 
a-Hydrolase enzymes operate in a similar way; product formation is a 
function of acid hydrolysis of the substrate. The active site of sucrase shares 
some homology with a-amylase; it has been proposed that flavanol inhibition 
of the enzyme requires the presence of delocalised electrons in a 
conjugated AC-ring and is dependent on the number of hydroxyl groups 
across the molecule. Based on this evidence, it would not be expected that 
flavanols, containing just two hydroxyl groups located on the B-ring and a 
non-conjugated AC-ring system, would have a propensity for strong 
inhibition of sucrase. The stereoisomerisation of hydroxyl groups has also 
been implicated in the capacity to inhibit a-hydrolase enzymes. In order to 
examine this hypothesis, greater concentrations of each flavanol monomer 
enantiomer require investigation to allow comparison with the (-)-epicatechin 
isomer.
Based on the evidence presented here, it appears that enhancement of 
sucrase activity is independent of isomerisation. However, it is possible that 
(+)-epicatechin, containing the 2S, 3S bond configuration, has less affinity 
for binding sucrase at the site which causes inhibition of sucrose hydrolysis. 
Enhancement of activity was sustained at a concentration in which the other 
flavanol monomers, and dimer, displayed a relative reduction in activity, 
compared to the enhanced activity. Analysis of the kinetic properties of 
sucrose hydrolysis in the presence of dark chocolate extract and individual 
flavanol compounds, would confirm the type of inhibition. Computational
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software could be used to predict the sites of interaction for ligands based on 
protein structure. Enhanced sucrose hydrolysis in the presence of moderate 
concentrations of flavanol monomers and dimer are proposed to be a 
consequence of flavanol-protein binding at a site other than the active site of 
sucrase. It has been suggested that such binding may stimulate a 
conformational change in the tertiary structure of the enzyme permitting 
more catalytic residues to be exposed to the hydrophilic environment (Gupta 
et al. 2010). In this instance the result may be enhanced hydrolysis of 
sucrose at the active site leading to an increase in the rate of product 
formation.
Impaired hydrolysis of sucrose in the small intestine is associated with 
congenital sucrase-isomaltase deficiency, a disease in which the patient 
experiences abdominal pain, bloating and diarrhoea. As there is no cure for 
the disease treatment involves elimination of sucrose, and other 
carbohydrates that are hydrolysed to maltose, from the diet or use of an 
enzyme replacement therapy. Inhibition of a-glucosidase enzymes by 
acarbose is an approved treatment for type-2 diabetes, although side-effects 
of flatulence and diarrhoea have been reported; the ability of dark chocolate 
extract and (-)-epicatechin to reduce sucrose hydrolysis could be considereds'-
to lead to similar side-effects. However this would depend upon whether 
sucrose hydrolysis was reduced sufficiently for sucrose to pass through to 
the colon where it would elicit negative side-effects, or whether hydrolysis 
was merely slowed down such that the peak in blood glucose concentration 
was lessened. This is a more probable outcome as consumption of dark 
chocolate is not associated with negative intestinal effects.
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6.3 Glucose transport
Dark chocolate extract reduced cellular uptake and transport of glucose. 
This was not attributed to commercially available individual flavanol 
monomer or dimer components of dark chocolate cr to caffeine and 
theobromine. It is hypothesised that a synergistic effect of the flavanol 
components is present. Individually caffeine and theobromine increased the 
rate of cellular glucose uptake without any change in the rate of transport. 
This supports previous reports that have observed greater glucose 
concentration in the plasma of subjects following ingestion of a caffeine 
containing beverage compared with a similar decaffeinated drink (Johnston 
et al. 2003). This is believed to be a result of increased sodium-dependent 
glucose transporter trafficking to the apical membrane due to elevated 
cellular concentrations of cAMP through inhibition of cyclic 3’, 5’-nucleotide 
phosphodiesterase activity.
Transport of glucose by Caco-2 cells, presented here, was not linear with 
increasing concentration therefore it was considered that the primary route 
of cellular uptake was via the sodium-dependent glucose transporter SGLT1. 
Kinetic analysis of glucose transport in the presence of different 
concentrations of dark chocolate extract revealed a dose-dependent 
reduction in the rate of transport but not cellular uptake. The concentration of 
glucose required to achieve half the maximum rate of transport was 
increased for apical to basolateral transport without any change in cellular 
uptake, at the highest concentration of dark chocolate extract investigated. It 
is proposed that glucose uptake by SGLT1 was non-competitively inhibited 
whereas basolateral efflux of glucose by the hexose transporter GLUT2 was
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inhibited by mixed-type. Non-competitive inhibition of GLUT2 is believed to 
be dose-dependent and responsible for the dose-dependent change in Vmax. 
Apparent enhancement of cellular glucose uptake in the presence of the 
lowest concentration of dark chocolate extract investigated, determined by a 
lower Km, was believed to be a result of methyl xanthine induced stimulation 
of SGLT1 trafficking to the apical membrane concurrent with non-competitive 
inhibition of the transporter by the flavanol components.
Increased intestinal glucose concentration stimulates the insertion of GLUT2 
into the apical membrane to assist with glucose absorption. In type-2 
diabetic patients GLUT2 at the apical membrane remains elevated such that 
high blood glucose concentration, due to impaired uptake by muscle and 
adipose cells, is exacerbated. A capacity to reduce the activity of glucose 
transporters may be of benefit to patients with diabetes or pre-diabetes. In 
healthy subjects a general reduction in the glycaemic impact of a food/meal 
is considered beneficial for health. The presence of sugars in the colon may 
result in abdominal pain and diarrhoea, however similarly to the 
consideration for sucrase inhibition, a reduction in the rate of transport that 
lessens the post-prandial peak of blood glucose concentration without 
affecting the total concentration absorbed, is less likely to have negative
side-effects.
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Figure 6.4 Illustration of the proposed mechanism for inhibition of glucose 
uptake and transport through the Caco-2 cell monolayer, and enhancement 
of glucose uptake by caffeine and/or theobromine.
6.4  E ffect of dark ch oco late  on g luco se  uptake in healthy  
hum an subjects
To date there have been many studies conducted to investigate the effect of 
plant extracts and polyphenolic components on blood glucose levels. 
Several in vivo animal studies have investigated the chronic effects of 
dietary supplementation on biomarkers of metabolic disease and expression 
of genes related to glucose metabolism (Bose et al. 2008, Oliveira et al.
2008, Hininger-Favier et al. 2009, Kannappan and Anuradha 2009, Jia et al.
2009, Chen et al. 2011, Sae-tan et al. 2011, Bnouham et al. 2012, Kobori et 
al. 2012, Qin et al. 2012). Overall these studies reveal lowered blood
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glucose concentration and insulin concentration/sensitivity following 
supplementation with the extract, in comparison to a non-supplemented 
control. Acute administration of various plant extracts has been shown to 
lower the rise in post-prandial blood glucose concentration in healthy and 
diabetic-induced animals (Motilva et al. 1983, Koga et al. 2006, Ishikawa et 
al. 2007, Ndong et al. 2007, Hogan et al. 2010, Abeywickrama et al. 2011, 
Ali et al. 2011, Ikarashi et al. 2011, Roy etal. 2011, Murase et al. 2012). The 
use of glucose, sucrose or maltose in the oral tolerance test of these studies 
has been useful to suggest a mechanism by which the hypoglycemic effects 
occur. For example 1 g kg-1 polyphenolic extract of Acacia mearnsii 
administered to rats along with glucose, sucrose or maltose significantly 
reduced the 0-3 h area under the curve (AUC), 0.5 g kg'1 of extract also 
reduced the 0-3 h AUC for maltose induced glycaemia. These results 
suggest that further to inhibition of glucose transport, the activity of sucrase 
and maltase enzymes may also be attenuated (Ikarashi et al. 2011). An 
extract of Nerium indicum leaves reduced the rise in blood glucose 
concentration in rats orally administered maltose or sucrose. Rise in blood 
glucose was suppressed at 30, 60 and 90 min following sucrose ingestion, 
and at 60 and 90 min following ingestion of maltose. Everted intestinal sacs 
were exposed to 1 mM chlorogenic acid, a component of the leaf extract, 
along with maltose or glucose. In both instances glucose absorption was 
significantly lower than the control (Ishikawa et al. 2007). Several ex wVo 
and in vitro assays have demonstrated the ability of plant extracts, and 
individual polyphenolic compounds to reduce glucose transport and sugar 
hydrolysis (Kobayashi et al. 2000, Song et al. 2002, Johnston et al. 2005, 
Hanamura et al. 2006, Kottra and Daniel 2007, Kwon et al. 2007, Wang et
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al. 2008, Manzano and Williamson 2010, Adisakwattana and Chanathong 
2011, Boath étal. 2012).
The results presented in Chapter 4 and Chapter 5 support the evidence that 
cocoa extracts, rich in polyphenols, are able to reduce sucrose hydrolysis 
and glucose transport in vitro.
A 50 g serving of dark chocolate, containing 31 g of carbohydrate, has a 
reported glycaemic index (Gl) of around 42 compared with a 50 g portion of 
glucose with a Gl of 100 (University of Sydney 1995-2007). The Gl is a 
measure of the glycaemic response to a food or beverage during 120 min 
post-ingestion; it is compared with the Gl of a standard reference food which 
is commonly glucose in water or white bread. The Gl of the test food is 
calculated as a percentage of the reference; the higher the Gl of a food, the 
greater its impact on glycaemia. The relatively low Gl of dark chocolate may 
be partly attributed to it containing mainly sucrose; a 50 g portion of sucrose 
has a Gl of ~60 compared with glucose (Foster-Powell et al. 2002). The 
glucose present in sucrose must first be liberated by the activity of intestinal 
sucrase before absorption can occur therefore attenuating the rise in blood 
glucose. Typically, post-prandial blood glucose concentration peaks at 
around 30 min; following ingestion of 50 g of glucose in water, the 30 min 
peak equates to a blood glucose concentration increase of approximately 2 
mM above the pre-ingestion baseline concentration (Chlup et al. 2010). The- 
change induced by ingestion of dark chocolate containing 50 g of 
carbohydrate was approximately 0.4 mM, at its maximum, however over the 
120 min post-prandial period a distinct peak was not observed as the 
change remained relatively constant throughout (Figure 6.5) (Chlup et al. 
2010).
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Figure 6.5 Mean glycaemic change from the pre-meal value following 
consumption of 50 g of carbohydrate in dark chocolate compared with 
glucose (Chlup et al. 2010).
The glycaemic index, determined in diabetic and non-diabetic subjects, of a 
variety of different foods containing 50 g of carbohydrate significantly 
correlated with polyphenol content (Thompson et al. 1984). Following 
ingestion of apple juice, compared with a control that was matched for sugar 
content, the rise in blood glucose concentration was significantly lower at 15 
and 30 min in healthy subjects. Blood glucose concentration over 3 h did not 
differ significantly suggesting that absorption was delayed (Johnston et al. 
2002). Ingestion of an Instant tea beverage containing 75 g of glucose did 
not alter the 0-150 min AUC but did lower the blood glucose concentration 
measured at 120 min suggesting that the return to baseline was more rapid 
(Bryans et al. 2007). Similar results were observed in healthy subjects 
following consumption of a mixed berry purée, plus 250 mL water, containing 
35 g sucrose, 4.5 g glucose and 5.1 g fructose, compared with 250 mL water 
containing the same sucrose, glucose and fructose content. There was no 
significant difference in the 0-3 h AUC, however blood glucose concentration
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was significantly lower at 15 and 30 min. At 120 min post-ingestion, blood 
glucose was significantly higher than the control indicating that the rate of 
glucose absorption was reduced, not the overall concentration (Torronen et 
al. 2010).
Based on the results of in vitro studies presented in chapters 3 and 4 and 
the reported potential for plant extracts to attenuate the post-prandial peak of 
blood glucose concentration, a human intervention study is proposed to 
investigate whether consumption of dark chocolate in combination with a 
glucose-containing beverage could attenuate the post-prandial rise in blood 
glucose concentration over a 120 min post-ingestion period compared with a 
nutrient-matched control chocolate bar free from cocoa polyphenols.
Studies that investigate the post-prandial blood glucose concentration rely 
on a standard blood glucose monitor to measure the concentration. In a 
glycaemic index test this is adequate, however the human study proposed 
here is intended to investigate glucose absorption. As dark chocolate 
contains only sucrose, in a study such as this the use of a standard blood 
glucose monitor would measure blood glucose concentration resuiting from 
the uptake of glucose from the beverage and of glucose liberated from the 
hydrolysis of sucrose. Thus the results would not be specific to glucose 
transport. The stable 13C-D-glucose isotope has been routinely used as a 
metabolic tracer in human studies. Enrichment of the test food with this 
compound would enable specific measurement of 13C-D-glucose and 
calculation of the 13C to 12C-D-glucose ratio; theoretically this should 
increase as glucose is absorbed from the test food. In order to measure 13C- 
D-glucose in plasma a method for sensitive and precise measurement of 
plasma enriched with 13C-D-glucose is described using HPLC separation
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and mass spectrometry detection of glucose. Compared with a standard 
blood glucose monitoring method, use of the 13C-D-glucose tracer provides a 
method to specifically investigate glucose absorption in the presence of a 
complex food matrix.
6.4.1 HPLC-MS Protocol
6.4.1.1 Parameters
A Shimadzu LC 2010 HPLC system equipped with a Phenomenex Rezex™ 
RNM-carbohydrate ion exclusion column, 8% cross-linked with sodium 
cations, 7.8 x 300 mm, was employed for the liquid chromatographic 
separation of glucose. The stationary phase was fitted in a thermostatted 
column compartment maintained at 60 ± 0.1 °C. The mobile phase consisted 
of T m M  sodium formate (71539) in water. An isocratic gradient was 
maintained at a flow rate of 0.4 mL m in1 throughout the duration of the run. 
Maximum pressure was set to 65 bar and minimum pressure was 10 bar. 
Mass spectrometric detection of glucose was performed using the Shimadzu 
LCMS 2020 Single Quad Mass Spectrometer. Instrument parameters were 
as follows: gas temperature and flow 350°C, 15 L min'1; nebuliser gas flow
1.5 L min'1; desolvation line temperature 250°C; heat block temperature 
200°C. The analytical method run time was divided into 2 segments; the first 
being a window of 0 to 27.5 min during which analytes were detected in 
positive electrospray ionisation (+ESI) mode. During the second time 
segment, 27.5 to 28 min, negative electrospray ionisation (-ESI) was 
performed to eliminate analyte residue accumulation at the source which 
may suppress ionisation and reduce sensitivity of the mass spectrometer.
» »
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The autosampler was set to 8°C and a needle rinse step incorporated into 
the method before and after sample aspiration.
6.4.1.2 Sample preparation for LCMS analysis
Blood samples were centrifuged at 2,000 x g for 3 minutes to separate 
cellular matter from the plasma. The plasma supernatant was collected into 
centrifuge tubes and 50 pL diluted 10-fold with ice-cold ethanol. The ethanol- 
plasma mix was vortexed and stored at -20°C for 1 h before being 
centrifuged at 13,000 x g  for 15 min and the supernatant syringe filtered 
through a 17 mm, 0.2 pm PTFE membrane (Chromacol, 17-SF-02(T)). The 
supernatant was evaporated to dry under vacuum and reconstituted in 50 pL 
water.
6.4.2 Pilot study
6.4.2.1 Ethical approval
Ethical approval was obtained from the University of Leeds Mathematics and 
Physical Sciences (MaPS) and Engineering joint Faculty Research Ethics 
Committee (MEEC FREC), reference MEEC 11-040.
6.4.2.2 Human study design
The design is a single-blind cross-over with participants required to attend 
two sessions, each session no longer than 3 h. Attendance at both sessions 
will qualify the volunteer to receive £5 to compensate for their time. 
Volunteers will be asked to complete an informed consent form and pre­
study questionnaire to determine suitability for the study. Volunteers will be 
excluded if they smoke, have been diagnosed with diabetes, pre-diabetes,
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digestive disease, sugar intolerance, food allergy or hypertension, are taking 
prescribed medication, regular dietary supplements or pregnant/lactating. 
Healthy, adult volunteers will be asked to maintain a normal, nutritionally 
balanced diet containing >150 g of carbohydrate per day and refrain from 
drinking alcohol and taking part in strenuous physical activity for 3 days prior 
to the study day. In addition the participants will be asked not to consume 
chocolate or cocoa during the 3 day period. On the evening prior to the 
study, subjects will be asked to consume a moderate meal then fast for 12 
hours before their allocated start time on the study day.
On the day of the study participants will arrive at the designated time and 
rest for 10 minutes before providing the first sample of blood (baseline, T=0). 
The subject will then be asked to consume a 40 g bar of Nestlé NOIR 
Intense dark chocolate containing 70% cocoa solids, or a 28 g bar of 
macronutrient-matched chocolate free from cocoa solids. Immediately 
following ingestion of the bar, subjects will be asked to drink an aqueous 
beverage containing 25 g of D-glucose and 0.1 g of 13C-D-glucose. Blood 
will be collected at 15, 30, 60, 90 and 120 min post-consumption. 
Micro-volumes of blood will be drawn from the finger tip using BD 
Microtainer contact-activated lancets (MidMeds, 366594) designed 
specifically for the single puncture collection of blood volume up to 500 pL. 
Blood will be collected into BD Microtainer tubes containing sodium- 
ethylenediaminetetraacetic acid (EDTA) to prevent cell aggregation and 
sodium fluoride to prevent cellular glycolysis diminishing the glucose 
concentration (Fisher Scientific, SZV-110-130Y).
At the end of each session participants will be provided with a snack.
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Subject confidentiality will be ensured by allocation of identification codes to 
each participant that will be kept securely in a restricted access area in a 
locked filing cabinet. Participants will be free to withdraw from the study at 
any point without providing a reason.
6.4.3 Qualification of D-glucose
12C-D-Glucose has a molecular weight of 180.16, in positive electrospray 
ionisation mode the mass to charge ratio (m/z) for selective ion monitoring 
(SIM) is 181.16. The Shimadzu LCMS 2020 Single Quad Mass 
Spectrometer is not sensitive to detect intervals <1, therefore all selective ion 
monitoring was set to integer m/z only. For example [12C-D-glucose + H+] = 
m/z 181. During a scan (+ESI) of standard 12C-D-glucose m/z ratios of 203, 
221,383, 384 and 385 were detected; these were qualified as follows:
Mass/charge ratio Compound + adduct
203 12C-D-glucose + scdium
221 12C-D-glucose + sodium + water
383 12C-D-glucose + 12C-D-glucose + sodium
384 12C-D-glucose + 13C-D-glucose + sodium
385 13C-D-glucose + 13C-D-glucose + sodium
____ f.___ ______ 1 ____ i__:__________ ___:___ t W/sTable 6.1 Mass/charge ratios detected during selective ion monitoring of 12C- 
D-glucose.
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During a scan (+ESI) of standard 13C-D-glucose m/z ratios of 204 and 222 
were detected and qualified as follows:
Mass/charge ratio Compound + adduct
204 13C-D-glucose + sodium
222 13C-D-glucose + sodium + water
___________________ _________________ i___ :_______________ __________ r  1 3 ^Table 6.2 Mass/charge ratios detected during selective ion monitoring of 13C- 
D-glucose.
In addition to the ratios shown above, selective ion monitoring of m/z ratios 
181 and 182 was included in the method to detect ionised 12C-D-glucose 
(181) and 13C-D-glucose (182). In the standards and plasma samples 
analysed during method development, m/z 181 and 182 were not detected. 
Figure 6.6 and Figure 6.7 show the absolute intensity of signals detected for 
ions of m/z 203, 221, 383, 384 and 385 from standard 12C-D-glucose, and 
204 and 222 from standard 13C-D-glucose. Analysis of 12C-D-glucose 
revealed the presence of 13C-D-glucose, this would be expected due to the 
natural abundance of the carbon-13 isotope of glucose. The standard 13C-D- 
glucose used in this study was enriched with D-glucose labelled with one 
carbon-13 atom. Natural abundance of carbon-13 isotopes of glucose 
decrease as the number of substituted carbon atoms increase.
The purity of the 12C-D-glucose isotope can be confirmed by calculating the 
atom percent which takes into account the isotopic abundance of the sample 
relative to that of an international standard. The international standard used 
for carbon is the ratio of carbon-13 to carbon-12 in Vienna Pee Dee 
Belemnite (VPDB) that is equal to 0.0112372 ± 0.0000009 (Rst). Calculation 
of isotopic abundance and atom percent are shown in Equation 6.1 and 
Equation 6.2, respectively.
171
S 1 3 C sam p ie (% o ) [ ®  - 1] xl00°
Atom percent (AP) i o o x R a X ( ( g ^ ^ )  + i )  
> + X + ‘ )
Equation 6.1
Equation 6.2
Where:
Rs = ratio of carbon-13 to carbon-12 in the sample
To calculate the isotopic abundance and subsequently the atom percent of 
D-glucose the number of carbon-12 and carbon-13 atoms in each isotope 
must be accounted for. Integration of ion count peak area for each m/z ratio 
was performed then the sum of peak areas for each isotope in the sample 
calculated; from this, the ratio of 12C-D-glucose to 13C-D-glucose peak areas 
was determined. The ratio was then converted to the ratio of carbon-12 
atoms to carbon-13 atoms by multiplying by 6 (6 carbon-12 atoms in one 
molecule of 12C-D-glucose) plus 5 (5 carbon-12 atoms in one molecule of 
13C-D-glucose). Inversion of the figure obtained in this last calculation 
provided the ratio of carbon-13 atoms to carbon-12 atoms which is used to 
calculate isotopic abundance. The isotopic abundance of standard 12C-D- 
glucose, used in the method development presented here, was equal to 65.5 
± 17.8 %o and the atom percent calculated from this was 1.18 ± 0.02 (n=3). 
Isotopic abundance >1 indicates that the sample is enriched with carbon-13 
atoms relative to the international standard (Godin et al. 2007). The plasma 
samples analysed in the development of this method contained an isotopic 
abundance of 63.9 ± 2.3 %o and an atom percent of 1.18 ± 0.00 (n=3).
6.4.4 Plasma enrichment with 13C-D-glucose
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A trial was undertaken to confirm the method was sensitive to measure 
plasma enrichment following ingestion of 0.1 g 13C-D-glucose and 25 g 12C- 
D-glucose dissolved in 200 mL of tap water. A volunteer provided a sample 
of blood at baseline before drinking the beverage, then at 30 and 60 min 
post-ingestion. At baseline, isotopic abundance was 50.9 %o and the atom 
percent calculated as 1.17. Plasma collected at 30 and 60 min post­
ingestion was calculated to have an isotopic abundance of 94.1 %0 and 97.2 
%o, respectively. Atom percent at 30 and 60 min was 1.21 and 1.22, 
respectively. These results demonstrate the ability of the method to detect 
enrichment of plasma with 13C-D-glucose following ingestion of a beverage 
containing a molar ratio of 13C- to 12C-D-glucose = 0.004.
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Figure 6.6 LCMS selective ion monitoring chromatograms extracted from the 
total ion count chromatogram of standard 12C-D-glucose.
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Figure 6.7 LCMS selective ion monitoring chromatograms extracted from the 
total ion count chromatogram of standard 13C-D-glucose.
6.5 Conclusion
The results of the investigations presented here demonstrate the interaction 
between cocoa polyphenols and sugars. Sucrose has been shown to 
enhance epicatechin transport through the Caco-2 cell monolayer whilst dark 
chocolate extract, glucose and fructose attenuate epicatechin methylation. 
The apparent low glycaemic index of dark chocolate, compared with glucose
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(and sucrose), may be attributable to its capacity to inhibit sucrose 
hydrolysis and glucose transport; the evidence presented here supports this 
hypothesis. The mechanism by which each of these outcomes occurs was 
not investigated but the hypotheses put forward provide a direction for future 
work to take. Namely, prospective investigations are recommended to 
include the following: determination of COMT activity in the presence of 
flavanols with a varying degree of polymerisation, and in the presence of 
glucose and fructose with sufficient magnesium (II) cofactor present in the 
transport solution; confirmation of enhanced sucrase activity at moderate 
concentrations, and reduced activity at high (£500 pM) concentrations of 
flavanols; measurement of sucrase kinetic properties to determine the type 
of inhibition and structure-activity associations using different stereoisomers 
and computational software to reveal the requirements for interaction and 
the binding sites at which interactions may occur; sodium-dependent 
glucose transport should be more thoroughly investigated to confirm, or 
refute, the capacity for dark chocolate extract to inhibit GLUT2; the kinetic 
properties of methyl xanthine induced SGLT1 activity and the effect of 
varying concentrations of flavanols would further the understanding of this 
process; sucrase activity and glucose transport in the presence of separated 
flavanol fractions of dark chocolate would help to narrow the range of 
possible compounds responsible for the effects of dark chocolate extract; 
and, implementation of a human study in which 13C-D-glucose plasma 
enrichment is measured following consumption of dark chocolate, compared 
with a nutrient-matched placebo control, may support the in vitro evidence 
for reduced glucose absorption induced by the flavanol components of dark 
chocolate.
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UNIVERSITY OF LEEDS RESEARCH ETHICS COMMITTEE APPLICATION FORM1
UNIVERSITY OF LEEDS
Please read each question carefully, taking note of Instructions and completing all parts. If a question Is not applicable 
please indicate so The superscripted numbers refer to sections of the guidance notes nailable at 
wwwlccds ac ul/ethics. Where a question asks for information which you hare previously provided In answer to 
another question, please Just referto your earlier answer rather than repeating inform abon.
To help uspmeessyour application enterthe following reference numbers. If known and if applicable:
Ethics refe re nee number;
Grant reference and/or student number 200374 84 0
PART A: Summary
A l  Which facility Rosnare h Ethics to rem itter would you Mia to consider this appbc atlon t
C Arts and PVAC (PVAR)
C Biological Sciences (BIOSCI)
C ESSU Environment/ LUBS (AREA)
&  MaPS and Engineering (MEEC)
f  Medicine and Health (Please specify a subcommittee);
C Leeds Dental Institute (DREC)
C Health Sciences/ LIGHT/ LSdM
T  School of Healthcare (SHREC)
C Medical and Dental Educational Research (EdREC)
r  Institute of Psychological Sciences (IPSREC)
UREO Etnica k m  varaion 11 (upikaed 17101/12)
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A.2 Title of the research
The effect of cocoa powder on blood glucose concentration following an oral glucose tolerance test.
A.3 Principal Invettlgator'i contact detailt4
Name (Title, first name, surname) Miss Samantha Ellam
Position PhD Research Student
Department/ School/ Institute School of Food Science and Nutrition
Faculty MAPS
Work address (including postcode) School of Food Science and Nutrition. University of Leeds, LS2 9JT
Telephone number 07843 171548
University of Leeds email address fs07sie#>ieeds.ac.uk
w
Research
Educational qualification:
r
Educational Research ft E 
Medical Audit or Health S
r
Other
.Doctor o f Philosophy.
UREO Ethics form version 11 (updated 17/01/12)
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A.5 Select from the list below to  describe your research: (You may select more than one)
I?
Research on or with human participants
Research with has potential significant environmental impact *  If yes, please give details:
Research working with data of human participants 
New data collected by questionnaires/interviews 
New data collected by qualitative methods 
New data collected from observing individuals or populations 
Research working with aggregated or population data 
Research using already published data or data in the public domain
Research working with human tissue samples
URÊC Ethic» tormvarticn 11 (updated 17*51/12)
A.6 Will t h e  rese a r c h  Involve a n y  o f t h e  following: (You may select more than one)
I f  your research involves any o f the fo llow ing an application must be m ade to  the N a tiona l Research Ethics Service 
(N R IS ) via IRAS WWW,mvreseorxhDroiect.org. uk as NHS ethical approval w ill be required. There Is no need to  complete  
q n x jrg rr  Q fjtm fo m v  Contact 09yernqnce-ethicsGleeds.ac.uk fo r advice.
f Patients and users of the NHS (including NHS patients treated in the private sector) 11
Individuals identified as potential participants because of their status as relatives or carers of patients and 
users of the NHS
Research involving adults in Scotland, Wales or England who lack the capacity to consent for themselves 12 
A prison or a young offender institution in England and Wales (and is health related)14 
Clinical trial of a medicinal product or medical device 11
Access to d ita , organs or other bodily mate.-lal of past and present NHS patients 9
Use of human tissue (including non-NHS sources) where the collection is not covered by a Human Tissue 
Authority licence*
Foetal material and IVF Involving NHS patients 
The recently deceased under NHS care
None of the above
You must inform the Research Ith ks  Administrator of your NRIS number and approval date once approval has 
been obtained.
I f  the University o f  Leeds is not the Lead Institution, or approval has been granted elsewhere (e.g. NHS) then you should 
contact the local Research Ethics Committee fo r  guidance. The UoL Ethics Com m ittee need to be assured tha t any 
relevant local ethical Issues have been addressed.
A.7 Will the research Involve NHS staff recruited as potential research participants (by virtue of their professional role) 
or NHS premises/ facilities?
U R E C  E th ic s  fo rm  ve rsio n  11 (updated 17/01/12)
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I f  yes, ethical approval must be sought from  the University o f Leeds. Please note that NHS R&D approval is needed in 
addition, and can be applied fo r  concurrently w w w .m vrneorchDroiect, ora, uk. Contact asxunan iLS Ltila^kC S li.iK .M h  
fo r  advice.
A.8 W ill the participants be from any of the following groups? (Tick as appropriale)
r
r
r
r
r
p?
Children under 16
Adults with learning disabilities 12
Adults with other forms of mental incapacity or mental illness 
Adults in emergency situations 
Prisoners or young offenders 14
Those who could be considered to have a particularly dependent relationship with the investigator, e.g. 
members of staff, students 1
Other vulnerable groups
No participants from any of the above groups
Please ju s tify  the inclusion o f  the above groups, explaining why the research cannot be conducted on non vulnerable 
groups.
There is likelihood that a staff member or student from the School of Food Science & Nutrition will be recruited to take 
part in this pilot study. Study participation is entirely voluntary and no person will be approached directly or coerced 
into taking part in the research. Vo'unteers will be free to withdraw from the study at any time without providing a 
reason.
A Criminal Record Bureau (CRB) check w ill be needed fo r  researchers working w ith children or vulnerable adults (see 
www.crb.Qov.uk)
UREC Ethic* form version 11 (updated 17/01712)
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A.9 Give a short summary of the research
This section must be completed In language comprehensible to  the lay person. Do no t simply reproduce or refer to the 
protocol, although the protocol con also be submitted to provide any technical Information that you think the ethics 
committee may require. This section should cover the main ports o f the proposai
In vitro  studies by the researcher demonstrated that an extract of dark chocolate reduced glucose transport through 
Caco-2 (colorectal adenocarcinoma) cells. These cells are commonly used as a model of the human small intestine.
The next step in this research is to assess whether consumption of cocoa by healthy human volunteers is able to reduce 
the absorption of glucose compared against a control. Volunteers will be r e t ir e d  to take part in a three-phase pilot 
study which will implement the current World Health Organisation/United Kingdom National Health Service protocol for 
measuring blood glucose Each phase will involve consumption of water containing 75 g of glucose followed by blood 
glucose monitoring over a two-hour period. 2 m l of blood will be collected from each subject at each time-point; plasma 
glucose concentration will be measured using mass spectrometry after the whole blood has been centrifuged and 
rendered acellular. Phases two and three will include cocoa powder dissolved in the beverage. Some subjects will only 
be required to provide up to 0.1 mL of blood per time-point.
Reduction of blood glucose concentration following consumption of a meal is desirable in healthy humans as well as 
those suffering from prediabetes and type-2 diabetes. Excessively high blood glucose concentration, particularly over a 
prolonged period, can damage arterial cells which increases the potential for narrowing of the arteries and consequently 
an increased risk of cardiovascular disease |1). Additionally it is likely that slowing glucose uptake may help to reduce 
body weight |2], being overweight is a risk factor for developing type-2 diabetes (31.
This research is funded by a 6BSRC industrial CASE award to Nestlé PTC, York. Recruitment will take place on the main 
University of Leeds campus.
A.10 What are the main ethical issues with the research and how will these be addressed?
Indicate any issues on which you would welcome advice from  the ethics committee.
Laiflgmtd&oragfli
The study co-ordmator will provide a clear, concise Participant Information Sheet (appendix 1) and Informed Consent 
Form (appendix 2) for the volunteers to read, complete and sign prior to commencement of the study. After the 
candidate has been determined as suitable to participate in the study, the background of the study (including purpose, 
duration, protocol, potential discomfort, associated risk, potential benefits, confidentiality, and disclosure of results, 
participation and withdrawal) will be explained to the participant. The study co-ordinator will fully answer all questions 
to the satisfaction of the individual. Written informed consent will be obtained by the study co-ordinator from each 
participant at least 7-days prior to enrolment in the study. The consent form will be signed and dated by both the 
participant and the study co-ordinator, and will be photocopied twice; one copy to be held with the study records (held 
by the study co-ordinator) and one copy for the individual. Written informed consent must be obtained before the 
individual can participate in the study and all participants will be free to withdraw from the study at any point without 
providing a reason.
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Pre-studv questionnaire
In order to assess candidate suitability for the study, each candidate will be required to complete a questionnaire 
(appendix 3) pertaining to lifestyle, including height and weight, gender, age, ethnicity and relevant medical history; this 
information may be considered a sensitive issue. Each volunteer will be assured that participation is entirely voluntary.
3-dav restricted diet & overnight fasting
There may be some mild discomfort/inconvenience caused by the 3 -day restricted diet and overnight fasting before the 
study. However the quantity and range of foods permitted is substantial and sufficient to provide a nutritionally 
balanced diet.
Subisti cQrrâfcnMift anti daia-Bigisflign
Confidentiality of all participants will be maintained; identification will be coded using 10 numbers that will be assigned 
on the day of the study. All data collected will be treated as confidential and stored securely in a locked filing cabinet 
according to current University regulations. It will not be possible to identify individual participants from the ID 
numbers; the linkage between individual identity and ID number will be kept in written form only and stored in a locked 
filing cabinet in a restricted access area. Data evaluation will only be performed using ID numbers. Anonymised data will 
be stored for no longer than 5 years in accordance with the University guidelines on the password protected M-drive of 
the University server.
Eihici commime approva!
This human study protocol will be submitted to the Faculty of Mathematics and Physical Sciences Ethics Committee at 
the University of Leeds, UK.
PART B: About the research team
B .l To be completed by students only ?0
Qualification working towards (eg 
Masters. PhD)
UREC Ethics form version 11 (updated 17/01/12)
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Supervisor's name (Title, f irs t name, 
surname)
Professer Gary Williamson
Department/ School/ Institute School of Food Science and Nutrition
Faculty MAPS
Work address (including postcode) School of Food Science & Nutrition, University of Leeds, LS2 9JT
Supervisor's telephone number 0 113  343 8380
Supervisor's email address K .w H iijn iw n e W lM t-u K
Module name and number ( if  
applicable)
B.2 O ther m embers o f th e  research team  (eg co-investigators, co-supervisors)21
Name (Title, f irs t nome, surname)
Position
Department/ School/ Institute
Faculty
Work address (including postcode)
Telephone number
Email address
Name (Title, first name, surname)
Position
Department/ School/ Institute
Faculty
Work address (including postcode)
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Telephone number
Email address
Part C: The Research
C .l  W hat are the aims of the study? (Must be in language comprehensible to a lay person.)
The main objective of this pilot study is to determine whether consumption of cocoa affects blood glucose concentration 
over a 2-hour period post-ingestion.
C.2 Describe the design of the research. Qualitative methods as well as quantitative methods should be included. (Must 
be in language comprehensible to a lay person.)
It Is Important tha t the study can provide Inform ation about the alms that It  Intends to address. I f  a study connat answer the  
questions /  add to the knowledge base that it  Intends to, due to the way that It is designed, then wasting partidpan ts ' tim e  
could be an ethical issue.
This is a placebo-controlled, crossover pilot study conducted over three-phases of no more than 3 hours per phase. All 
volunteers will be asked to complete a consent form and pre-study questionnaire prior to participation. It is anticipated that 
the pilot study will require no more than 12  subjects.
Days 1-3  prior to study day
Subjects will be required to maintain a normal nutritionally balanced diet containing > 150  g of carbohydrate per day 
(appendix 4), and refrain from drinking alcohol and taking strenuous physical activity. Additionally the subjects will be asked 
not to consume chocolate or cocoa during this 3 -day period. On the evening prior to the study, subjects will be asked to eat 
a moderate meal then fast for 12  hours before their allocated start time on the day of the study.
Day 4 -  Study day
Subjects will be asked to arrive at a pre-designated time; they will then rest for 10  minutes before providing the first 2 m l 
sample of blood for glucose analysis (baseline). After this first sample has been taken, the subject will be asked to consume 
the beverage containing 75 g of ,?C-D-glucose plus 0.15 g of nQ-D-glucose* within 5 minutes. The subject will then provide 
a 2m L blood sample at 15, 30, 60, 90 and 120  minutes post-consumption. 5ome subjects will be required to provide up to 
0.1 m l of blood per time-point, drawn using a standard finger-prick device.
Sample flhfllVW
Whole blood samples will be centrifuged within 30 minutes of collection and the acellular plasma fraction collected and 
stored at -80’C until required for analysis (appendix 5 and 6). The remaining cellular fraction will be treated with a
UREC Ethics form version 11 (updated 17/01/12)
2 0 6
disinfectant to destroy the cells, as per manufacturer guidelines. Glucose concentration in the plasma samples will be 
analysed using liquid chromatography with mass spectrometry detection (LC-MS).
S la t li& iljQ ito ii
Blood glucose concentration in the test conditions will be assessed for statistically significant difference from the control 
condition at each time point using the Students T-test. Statistically significant difference will also be calculated between the 
two test conditions.
C.3 W hat w ill participants be asked to  do in the  study? 23 (e.g. number o f visits, time, travel required, Interviews etc)
Participants will initially be asked to complete a consent form and pre-study questionnaire. The information provided 
on the questionnaire will be used to determine suitability for the study, and will include:
Height, weight, age. gender, ethnic background, smoking habit, pre-diagnosed gastrointestinal disease, pre-diabetes or 
diabetes, hyper tension, pregnancy/lactation, use of prescribed medication or dietary supplements.
f or 3 days prior to the study day, subjects will be asked to maintain a normal nutritionally balanced diet avoiding cocoa, 
chocolate and alcohol. Additionally each subject will be asked to refrain from strenuous physical activity during the 3- 
day period. The night before the study the participants will be required to fast for 12 hours (water to be permitted).
On the morning of the study, subjects will be asked to arrive at the study venue at an allocated time and then be asked 
to rest for 10 minutes before the first (baseline) blood sample is collected. The participants will then be asked to drink 
the beverage within 5 minutes and subsequent blood samples will be collected at 15, 30, 60,90 and 120  minutes post­
consumption. At the end of each study phase each subject will be provided with a snack
Each participant will not be required to be present for longer than 3 hours during each phase of the study. There are 
three phases to the study so the total time required from each subject will be 9 hours (appendix 7 and 8).
The study will take place in the School of Food Science and Nutrition on weekdays during the University's normal 
opening hours. Subjects may have to travel to the building from elsewhere on campus or from outside the University 
campus, however it is envisaged that many of the volunteers will be staff or students at the University of leed and 
therefore travel will be minimal.
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•There are two naturally occurring stable isotopes of carbon, carbon-12 and carbon-13 with an abundance of 98.9% 
and 1 . 1 %  respectively |4]. In this study the carbon atom in position 6 of the glucose molecule has an atomic mass of 13 
(the remaining 5 carbon atoms have a mass of 12) therefore giving the glucose a molecular mass of 18 1.2  rather than 
180.2 as in most cases. This difference in mass allows the specific analysis of u C6-0-glucose concentration in the 
plasma samples, the presence of which will only originate from the beverage consumed at the beginning of the study. 
The use of ,3C6-D-glucose in this study provides a sensitive and precise method to analyse the changes in blood glucose 
during the study period and compare the effects of cocoa consumption on the appearance of glucose in the blood. The 
use of carbon-13 in nutritional investigations is well documented and completely safe due to the stability of the carbon 
atom nucleus |5].
C.4 Does the research involve an international collaborator or research conducted overseas:54
(Tick as appropriate)
r  Yes W  No
If yes, describe any ethical review procedures that you will need to comply with in that country:
Describe the measures you have taken to comply with these:
Include copies of any ethical approval letters/ certificates with your application
C.S Proposed study dates and duration
Research stari date (DO/MM/YY) 30 /0 4 /12 Research end uate (DD/MM/YY): 29/06/12
Fieldwork start date (DD/MM/YY): 30/04/12 Fieldwork end date (DD/MM/YY): 29/D6/12
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C.6. Where will the research be undertaken? (i.e. in the street, on UoL premises, in schools)29
The study will be conducted in the School o f fo o d  Science and Nutrition at the University o f  Leeds.
K RECRUITMENT & CONSENT PROCESSES
H ow  portkiponts ore recruited is im portant to ensure that they are not induced or coerced into participation. The way  
participants ore identified m ay have a  beo.ing on whether the results con be generalised. Explain each point and give 
details for subgroups separately If appropriate.
C.7 How will potential participants in the study be:
(i) identified?
Individual subject identification will be in the form of code and no personal details will be referred to in this study. 
Personal details are only required to determine subject suitability such that results will be generalised not specific to 
individual participants.
(li) approached?
Volunteers will be sought by way of general invitation in the form of posters (appendix 9) displayed around the 
University of Leeds campus and by general email (appendix 10) to all staff and students within the School of food 
Science and Nutrition.
(Hi) recruited? 14
Subjects wilt be recruited from the staff and student population. Participation in the study is entirely voluntary and 
participants will be free to withdraw from the study at any point without giving a reason.
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CM Will you be excluding any group* of people, and if so what is the rationale for that? 27
Excluding certain groups o f  people, Intentionally or unintentionally m ay be unethical in some circumstances, ft may 
be wholly appropriate to  exclude groups o f  people in other coses.
The selection criteria have been chosen to minimise variable factors that can affect glucose absorption based on age, 
ethnicity, body mass index, pre-existing illnesses, pregnancy/iactation and use of prescribed medication.
C.9 How many participants will be recruited and how was the number decided upon?
I t  is Im portant to ensure tha t enough participants ore recruited to  be able to answ er the aims o f  the  research.
This is a pilot study to determine whether a main study will be required and if so how many participants would be 
required based on power analysis, in this case, based on previous experience of the research team supervisor, it has 
been decided that 12 subjects will be sufficient to provide a reliable result.
Remember to include a ll advertising m ateria l {posters, emails etc) os port o f  your application
C IO  Wilt the research involve any element of deception? M If yes, please describe why this is necessary and 
whether participants wilt be informed at the end of the study.
No
C . l l  Will informed consent be obtained from the research participants?30
15 V „  r  NO
If yes, give details of how H will be done. Give details of any portfcutar steps to provide Information (In addition to o written 
Information sheet} e.g. videos, interactive m aterial. if  you ore not going to be obtaining informed consent you wiU need to 
justify this.
Written consent will be sought horn each volunteer prior to commencement of the study. Volunteers will receive a participant 
information sheet and informed consent form after a positive reply to the recruitment advertisement. The main investigator 
will verbally explain the participant information sheet and Informed consent form; all questions from the volunteer will be
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answered at any time. The prospective participant will have approximately 7 days before the study commences to finally 
decide, sign and return the completed informed consent form ( in duplicate -  one copy for the participant and one for the 
research records, both to be consigned by the main investigator).
If participants art to be recruited from any of potentially vulnerable groups, alve details of extra steps token to assure their 
protection. Describe any arrangements to be mode for obtaining consent from a legal representative.
Copies of any m itten consent form, written information and all other explanatory m aterial should accompany this 
application. The Information sheet should moke explicit that participants can withdrawn from the research at any time, If the 
research design permits.
5amp/e Information sheets and consent forms are available from the University ethical review webpage at
httû '/ /re s t  QtchsuQOQft.tccds.oc.uk/lndex.Dho/ocodcfnfc s taff/aood oracticc/cthlcol review orocess/unlvtrsltv ethical review-
l
€.12 Describe whether participants will be able to withdraw from the study, and up to what point (eg if data is to be 
anonymised). H withdrawal is QfiS possible, explain why no t
Volunteers will be informed that withdrawal from the study is possible at any time without giving a reason and without 
questions being asked. No negative consequences or change of treatment of the participant will ensue.
€.11 How long wilt the participant nave to  decide whether to take part In the research?11
It may be appropriate to recruit participants on the spot for low risk research; however considère don Is usually necessary 
for riskier projects.
The participant should decide whether or not to take part in the study in the 7 days prior to commencement of the 
study.
€.14 What arrangements have been made for participants who might not adequately understand verbal explanations 
or written information given in English, or who have special communication needs? **(e.g. translation, use of 
interpreters etc. it Is Important that groups of people are not excluded due to kmguoge borders or disabilities, where 
assistance can be given.)
Volunteers who do not adequately understand the English language will not be recruited in the study. Email and mobile
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phone contact details will be provided on the recruitment advert and participant information sheet.
C.15 Will individual or group interviews/ questionnaires discuss any topics or issues that might be sensitive, 
embarrassing or upsetting, or Is it possible that criminal or other disclosures requiring action could take place during 
the study (e.g. during Interviews/group discussions, o r use of screening tests for drugs)? **
Yes No
i f  Yes, give details o f  procedures in place to  deal w ith these issues
The information sheet should explain under what circumstances action may be token
C.16 Will individual research participants receive any payments, fees, reimbursement of expenses or any other 
Incentives or benefits for taking part in this research? u
P  V -  r  No
if  Yes, please describe the amount, number and site of incentives and on what basis this was decided.
Participants will receive a snack at the end of each study phase to compensate for 12-hour fasting and study 
participation.
RISKS OF THE STUDY
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C.17 What i r e  th t  potential benefit» and/ or risks tor research participant»? 33
There it very low potential risk involved in this pilot study. The participants may feel some discomfort from blood 
sampling, which will be conducted by a trained phlebotomist; and from the 12-hour fasting, however a snack will be 
provided at the end of each study phase to compensate for this. There are no direct benefits to the participant although 
following a 3-day nutritionally balanced diet may be considered a benefit to some individuals who would not normally 
follow such a diet.
C.18 Does the research Involve any risks fen the researchers themselves, or people not directly involved in the 
research? Bg lone working **
r  Yes *  No
If yes, pleas* deserto*: _
Is a risk assessment necessary for this research?
r  p
Yes No tf yes, please include a copy of your risk assessment form with your application.
Further information on fieldwork risk assessments is availabie at http^/www.leeds.ac.uk/safetv/fieldwork/index.htm.
DATA ISSUES
C.19 WUI the research involve any of the following activities at any stage (including identification of potential research 
participants)? (Tick as appropriate)
r
Examination of personal records by those who would not normally have access 
Access to research data on Individuals by people from outside the research team
Electronic transfer of data
Sharing data with other organisations
Exportirç data outside the European Union
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Use of personal addresses, postcodes, faxes, e-mails or telephone numbers 
Publication of direct quotations from respondents
Publication of data that might allow Identification of Individuals to be identified 
Use of audio/visual recording devices
FLASH memory or other portable storage devices 
Storage of personal data on or including any of the following:
Manual files
Home or other personal computers 
Private company computers
Laptop computers
C.20. How will the research team ensure confidentiality and security of personal data? I.g. anonymisation procedures, 
Mcurc storage and coding of data. 7 You may wish to refer to thedtu  protection and research webmg.
See the answer explained in question A10.
C J l  For how long will date from the study be stored? Please explain why ttm  length of time has been chosen.
___5_____ years, _________ months
Nd.' ftCUK ouidtroce states thot doto should normally be preserved t  'td accessible for ten yean, but for some prt^ects ft 
may be 20 years or longer.
Students: It would be reasonable to retain data for at least 2 years after publication or three years after the end of 
data collection, whichever Is longer
CONFLICTS Of INTEREST
I C.22 Will any of the researchers or their Institutions receive any other benefits or Incentives for taking part In this
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research over and above normal salary or th e  costs o f undertaking th e  research?
Yes 19 No
I f  yes, indicate how  much and on w h at basis this has been decided
4« 1
C.23 Is th e re  scope fo r any o ther conflict o f interest? For example w ill the research funder have control o f publication 
o f research findings ?
P r
Yes No I f  yes, please explain _
C.24 Does the  research involve external funding? (Tick as appropriate)
p r*
Yes No I f  yes, w h at is the source o f this fund ing ? Nestlé PTC, York and Biotechnology a nd
Biological Sciences Research Council (BBSRC)
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PART D Declarations
Declaration by Chief Investigators
1. The information in this form  is accurate to  the best o f my knowledge and belief and I take full responsibility for it.
2. I undertake to  abide by the  University's ethical and health & safety guidelines, and the  ethical principles 
underlying good practice guidelines appropriate to my discipline.
3. If the research is approved I undertake to  adhere to  the study protocol, the  terms o f this application and any 
conditions set out by the Research Ethics Com m ittee.
4. I undertake to  seek an ethical opinion from  the  REC before im plementing substantial am endm ents to  the  
protocol.
5. I undertake to submit progress reports if required.
6. I am aware o f my responsibility to be up to date and comply w ith the requirements o f the law and relevant 
guidelines relating to security and confidentiality o f patient or other personal data, including the  need to register 
w hen necessary w ith  the appropriate Data Protection Officer.
7. I understand that research records/ data may be subject to inspection for audit purposes if required in future
8. I understand that personal data about m e as a researcher in this application will be held by the relevant RECs and 
that this will be managed according to the principles established in the Data Protection Act.
9. I understand that the Ethics Com m ittee may choose to audit this project at any point after approval.
Sharing inform ation fo r training purposes
Optional -  please tick as appropriate:
I would be content for members of o ther Research Ethics Committees to have access to  the inform ation in the  
application in confidence for training purposes. All personal identifiers and references to  researchers, funders 
and research units would be removed.
Principal Investigator
Signature of Principal Investigator:................................ ............................................. (This needs to  be an actual signature rather
than just typed. Electronic signatures are acceptable)
Print n a m e :..............................................................................
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Date: (dd/mm/yyyy):
Supervisor of student research
/ have read, edited and agree with the form obove.
Supervisor's signature:.................................. ......................... ....... . (This needs to be an actual signature rather than just
typed. Electronic signature* are acceptable)
Print name:
Date: Idd/m m /yyyy)
Please submit your form by em ail to  J.M BUihieCHeeds.ac.ufc or if you are in the Faculty of Medicine and Health 
ac uÉ. Remember to  Indude any supporting materiel such as your participant information sheet, 
consent form, interview questions and recruitment material w ith your application.
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CheckRat:
□  I have used tayman'sterms to  describe my research (applications are r#vt#w*d by lay members o f the  commet## as 
well].
□  I have answered all the questions on the form. Including those wrth several parts {refer to the guidance if you're not 
sure how to answer a question or how much detail is required)
Q  I have included any relevant supplementary materials such es
□  Recruitment material (posters, emails etc)
□  Sampto M ftlcuM nt inforrmtion th t«t
U  hmpte conb.nl tom.
Include different versions for different groups of participants eg for children and adults.
□  If I am not going to  b t using participant information sheets or consent forms I have explained why not and how 
Informed consent wUI be otherwise obtained.
Q  If you are a student have you discussed your application with your supervisor and are they satisfied that you have 
completed the form  correctly? (This w ill speed upyour application).
□  I have submitted e signed eoov o f my application (if you are a student your supervoor also needs to  sign the form)
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Ethical review 
NOTICE OF AMENDMENT
To be completed in typescript by the Principal Investigator in language comprehensible to a 
lay person and submitted to the FREC that gave the favourable opinion o f the research.
Further guidance ¡s ovoUobh ot
Mtc://researctuuBBort.lteds.oc.h </lndex.BhB/ocodemlc staff/aood oroctlce/manaaina approved projects- 
1/aooM na for an am endm ent1,
Principal Investigator's details:
Name:
Samantha Ellam
Address: School of Food Science and Nutrition
Telephone: 07843171548
Email: fs Q 7s le@ leed s .ac .uk
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Full title of study:
The effect of dark chocolate on blood glucose 
concentration following oral ingestion o f a  glucose 
beverage
Ethics reference 
number:
MEEC11-040
Date study 
commenced:
Not yet started
Amendment number 
and date:
*1,13.11.2012
Type of amendment (indicate all that apply In bold)
(a) Am endm ent to Inform ation previously given on the University o f Leeds ethical review application form  
Yet No
I f  yes, pleose refer to relevant sections o f  the FREC application In the "summary o f 
changes'section below.
(b ) A m en d m e n t to th e in fo rm a tio n  sh e e t(s) a n d  o r  c o n se n t fo m t (s )  fo r p a rt ic ip a n t s , o r  to  a n y  o th e r su p p o rn n g  
d o cu m e n ta tio n  f o r  th e stu d y
Ye» No
I f  yes, pleose submit a ll revised documents w ith  new  version numbers ond dates, 
highlighting new  text using a different colour fo n t o r the track changes fe a tu re ,
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Summary of changes
Briefly summarise the m ain changes proposed in this am endm ent using language comprehensible to o  lay 
person. Explain the purpose a f  the changes and their significance fo r the  study, In the cose o f  a  m odified 
am endm ent, highlight the modifications that have been mode.
I f  the  am endm ent significantly alters the  research design o r  methodology, o r  could otherwise o f  fe e t the  
scientific value o f the study, supporting scientific Information should be given (or enclosed separately!. 
Indicate whether or not additional scientific critique hos been obtained.
Initially the study was intended to provide the participants with a  cocoa containing beverage 
however the sponsor prefers to use a dark chocolate bar matched with a white chocolate bar as the 
control. The glucose will still be consumed in beverage form following consumption o f the 
chocolate bar, the glucose concentration has also been reduced. The change will make the results 
more comparable with the in  v i t r o  investigations previously conducted and more relevant for the 
sponsor who is providing the chocolate bars.
Blood collection has changed. Depending upon further method development It may be necessary 
to insert a cannula device in to the arm and collect up to 6 m l of blood per time point. A cannula 
allows blood to be drawn without a  needle so is more suitable for multiple collections during a short 
period. However if the analytical method is suitable for a small volume o f blood then only a finger 
prick will be required to draw the blood and the sample volume required will be a maximum of 0.6 
mL per time point.
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Any other relevant information
A p p lic a n ts  m a y  in d ic a te  an y  specific e th ica l issues re la t in g  to the  
a m e n d m e n t, on w h ich  th e  o p in io n  o f  the R E C  is sought.
List o f enclosed documents
D ocum ent Version Date
P articipant info rm ation  Sheet v3 23.11.12
P re p a ra tio n  o f  a c e llu la r  h u m a n  p la sm a v2 09.11.12
P ro g ra m m e  o f  S tu d s
v2 09.11.12
R e c ru i tm e n t e m a il
v2 09.11 .12
S tu d y  flo w c h a rt
v2 16.11.12
R e c ru i tm e n t p o s te r
v2 16.11.12
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Declaration
• I confirm that the information in this form is accurate to the best of my knowledge and I take full 
responsibility for it.
• I consider that it would be reasonable for the proposed amendment to be implemented
Signature o f Principle! Investigator ......... ....................
Print name:  Samantha Ellam.....................
D ate  o f  submission:  1 6 .1 1 . 12 .....
Signature o f supervisor o f student project: ....................................». ».
Print name: „....Professor Gary Williamson....
Dote o f submission: ........ 1 6 .1 1 . 1 2 .............
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Please submit your form by email to J.M.Blaikie@leeds.ac.uk or if you are in tbe Faculty of Medicine and 
Health FMHUn!Ethics@lceds,ac,uk.
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Study flowchart
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Participant Information Sheet
JtoMTifr proisfl I'tlt
The effect o f chocolata on blood glucose concantration following oral Ingestion o f a glucose 
beverage.
You are being invited to take part in a research project. Before you decide it is Important for you to 
understand why the research is being done and what It will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Ask us if there is anything that 
is not clear or If you would like more information. Take time to decide whether or not you wish to 
take part.
What Is the Purpose of the project?
following consumption o f carbohydrate-rich food or sugary drinks there is a  rise in blood glucose 
concentration that usually reaches a peak after approximately 30 minutes. After this time the 
concentration of glucose declines until it returns to approximately the starting concentration, this 
usually occurs around 2 hours after eating or drinking. Different foods and beverages have different 
effects on blood glucose levels depending on how much carbohydrate is present and how quickly it 
is digested and absorbed. It is now widely recognised that eating foods which raise blood glucose 
levels gradually, rather than rapidly, has health benefits and may help control weight.
This research project will determine whether chocolate affects the absorption of glucose over a  2 
hour period following consumption of a  beverage containing 200 m l o f water and 25 g of glucose. 
Two conditions will be tested over 2 sessions:
1, 2 8  a  white chocolate + g lu co se  beverage
2 . 4 0  g dark chocolate ♦  g lu cose  beverage
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Why have I been chosen?
The participant selection criteria are based upon the Following:
•  Healthy male or female
•  Aged 18 to 60 years
•  Normal body mass index (BMI) between 18.5 and 24.9 kg/m*
•  Non-smoker
•  No known gastrointestinal, metabolic or other chronic disease
•  Not pregnant or lactabng
•  Not taking prescribed medication or dietary supplements
It is up to you to decide whether or not to take part. If you do decide to take part you will be given 
this information sheet to keep (and be asked to sign a consent form) and you can still withdraw at 
any time without it affecting any benefits that you are entitled to in anyway. You do not have to 
give a  reason.
What will happen to me if I take part?
This is a  two phase study that will take place over two weeks; you will be required to  attend the 
School of Food Science and Nutrition twice, once per week on two separate weeks, for a  maximum 
of 3 hours per visit.
Before the study can begin you will be asked to read, complete and sign an informed consent form 
and pre-study questionnaire. All information provided on the pre-study questionnaire is confide itial 
and will only be used to determine suitability for participation in the study.
For three days prior to the study day you will be asked to eat a normal, nutritionally balanced diet 
avoiding alcohol and strenuous physical activity. You will also be asked not to eat foods or drinks 
containing chocolate or cocoa. On the evening before the study day,, you will be asked to eat a 
moderate meal then fast for 12 hours before arriving at your allocated time.
On the study day you will arrive at your allocated time and rest for 10 minutes before providing your 
first sample of blood. You will then be asked to eat a chocolate bar and drink a beverage, , 
containing 200 mL of water, 25 g of ’ 'C-D-glucose and 0.1 g of "C,-D glucose*;within 5 minutes. 
Further blood samples will be collected at 15, 30, 60, 90 and 120 minutes after finishing the 
beverage. At the end of the session you will be provided with a snack.
To be confirmed:
Up to 6 mL of blood will be collected at each time point using a cannula device that allows blood to 
be drawn without the use of a needle.
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Blood will be drawn from a  fingertip using a single-use disposable lancet. The area where the finger- 
prick is performed will initially be sterilised using an alcohol wipe, and allowed to dry. A minimum 
0.4 m l, maximum 0 .6  ml, of blood will b e  collected i n to  a  m ic ro c o lle c t io n  tu b e  a t  e a c h  t im e -p o in t .
•This is a naturally occurring stable isotope-containing form of glucose. It is used in this study due to 
its low natural abundance which allows distinction between the glucose added to and consumed in 
the beverage, and any that may be naturally present in the chocolate.
What are the possible disadvantages and risks of taking part?
There are no additional risks involved as the procedures are according to standard guidelines. Due 
to the short duration o f the study and the consumption of normal food, the risk o f non-routine 
medication being required by a volunteer whilst the study is in progress is very low. This occurrence 
will be dealt with on a case-by-case basis at the discretion o f the volunteer, and recorded by the 
study co-ordinator should the volunteer decide to participate, and be deemed suitable to continue. 
Any adverse effects observed will be treated in the sam e way, with emphasis on the choice of the 
volunteer whether or not to continue with the study. A decision by any volunteer to discontinue 
their involvement In the study shall not Interfere in any way with the manner In which the volunteer 
Is treated by the study co-ordinator. All data will be used even from subjects who withdraw 
(provided that the volunteer consents to this).
What are the possible benefits of taking part?
You may not personally benefit from participating in the study, but results may be used for the 
advancement of knowledge and the future benefit of other individuals.
Will mv taking part in this project be kept confidential?
The result of the data obtained will be reported in a collected manner with no reference to a specific 
individual. Hence, the data from each individual will remain confidential. As a subject only you have 
the right to  know the results o f the total analysis.
i
UREC Ethics form version 11 (updMM 17/01/121
229
What type of information will be sought from mg and why is the collection of this information 
relevant for achieving the research project's objectives?
Data on your general health and blood plasma samples will be collected in the study.
What will happen to the results o f the research project?
Once all participants have completed the study, the information obtained will need to be collected 
and analysed before any results are published. This is likely to take at least one year to be finalised. 
If you would also like to know the results of the study, the research team will be able to give this 
information to you when it becomes available. You will not be identified in any report or 
publication.
Who is organising and funding the research?
This study is organised by Professor Gary Williamson, Food Biochemistry Group, School of Food 
Science and Nutrition, University of Leeds, UK. The research is funded by a  BBSRC industrial case 
award to Nestlé PTC, York, UK.
Who do I contact for further information?
Samantha Ellam, Study Co-ordinator 
School o f Food Science and Nutrition 
Faculty of Mathematics and Physical Sciences 
University of teeds 
Email: fs07sleifflleeds.ac.uk 
Mobile: 07843 171548
Thank you for taking the time to  lead  this information sh e e t
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Informed Consgrrt Form
Research protect lit le The effect of cocoa powder on blood glucose concentration following an oral
glucose tolerance test
Name of researcher Samantha Ellam
In itia l the box i f  you agree with the statement to the left
1 1 confirm that I have read and understand the Participant Information Sheet (dated TBC) 
explaining the above research project and I have had the opportunity to ask questions about 
the project.
2 1 understand that my paitic^ttion is voluntary and that I am free to withdraw at any time 
without giving any reason and without there being any negative consequences, in addiuon, 
should 1 not wish to answer any particular question or questions, I am free to decline. (You 
can contact the study co-ordinator by email fs07slctfIccds ac uk or mobile: 07843 
171548.)
3 I understand that my responses will be kept strictly confidential I give permission for 
members of the research team to have access to my anonymised responses I understand 
that my name will not be linked with the research materials, and I will not be identified or 
idenufiahle in tte report or reports that result from the research
4 I agree for the data collected from me to be used m future research
5 1 agree to take part in the above research project and will inform the principal investigator
should my contact details change
6 1 agree to be recontacted for future research projects related to this study
Name of participant Dale Signalize
Name of person taking consent Dale Signature
Lead Researcher Dale Signature
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Pre-study Questionnaire
Full name
Age; __ Height. Weight
Contact phone no :
F.mail address:
Please circle or tick the appropriate answer.
Q1 What is your gender'’
Mate Female
Q2 Do you smoke’’
Yes No
Q3 Have you been diagnosed with any of the following0
Diabetes Yes No
Pre-diaheles (also known as impaired fasting 
glucose, impaired glucose tolerance)
Yes No
Digestive disease (e g Crohn's disease, celiac 
disease)
Yes No
Sugar intolerance (sucrose, glucose, fructose) Yes No
Food allergy (trace amounts of nuts and gluten may 
be present in the cocoa powder)
Yes No
Hypertension Yes ‘ No
Q4 Are you currently taking any prescribed medication'’
Yes No
Q5. Do you regularly take any dietary supplements
Yes No
Q6 Are you pregnant or Isolating0
Yes No
UREC Ethic* form version 11 (updated 17/01/12)
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Q7 What is your ethnic background'1
D White -  British D Asian or Asian British -  Bangladeshi
□ White -  Irish □ Chinese
□ White -  Scottish □ Other Asian background
□ Irish traveller 0 Mixed -  White and Black Caribbean
D Other white background □ Mixed -  White and Black African
□ Black or Black British -  Caribbean □ Mixed -  White and Black Asian
□ Black or Black British -  African □ Other Mixed background
□ Other Black background □ Other Ethnic background
□ .Asian or Asian British -  Indian □ Prefer not to state
□ Asian or Asian British -  Pakistani
-ft « -
U R E O  E ttu c s fo rm  ve rs io n  11 (updeted 17/01/12)
Pre-study dipt
For 3 days prior to the study day you will be required to  maintain a nutritionally balanced diet 
containing at least 150 g of carbohydrate per day. Below is some Information regarding what a 
nutritionally balanced diet Is, followed by a list of carbohydrate-nch foods and some examples of 
how m uch to consume throughout the day to achieve the required intake.
T h h  h  th e  'e a t w e l  p la te *. I t  show s th e  
d iffe re n t types  of fo o d  w e  n eed  a n d  th e  
p ro p o rtio n s  in  w h ic h  th e y  shou ld  be  
consum ed.
For m o re  in fo rm a tio n , v is it: 
h t tp : / /w w w .n h s .u k /l iv e w e ll /g o o d fo o d
As you can see carbohydrate-rich (starchy) foods should make up approximately one third of your 
daily diet. These foods include bread, rice, potatoes, pasta, oats and breakfast cereals; the table 
below shows average carbohydrate content based on m edium portion sizes.
F o o d P o rtion  s u e C arbohydrate'
B re a d 2 m ed iu m  s l ic e s  (7 2  g ) 32 g
R ic e , b o ile d 180 g 57  g
P o ta to es
O v en  ch ips 165 g 30  g
C n s p s 1 b a g ( 3 0  g ) 1 5 g
B a le d 2 0 0  g
, , „ „ . 1, ... . .'-/li nil-mi. I.-1I -------- n - i  mi ..I. . .  nr. | J
63 g
L________ __________ _____
B o ile d 175 g 30 g
Sp a gh e tti, c o o le d 2 3 0  g 5 1 g
B re a k fa s t  ce rea ls
P o m d g e  o a ts 160 g 106 g
W eetab ix 2 b isc u a ts (3 8  g ) [ » g
C o m H a k e s 3 0  g 2 6 g
Food Standards Agency (1995) Manual of Nutrition Tenth Edition, UK: The Stationery Office
So, If you eat 2 slices of bread and a bowl of cornflakes for breakfast; a baked potato for lunch and 
spaghetti Bolognese for dinner you would consume approximately 170 g of carbohydrate.
Fruit and 
vegetables
M ilk  and
da iry foods
Maat, fish, 
eggs, baans
and other non-dairy 
sources of protein
Food and d rinks 
h igh  In fat and/or sugar
Bread, lice, 
potatoes, pasta
•nd  other starchy foods
U R E C  E th ic s  torm ve rs io n  11 (updated 17X51/12)
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Plasma collection form 
To b« completed by the study co-ordinator
Subject ID code
Test condition
Time point
Collection time
Total »ample volume (m l)
Comment»
UREC Ethics torm version 11 (updated 17/01/12)
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Preparation of acellular human plasm«
Equipment
0.6 m l Sodium fluoride tubes 
1.5 m l centrifuge tubes 
Tube labels
Protocol
1. Collect 0.4-0.6 m l of vrfiole blood into a labelled medical grade PET tube containing 
sodium fluoride (required for inhibition of glycolysis). Immediately place on ice.
2. Within 15 minutes, centrifuge the whole blood sample for 10 minutes at 3000 x g.
3. Using a non-sterile tip, pipette 0.05 mL of supernatant and transfer to a labelled 1 5 
mL centrifuge tube. Several aliquots may be prepared.
4. Seal and freeze upright at S  -20 'C  until required for analysis.
labellina
Blood collection tubes and centrifuge tubes will be labelled as follows:
•  Subject ID code
•  Study code, comprised of:
o  Test condition identification (C1.C2,) 
o  Timepoint (0 ,15, 30 ,60, 90, 120)
•  Date
•  Investigator initials
UREC Etmc« form wrvan I t  <updtf«d 17At/1?)
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Recruitment «mall
Subject: Invitation to eat chocolate...
Main text:
As part of a PhD research project, healthy male and female adults aged 18 to 60 years are invited to 
take part in this pilot study. You will be required to attend 2 sessions over 2 weeks and provide 
blood samples over a 2 hour period at each session. There will be a  12 hour fasting period overnight 
before each session and a snack will be provided at the end of each session.
Volunteers will be asked to follow a nutritionally balanced diet for 3 days prior to each session and 
to avoid alcohol and strenuous physical activity during that time.
The aim of this pilot study is to  determine whether absorption of glucose into the blood is affected 
by consumption of dark chocolate.
For more Information please contact Samantha Ellam by email: fs07sleifflleeds.ac.uk or mobile: 
07843 171548.
This study Is organised by Professor Gary Williamson, Food Biochemistry Group, School of Food 
Science and Nutrition, University o f Leeds.
Participation is entirely voluntary and you are free to withdraw at any time without providing a 
reason. All information that is collected during the study is anonymous and kept strictly confidential.
Thank you for your time.
Samantha Ellam
PhD Research Student
School of Food Science and Nutrition
University of Leeds
UREC Ethics form version 11 (updated 17/01/12>
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8.2 International Conference on Polyphenols and Health 
2009: Cocoa polyphenols inhibit sucrose hydrolysis in
Caco-2 cells
2 3 8
Cocoa polyphenols inhibit sucrose hydrolysis 
in Caco-2 cells
School of Food Science and Nutrition University of Leeds
Introduction
■ Dietary sucrose is hydrolysed in the small intestine by 
; sucrose alpha-glucosidase (EC 3 2 1 48)
¡ • Liberated glucose is primarily transported across the 
epithelium by a process of secondary active transport 
involving the sodium-dependent glucose transporter SGLT1
• During periods of elevated blood glucose passive diffusion 
| of glucose across the apical membrane is additionally
facilitated by the sugar transporter GLUT2
• Rising blood glucose stimulates the release of insulin from 
pancreatic beta cells
• Insulin binds with receptors on the basolateral surface of 
skeletal muscle cells consequently promoting the uptake of
j glucose via the sugar transporter GLUT4
• Attenuation of glucose liberation and transport from the 
intestinal lumen may reduce post-prandial blood glucose 
concentration thereby reducing glycémie load
Methodology
• Caco-2 cells were seeded into 6-well Transwell® plates at a 
density of 282,000 cells per well
• 21 days post-seeding cells were ready for experiment:
| /  Confluent
■ f Polarised 
v  Differentiated
j V Presence of tight junctions
| • Cells were incubated with 20 mM sucrose plus test 
: compound or exlract (pH 7.4) for 20 minutes at 37°C, 5% C 02
| • Solid phase extraction of each sample was performed to 
remove polyphenols
• The concentration of glucose in each sample was measured 
using the glucose oxidase/peroxidase assay
Results and Discussion
Figure 1 i  ineweaver Bur* plot of the mean rate of tucroM hydrotyns (n ■  3) 
m the Caco-2 cell model The maximum rate of reaction (V ^,) and Michael»' 
Men ten constant (K J calculated from the linear regression equation is given
3 00 
2 50 
-, 2 00 
1  150
^  100 -j
>  0 50 
000 
•0 50
1 0 0 ,M 100 jiM 03 nM 4 mg mL ’ 
Catechm Epícatectun ProcyamOtn Cocos
82 extract
Figure 2 The effect of cocoa extract and cocoa polyphenols on the rate of 
sucrose hydrolysis in the Caco-2 cell model
Conclusion and Future Work
• Preliminary results suggest that cocoa extract substantially 
inhibits the rate of sucrose hydrolysis In Caco-2 cells
• 100 ,iM (-)-Epicatechin demonstrated the greatest inhibition 
(45%) followed by 83 pM Procyanidin B2 (32%) and 100 pM 
(v)-Catechin (23%)
• Future work will include determining
-  The kinetic inhibition parameters of sucrose hydrolysis 
using the Caco-2 cell model
-  The effect of cocoa polyphenols on glucose transpod 
across the Caco-2 cell monolayer
UNIVERSITY O F LEEDS
T h i s  project i s  funded by a B B S R C  in d u stria l case award to N estlé , Yo rk U K
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8.3 E llam , S. and W illiam son, G. (2013) ‘C ocoa and Hum an  
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44 Abstract:
45 Cocoa is a dry powdered non-fat component product prepared from the
46 seeds of the Theobroma cacao L. tree and a common ingredient of many
47 food products, especially chocolate. Nutritionally cocoa contains biologically
48 active substances which may affect human health: flavonoids (epicatechin
49 and oligomeric procyanidins), theobromine and magnesium. Theobromine
50 and epicatechin are absorbed efficiently in the small intestine, and the nature
51 of the conjugates and metabolites are now known. Oligomeric procyanidins
52 are poorly absorbed in the small intestine, but catabolites are very efficiently
53 absorbed after microbial biotransformation in the colon. There have now
54 been a significant number of studies on the effects of cocoa and its
55 constituent flavonoids, using in vitro and in vivo approaches. Most human
56 intervention studies have been performed on cocoa as an ingredient,
57 whereas many in vitro studies have been performed on individual
58 components. ~70 human intervention studies have been carried out on
59 cocoa and cocoa-containing products over the last 12 years with a variety of
60 endpoints. These studies indicate that the most robust biomarkers affected
61 remain as endothelial function, blood pressure and cholesterol level.
62 Mechanistically, there is supporting evidence to show that epicatechin
63 affects, amongst other targets, nitric oxide synthesis (eNOS), breakdown
64 (via inhibition of NADPH oxidase) and the substrate arginine (via inhibition of
65 arginase). The evidence further supports cocoa as a biologically-active
66 ingredient with potential benefits on biomarkers related to cardiovascular .
67 . disease. However, when present in chocolate, consideration should always
68 be given to the calorie and sugar content in the total diet.
69
4
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70 INTRODUCTION
71
72 Cocoa is a dry powdered non-fat component product manufactured from
73 seeds of the Theobroma cacao L. tree, and is the ingredient considered in
74 this review. Cocoa liquor also contains cocoa butter (~55%) and is the
75 material used in chocolate confectionery manufacture along with other
76 ingredients such as sugar, emulsifier, milk protein, etc. depending on the
77 desired product. The production of cocoa liquor begins with cleaning the
78 seeds followed by a fermentation stage during which the chemical
79 composition of the bean is altered. After drying, the beans are roasted either
80 before or after shelling (winnowing), a fundamental part of the process that
81 affects the flavour characteristics and nutrient profile of the final product (1).
82 The shelled bean, known as the nib, is then ground to a paste, which causes
83 melting of the fat and formation of the cocoa liquor. The liquor may then be
84 treated with an alkali solution, termed ‘Dutching’, to increase the pH and
85 improve palatability. Similar to the roasting process, the alkalising step
86 affects the chemical composition of the cocoa liquor such that both stages in
87 processing may be refined and strictly controlled to develop a product with a
88 specific chemical profile (2). Being a roasted natural product, cocoa is a
89 complex material. The primary components impacting on health are currently
90 considered to be the naturally-occurring or process-derived flavonoids,
91 theobromine, and magnesium. The ingredients added to make chocolate,
92 sugar and cocoa butter, will not be discussed here.
93
94 In Europe, consumers prefer milk chocolate but dark chocolate is almost as
popular (3). In the US, milk chocolate is also the most popular, although the
5
95
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96 majority of US confectionery consumption (~87 %) is not as pure chocolate
97 but rather enrobed with nuts, wafer, fruit, etc (4). Cocoa taken as a beverage
98 is also popular in some countries like Spain and this should also be taken
99 into account when surveying intake of chocolate and cocoa products.
100 Nutritionally, chocolate generates vehement debate in popular articles, and
t
101 opinions on the internet can be found that cover the whole range from
102 glorification of the benefits to emphasis on the evils of consumption! News
103 articles can be found claiming that “chocolate should be taxed to control
104 obesity" and at the other end of the scale that “chocolate may help keep you
105 slim”. The 2008/2009 UK National Dietary Nutrition Survey (5) reported that
106 adults were consuming an average of 21 g of chocolate confectionery per
107 day and the 2010 Family Food survey (6) reported an average contribution
108 to energy intake from confectionery (including chocolate) of 4% per person
109 per day. In 2010 confectionery as a whole contributed 15% of the total non- 
no milk extrinsic sugars consumed per person per day from household
111 purchases and 13% from foods purchased outside the home (6); the current
112 UK reference nutrient intake recommends that non-milk extrinsic sugars
113 should not provide more than 11 % of the daily energy intake (7). A recent
114 report (8) demonstrated that whilst economies globally have been in
115 recession, the chocolate market has remained stable; in fact its retail market
116 value has risen marginally each year since 2007 and is predicted to continue
117 growing at a rate of 2% per year over the next 5 years. The majority of the
118 global market is held by Western Europe (32%) followed by North America
119 . (20%), Asia (17%), Latin America (13%), Eastern Europe (12%), Middle East
120 and Africa (4%) and Australasia (2%), with large growth predicted in the
121 smaller markets over the coming years.
6
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123 There have now been several hundred human intervention studies on
124 flavonoids and flavonoid-rich foods, reviewed in many publications (3;9-12).
125 The role of flavonoid-rich foods on health has further been supported by
126 many epidemiological studies including meta-analyses comprising large total
127 numbers of volunteers (13). These studies infer a general and fairly
128 consistent protection by flavonoids against heart disease and biomarkers of
129 cardiovascular risk, while the evidence for protection against cancer is
130 weaker. This review will focus on recent work on the effect of cocoa,
131 including cocoa flavonoids, on biomarkers related to cardiovascular health.
132 Previously studies have shown that cocoa may improve cardiovascular
133 health by improving flow mediated dilation, a marker of endothelial function,
134 decreasing the susceptibility of LDL to oxidation, inhibiting platelet
135 aggregation and activation, and decreasing levels of F2-isoprostanes (3).
136 Recent meta-analyses on human intervention studies associated dark
137 chocolate with a reduction in systolic hypertension or diastolic pre-
138 hypertension (14) and both chocolate and cocoa with improvements in flow
139 mediated dilation (15).
140
141 BIOLOGICALLY ACTIVE COMPONENTS OF COCOA
142
143 Flavonoids
144
145 Cocoa beans contain a high amount of flavonoids, a member of the broader
146 polyphenol class. The main constituents are flavan-3-ols (Figure 1 ), present
147 as monomeric (-)-epicatechin and (+)-catechin, together with type-B
7
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148 proanthocyanidins, formed from monomeric flavanols by oxidative coupling
149 between the C-4 of the heterocyclic ring and the C-6 or C-8 positions of the
150 adjacent unit to create oligomers and polymers. Procyanidins in cocoa
151 include the B2 and B5 dimers and the C1 trimer, together with high levels of
152 longer chain polymers comprising four or more monomeric units (16; 17).
153 Flavan-3-ols are lost during fermentation, treatment with alkali and roasting
154 (18) so that the total flavan-3-ol content of commercial cocoa varies by >10-
155 fold (19). Processing can also result in some epimerisation of (-)-epicatechin
156 to form (-)-catechin (20;21).
157
158 Theobrom ine
159
160 Theobromine (Figure 2) is a 3,7-dimethylated xanthine alkaloid that is also
161 formed during caffeine metabolism. It is most commonly consumed in the
162 human diet from chocolate and cocoa but is also present in tea. Especially
163 high levels are present in cocoa, about 2.5% of dry weight, whereas caffeine
164 is - 1 0-fold lower (~0.24%) (22). Theobromine is not degraded during cocoa
165 processing and can be used as a marker of cocoa content (21). The effect of
166 theobromine on arteriosclerotic pain was reported as far back as 1926 (23).
167 The more recent focus on cocoa flavonoids has meant that theobromine is
168 often not considered as a component responsible for an observed activity,
169 but its high bioavailability and potential biological activities mean that it
170 should not be ignored in cocoa intervention studies.
171
172 M agnesium
173
8
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174 According to the USDA National Nutrient Database, magnesium is found at
175 significant levels in cocoa (2-4 mg/g dry powder). Although dependent on the
176 type of chocolate, this means that a 40 g portion of 70%-cocoa dark
177 chocolate would contain «40 mg of magnesium, enough to make a modest
178 -10% contribution to the recommended daily allowance (300-400 mg
179 magnesium /day in adults) (24). Magnesium is an essential co-factor in
180 many hundreds of enzyme-catalysed reactions in vivo, and is essential for
181 maintenance of blood pressure, neuronal transmission and muscular
182 contraction. Deficiency has been linked to the metabolic syndrome, insulin
183 resistance and diabetes (24).
184
185 BIOAVAILABILITY OF INTACT FLAVONOIDS FROM COCOA
186
187 After consumption of food, any biologically active component must survive in
188 the digestive tract and be absorbed and metabolised in a form which
189 reaches and influences the target tissue, 'n the mouth, procyanidins bind to
190 salivary proteins, the degree of binding influenced strongly by the inter-
191 flavan-3-ol linkage and the chemical nature of the structural monomeric units
192 rather than size of the oligomers (25;26). In vivo, flavanols are stable in the
193 stomach (27), and reach the small intestine intact. The jejunal pH can reach
194 8.5, where flavanols are expected to be unstable, but epicatechin and
195 procyanidins appear to remain largely unaffected in the small intestinal
196 lumen, dependent on the food matrix, presumably due to the stabilising
197 influence of protein and other food constituents (28;29). Flavanols may also
198 be stabilised by the presence of fat in the intestinal lumen (30). Epicatechin
is absorbed in the small intestine and after consumption of dark chocolate,
9
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200 conjugation produces (-)-epicatechin-3'-0-(3-D-glucuronide, (-)-epicatechin
201 3-O-sulfate, and 3'-0-methyl epicatechin sulfates (substituted in the 4', 5,
202 and 7 positions) in the plasma with a time of maximal concentration in the
203 blood of at 3-4 h (31). Epicatechin is subsequently excreted in urine with a
204 similar, but not identical, profile of conjugates and urinary data show that a
*
205 minimum of 20% of the epicatechin dose from cocoa is absorbed (31),
206 apparently higher than the dose of epicatechin absorbed from green tea
207 (32). The food matrix affects the rate and extent of absorption (33). Studies
208 on rats have indicated that flavan-3-ol monomer conjugates may be
209 transferred from the blood stream to the liver and subsequently returned to
210 the small intestine via bile (34;35). Regarding the oligomers, intact
211 procyanidin dimer B2 is poorly absorbed intact both in humans and animals
212 (36-38), and has only been detected at very low levels in human urine after
213 consumption of cocoa (39). Individual human intervention studies on
214 absorption and metabolism have been reviewed in detail (10;33).
215
216 METABOLISM AND ABSORPTION OF PHENOLICS AFTER MICROBIAL
217 CATABOLISM
218
219 There is now compelling evidence that the microbiota play a major role in the
220 metabolism of flavanols which reach the colon i.e. the proportion which are
221 not absorbed in the small intestine. After cocoa consumption by humans, 3-
222 (3'-hydroxyphenylpropionic acid, 3'-hydroxy-phenylacetic acid, 3',4'-
223 dihydroxy-phenylacetic acid, 3-hydroxybenzoic acid, ferulic acid, 5-(3',4'-
224 dihydroxy-phenyl)-y-valerolactone (5) and 5-(3'-methoxy-4'-hydroxyphenyl)-
10
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225 y-valerolactone were excreted in urine, peaking between 9 and 48 h,
226 indicative of microbial catabolism (39;40). These microbial metabolites
227 constitute about 80% of the dose of radiolabelled procyanidin B2 in rats, as
228 judged by urinary appearance and a late Tmax (41), even though the intact
229 parent compound is almost absent from plasma and urine. The broad range
230 of metabolites produced by the microbiota has been shown using in vitro
231 incubations and analysis of the intermediate and final products, where
232 catabolism favoured removal of the 4' rather than the 3'-hydroxyl group,
233 along with both p-oxidation and a-oxidation and some scission of the
234 interflavan bond (42;43). Metabolism of radiolabelled procyanidin polymers
235 (average dp ~6 ) by human colonic microflora in vitro showed that they were
236 almost totally degraded after 48 h. The main metabolites detected were
237 similar to those described above found in urine (44). Some patterns in the
238 appearance of gut microbiota metabolites are apparent depending on the
239 class of parent polyphenol, and in general after consumption of
240 procyanidins, the flavan-3-ols are mainly converted to CeC2 and C6C3-
241 dihydro forms partly via C6-C5 intermediates, the latter being unique to
242 flavan-3-ols (45).
243
244 BIOAVAILABILITY OF THEOBROMINE
245
246 Theobromine is absorbed extensively in the small intestine and the
247 metabolic pathway is quite well understood. The main metabolite is 7-
248 methylxanthine which accounts for up to 30% of the dose, 3-methylxanthine
249 accounting for ~20% and 7-methyluric acid for ~4% of the dose (46). 3,7-
dimethyluric acid and 6-amino-5-(N-methyl-formylamino)-1-methyluracil are
11
250
250
251 also present in urine following consumption of cocoa powder (47-49).
252 Unmodified theobromine is also found in urine and a small amount in feces
253 (<1.5% of the ingested dose) (49). The half-life of theobromine in plasma
254 was 7.2 h when consumed in the form of a gelatine capsule (50) and 10 h
255 when ingested from an aqueous solution (49). The maximum plasma
*
256 concentration of theobromine from chocolate is reached approximately 2 h
257 post-ingestion suggesting that it is entirely absorbed in the small intestine
258 (49). Although the mechanism for absorption through the intestinal
259 epithelium has not been described exactly, based on in vitro absorption of
260 caffeine using Caco-2cells (51), it can be surmised that theobromine
261 similarly diffuses passively through the enterocytes into the hepatic
262 circulation.
264 The mechanisms by which theobromine is demethylated and oxidized to
265 methyluric acid involve hepatic cytochrome P450 enzymes with specific
266 involvement of the monooxygenase (EC 1.14.14.1) isoforms CYP1A2 and
267 CYP2E1 (52-54). The primary metabolite, 7-methylxanthine, is a product of
268 both enzyme isoforms. CYP2E1 appears to be the least specific as it also
269 catalyses the formation of 3-methylxanthine and 3,7-dimethyluric acid (55).
270 Whilst the 3-methylxanthine isomer may undergo limited further metabolism
271 to 3-methyluric acid (-1 % of dose) (53), 7-methylxanthine is the main
272 substrate from theobromine catabolism for xanthine oxidase (EC 1.17.3.2)
273 which catalyses the oxidation of carbon-8 to form 7-methyluric acid. The .
274 bioavailability of theobromine and high levels in cocoa mean that levels will
275 reach micromolar levels in plasma after consumption of modest amounts of
276 cocoa.
12
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278 EFFECTS OF COCOA IN HUMAN INTERVENTION STUDIES
279
280 The 28 human intervention studies on the effect of cocoa between 2000 and
281 2007 have been reviewed (3). The main outcomes were improved
282 endothelial function, decreased susceptibility of LDL to oxidation, inhibition
283 of platelet aggregation and activation, and decreased levels of F2-
284 isoprostanes. Since then, there have been numerous reviews regarding the
285 role of cocoa in specific health issues, in addition to a small number of
286 epidemiological studies. Since 2007, the majority of published work in
287 human and non-human intervention trials focused on the effect of cocoa
288 products, or individual chemical components of cocoa, on risk of
289 cardiovascular disease as estimated using surrogate biomarkers. Discussion
290 in this section predominantly considers the literature pertaining to
291 cardiovascular disease but is inclusive of other areas of study, with all
292 human intervention trials conducted since 2007 summarised in Table 1. Of
293 these studies,, 15 have measured changes in parameters related to
294 endothelial function, either flow mediated dilation, angiotensin converting
295 enzyme activity or nitric oxide/nitrite levels. Blood pressure changed in 9 of
296 the studies and cholesterol levels were affected in 13 studies. Oxidative
297 parameters, such as F2-isoprostanes and susceptibility of LDL to oxidation,
298 were changed in 9 of the studies. Other parameters reported to be affected
299 by cocoa intervention were glucose/insulin levels (5 studies), platelet
300 function (5 studies), brain blood flow and cognitive function (4 studies),
301 inflammation (2 studies) and skin (2 studies). Six of the studies used
exercise in some form as a variable in at least one of the study arms. These
13
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303 studies indicate that the largest changes measured remain as endothelial
304 function, blood pressure and cholesterol levels. However, variations in study
305 time, from a single dose up to 3 months intervention, and in the type of
306 cocoa given, make rigorous interpretation difficult. It is interesting to note
307 that positive changes in flow mediated dilation may be greatest when cocoa
308 is administered in the absence of sugar (56).
309 '
310 Epidemiological evidence
311
312 In the last few years, several epidemiological studies have reported on the
313 effects of cocoa intake in various population groups. Elderly male
314 participants in the Zutphen Elderly Study had lower cardiovascular mortality
315 when correlated with long-term cocoa intake (57). The risk of death from
316 stroke, coronary heart disease and cardiovascular disease amongst
317 participants of the Iowa Women’s Health Study was lower in women who
318 consumed chocolate relative to those who consumed no chocolate (58).
319 Similarly data taken from the United States National Heart, Lung and Blood
320 Institute Family Heart Study (59) suggests that compared with no intake,
321 participants with a greater frequency of chocolate intake have reduced
322 coronary heart disease prevalence, the lowest found for consumers of 5 or
323 more servings per week. In contrast, a study of women participating in the
324 Swedish Mammography Cohort (60) demonstrated that the beneficial effect
325 of chocolate consumption on risk of heart failure was reversed as intake
326 exceeded 2 servings per week. It is relevant to note at this point that exact
327 serving size is not stated in the aforementioned studies, although the
328 authors of the Swedish investigation do suggest an average portion size
14
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329 somewhere between 19 and 30 g. There was an inverse association
330 between chocolate consumption up to 7.5 g per day and risk of
331 cardiovascular disease among German adults participating in the European
332 Prospective Investigation into Cancer (61). In the latter study and that of the
333 Iowa Women’s Health Study, the association appeared most compelling for
334 stroke. Evaluation of data taken from The Stockholm Heart Epidemiology
335 Program (62) of individuals who have experienced a first acute myocardial
336 infarction show that the risk of cardiac mortality was lowest in those who
337 consumed a 50 g portion of chocolate at least twice per week, and the risk of
338 a non-fatal stroke was shown to be lowest in those consuming up to one
339 portion per week.
340
341 From these epidemiological studies it can be inferred that the consumption
342 of 50-100 g per week of chocolate may reduce the risk of cardiovascular
343 disease, in particular stroke. What is not established in any of these
344 investigations is the type of chocolate consumed i.e. dark, milk or white, and
345 the possible addition of other ingredients such as fruit or nuts, important
346 factors in the overall analysis of the evidence, in addition to total diet and
347 numerous other cardiovascular disease risk factors. Dark chocolate typically
348 contains more non-fat cocoa solids than milk chocolate, while white
349 chocolate contains none. As the percentage of non-fat cocoa solids content
350 increases, the percentage content of sugar decreases. Further, milk and
351 white chocolate also contain milk powder that is not present in dark
352 chocolate. A case in point is demonstrated in a study (63) where the lipid
353 profile and inflammation biomarker concentration was improved following
consumption of a cocoa product with the addition of hazelnuts, phytosterols
15
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355 and soluble fibre. However, the cocoa product without added ingredients had
356 no significant effect.
357
358 Some epidemiologists have investigated more specific interactions by
359 focusing on particular components of cocoa rather than the product per se.
360 As with the majority of all evidence discussed in this review, the
361 overwhelming theme is flavonoids and in particular the flavan-3-ol and
362 proanthocyanidin sub-classes of polyphenols, although other components
363 could conceivably have complementary, antagonistic or synergistic effects.
364 An evaluation of incident hypertension, biomarkers of inflammation and
365 endothelial dysfunction in relation to flavonoid intake of participants in the
366 Nurses’ Health Study I and II, and the Health Professionals Follow-Up Study
367 (64;65), did not find any relationship with flavan-3-ol or proanthocyanidin
368 intake. However, at the highest daily intake of catechin and epicatechin, the
369 primary flavan-3-ol constituents of cocoa, a significantly lower risk of incident
370 hypertension was found. In contrast, a recent study (66) demonstrated a
371 significant reduction in the risk of cardiovascular disease with increased
372 intake of flavan-3-ols and proanthocyanidins although this attenuation was
373 not linear and, similar to other evidence from epidemiological studies,
374 reversed in the highest intake groups.
375
376
377
378 M echanism s of biological effects
379
380 E n d o th e lia l ce ll dysfunction
1 6
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381
382 Endothelial cell dysfunction represents a risk factor for cardiovascular
383 disease and as such has been widely studied in vivo and in vitro (67). Many
384 of the human intervention trials discussed here involve quantification of
385 products secreted by the endothelium such as nitric oxide, or expression of
386 inflammatory response proteins such as interleukin-6 (IL-6). For example,
387 nitric oxide (NO) production by platelets isolated from healthy subjects was
388 increased following 3 weeks daily consumption of dark chocolate (68). At
389 least half of the studies listed in Table 1 reported improvements in
390 parameters related to endothelial function. Generally these are biomarkers
391 related to NO metabolism, including flow mediated dilation, angiotensin
392 converting enzyme activity or nitric oxide/nitrite levels. Mostly favourable
393 changes in blood pressure were reported in 9 of the studies. This marker is
394 especially important since average decrease in diastolic blood pressure in a
395 population of 1 mmHg is enough to reduce the incidence of coronary heart
396 disease events by 5% and of stroke by 7% in persons aged 50-69 y with a
397 systemic (high) blood pressure of 150 mm Hg and a diastolic blood pressure
398 of 90 mm Hg (69). Although an association between a sharp increase in
399 cardiovascular disease (CVD) mortality and blood pressure (BP) was made
400 very early, newer studies have introduced the notion of “background"
401 hypertension (pre-hypertension) and support the idea that pre-hypertension
402 increases the rate of cardiovascular disease only when accompanied with
403 other risk factors, the age having a major impact.
404
405 Systolic blood pressure in spontaneously hypertensive rats was reduced,
considered to be a consequence of increased nitric oxide production,
17
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following an acute dose of CocoanOX; the effect was prevented in the 
presence of an endothelial nitric oxide synthase (eNOS) inhibitor (70). The 
same authors investigated the long-term effect of CocoanOX 
supplementation and observed attenuated development of hypertension in 
spontaneously hypertensive rats with the effect being greatest in animals 
given the lowest dose (71). In another study, spontaneously hypertensive 
rats whose diets were supplemented with soluble cocoa fibre exhibited lower 
systolic and diastolic blood pressure during the treatment period. Throughout 
a 4 week post-treatment period when the test diet had been discontinued, 
systolic blood pressure increased equivalent to control and diastolic blood 
pressure increased beyond that of control animals (72).
Spontaneously hypertensive rats administered 200 and 400 mg kg'1 body 
weight doses of CocoanoX exhibited higher plasma angiotensin converting 
enzyme activity at the end of the intervention period, and plasma 
concentration of angiotensin II was also raised. The latter remained elevated 
after the treatment ended. The same study measured relaxation of pre­
contracted intact aorta rings extracted from control animals induced by 
incubation with CocoanOX. Relaxation was reduced in the presence of Nw- 
nitro-L-arginine methyl ester but not indomethacin implying that dilation was 
a result of eNOS activity rather than prostaglandin-l synthase (73). Similar 
effects were reported using pre-contracted renal arteries isolated from wild- 
type and atherosclerotic mice (74). Catechin treatment in wild-type mice .. 
during months 9 to 12 improved dilation, at 12 months compared with the 
untreated group; however this effect was not replicated in atherosclerotic
mice. Incubation with NG-nitro L-arginine attenuated dilation in untreated
■ 18
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433 wild-type mice but animals exposed to 3 months catechin treatment were
434 unaffected, suggesting that eNOS was not inhibited in catechin treated cells
435 or that addition of indomethacin to the incubation did not further affect this
436 result.
437
438 In vitro studies using human umbilical vein endothelial cells (HUVEC) are
439 widely used as a model to study endothelial function. On incubation of
440 HUVEC cells with (-)-up to 1 pM epicatechin for 2 h, nitrite, as an indirect
441 marker of the intracellular nitric oxide level, increased significantly (75).
442 Similarly the greatest augmentation of nitric oxide produced by human
443 coronary artery endothelial cells followed a 10 min incubation with 1 pM (-)-
444 epicatechin (76). Following a 24 h incubation with (-)-epicatechin, there was
445 no significant change in endothelial nitric oxide synthase (eNOS) mRNA
446 expression nor any variation in its stability (75). It is hypothesized that
447 increased production of nitric oxide is attributable to an interaction with the
448 phosphatidylinositol 3-kinase pathway which is involved in controlling
449 phosphorylation of the activation residues Seri 177 and Ser633. Treatment
450 of human coronary artery endothelial cells with epicatechin increased
451 phosphorylation of these serine residues and reduced phosphorylation of
452 Thr495. In addition, epicatechin treatment appeared to induce activation of
453 eNOS through uncoupling from caveolin-1 (Figure 3). The latter binds to the
454 cytosolic side of the cell membrane in its inactive form, and binding with
455 calmodulin stimulates solubilisation of the active form, mediated via
456 interaction with phospholipase C. Whilst these conditions were dependent
457 on the presence of calcium, epicatechin is able to stimulate NO production
induced by phosphorylation of serine residues and activation of eNOS
19
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459 without uncoupling from caveolin-1 in calcium-free conditions (77). Similarly
460 enhanced phosphorylation of non-specific serine/threonine protein kinase
461 (Akt), an enzyme involved in the phosphatidylinositol 3-kinase pathway, was
462 measured in mice subjected to ischemia-reperfusion injury following 10 d of
463 supplementation with 1 mg kg'1 body weight (-)-epicatechin; infarct size was
*
464 reduced. Co-supplementation with the opioid antagonists naloxone or
465 naltrindole eliminated the effect on Akt phosphorylation and infarct size. The
466 results suggest that the protection conveyed by epicatechin was dependent
467 on interaction with opioid receptors in the heart (78). Endothelium secretion
468 of endothelin-1 is associated with vascular constriction and therefore
469 increased concentration has negative cardiovascular consequences. Bovine
470 aortic endothelial cells treated with a procyanidin-rich extract of cocoa
471 produced less endothelin-1 than control cells; the response was dose-
472 dependent (79). Procyanidin-rich extracts of other fruits elicited similar
473 results and the trimer to pentamer fractions of a cranberry extract were
474 shown to down-regulate expression of endothelin-1 mRNA and up-regulate
475 Kruppel-like factor 2 mRNA, a transcription factor that mediates the
476 synthesis of endothelin-1. There was a similar reduction in endothelin-1
477 synthesis in HUVEC treated with a procyanidin-rich fraction of apple (80).
s '-
478 Epicatechin also inhibits NADPH oxidase (81) and arginase activity (82),
479 leading to elevated intracellular NO levels (Figure 4).
480
481 An elevated nitric oxide concentration in vivo is generally regarded as
482 beneficial due to its vasodilating properties and inhibition of platelet
483 aggregation. It is possible that reported increases in flow-mediated dilation
484 and reduction of blood pressure following cocoa consumption (see Table 1)
20
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485 are due to an increase in the production of nitric oxide stimulated by
486 epicatechin. Therefore, chronic intake may have a long-term protective
487 effect against cardiovascular disease via these mechanisms.
488
489 In flam m ation
490
491 Inflammation is a complex process and several biomarkers are used to
492 identify chronic inflammation in humans. Although multiple biomarkers are
493 now recommended to assess cardiovascular disease risk, a higher C-
494 reactive protein concentration is associated with a higher risk of coronary
495 heart disease (83-86). In a cohort of healthy Italian adult participants in the
496 Moli-sani Project, consumers of less than 3 x 20 g servings per week of dark
497 chocolate had lower plasma concentrations of C-reactive protein (87), but,
498 as observed in other studies, this effect was negated in those consuming 3
499 or more servings per week. The overall effect, as assessed from human
500 intervention trials published since 2007 in which serum C-reactive protein
501 concentration was quantified following chronic cocoa supplementation, is
502 inconclusive. In healthy subjects, significant reductions in C-reactive protein
503 following intervention were seen (88;89), whereas in subjects suffering from
504 hypertension, hypercholesterolemia or type-2 diabetes, no significant
505 changes were observed (90-92). In comparison, a study of diabetic mice,
506 where diets were supplemented with epicatechin, reported significantly lower
507 C-reactive protein levels compared with control diabetic mice (93). Although
508 serum C-reactive protein concentration is indicative of cardiovascular
509 disease, it is yet to be determined whether a high serum concentration
510 contributes to the development of disease or whether it is a consequence of
21
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511 the disease. So at this point the level of intake of cocoa products or
512 individual components, and whether any ability to lower C-reactive protein
513 levels improves prognosis in patients or reduces risk in a healthy population,
514 is yet to be evaluated.
515
*
516 O xidative  s tress  a n d  dys iip idem ia
517
518 Oxidative stress is a broad term covering many aspects related to
519 generation of reactive oxygen species, with both chemical and biological
520 consequences. In a biological sense, the term must be carefully defined and
521 several biomarkers have been used to indicate a general oxidative stress in
522 vivo (94;95). Dyslipidemia constitutes a major risk factor for cardiovascular
523 disease that has prompted an abundance of investigations, not least in
524 relation to cocoa consumption. Many of the intervention trials listed in Table
525 1 have reported increased HDL cholesterol levels and improved total
526 cholesterol/HDL cholesterol ratio following dietary cocoa intervention
527
528 Animal models have also supported the association. When fed to rats, a
529 cocoa fiber product protected against the effects of a high cholesterol diet,
530 namely total-, LDL and HDL-cholesterol and serum malondialdehyde (96;97)
531 and a similar effect was seen with 0.5 or 1.0% cocoa procyanidins (98). In
532 the Zucker rat model of obesity and metabolic syndrome, 5% soluble cocoa
533 fibre diet reduced plasma malondialdehyde and increased adiponectin (99).
534 The 5% soluble cocoa fibre diet also reduced malondialdehyde plasma
535 concentration in spontaneously hypertensive rats (72). A similar reduction in
536 plasma malondialdehyde concentration was observed when spontaneously
22
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537 hypertensive rats were treated with 100, 200 and 4C0 mg kg'1 body weight
538 doses of CocoanOX, while the effect was reversed by the end of a 4 week
539 post-treatment period (73). Obese-diabetic rats fed a diet supplemented with
540 cocoa extract for 4 weeks demonstrated improved levels of plasma total
541 cholesterol, plasma triglycerides and LDL cholesterol. There were no
542 significant changes in plasma HDL cholesterol concentration (100). Similar
543 improvements were observed in diabetic mice treated with epicatechin for 15
544 weeks together with enhanced longevity. Compared with non-treated
545 diabetic mice, insulin-like growth factor-1, C-reactive protein, interleukin-1 p
546 and glutathione were either returned to control levels or reduced significantly
547 (93). Daily oral supplementation of rats with 1 mg kg'1 body weight
548 epicatechin for 10 d prior to ischemia-reperfusion injury reduced infarct size
549 and oxidized glutathione/reduced glutathione ratio (GSSH/GSH) at 48 h
550 post-injury. Infarct size remained significantly smaller at 3 weeks post-injury
551 (101). A further study by the same authors performed on animals exposed to
552 permanent coronary occlusion (POC) yielded very similar results of infarct
553 size (102).
554
555 Cognitive function
. 556
557 Of the studies shown in Table 1, four have shown an improvement in some
558 biomarkers of cognitive function including cerebral blood flow, lowered
559 fatigue and increased processing of tasks (103-106). The changes are
560 modest but significant, and the mechanism may be related to vasodilation
561 and increased blood flow to the brain and nervous system.
562
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563 Conclusions
564
565 Cardiovascular diseases are responsible for more deaths globally than any
566 other cause (107) and are the focus of much research, not least in relation to
567 cocoa. The main target of such research has been to identify associations
*
568 between intake and disease, and to discover mechanisms by which onset of
569 disease can be delayed or prevented, or where treatment of cardiovascular
570 events can be facilitated. Many of the human intervention studies described
571 in Table 1 have involved intervention treatments that have demonstrated .
572 improvements in markers of disease risk factors such as total/HDL
573 cholesterol ratio and flow-mediated dilation. Nitric oxide synthesis is
574 possibly the most investigated endothelial function in relation to cocoa over
575 the last 5 years with many authors reporting increases jn NO concentration
576 of plasma. The predominant mechanistic hypothesis is that cocoa, especially
577 epicatechin, stimulates eNOS activity, inhibits arginase and inhibits NADPH
578 oxidase, leading to lower levels of superoxide and hence higher levels of
579 NO. Although this is not the only mechanism involved, a substantial increase
580 in NO synthesis may account for flow-mediated dilation and lower blood
581 pressure following intervention treatments.
582
583 Future prospects
584 Despite a substantial number of human studies which consolidated the
585 effects on endothelial function, blood pressure and cholesterol, the advances
586 in the last 5 years have been incremental and supportive, rather than
587 revolutionary. While important, there are other aspects that need addressing
588 in the future. One of the most important is the assessment of long term
24
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589 nutritional doses as compared to high dose acute studies, and the relative
590 benefits of each. There are no easy ways to measure chronic effects, and
591 usually epidemiological studies have been used to fill this gap. Controlling
592 the diet of human in the long term is almost impossible, and novel strategies
593 need to be devised to test chronic effects. An important fact is that most
594 cocoa consumption worldwide is as chocolate, which also contains
595 additional calories, and these should be taken into account in any
596 intervention studies. Most of the recommendations made previously are still
597 relevant (3), especially the design of a relevant “edible” placebo (especially
598 important for chronic studies, and milk chocolate is not a real control for dark
599 chocolate owing to the milk content) and the need to publish the results of
600 studies where cocoa does not give a measured effect. (3)
601 
602
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613 A cronym s and definitions:
614
615 “Polyphenol(s)” is used as a collective term for phenolic acids, flavonolds,
616 isoflavones and tannins. Hence polyphenols strictly should be written as
617 (poly)phenols, since phenolic acids are (mono)phenols, flavonoids and
is
618 isoflavones are (di)phenols (the C ring is not a true phenolic ring) and
619 tannins are (poly)phenols. Flavonoids consists of several classes, of which
620 the flavanols (also called flavan-3-ols, and including their oligomers, the
621 proanthocyanidins), flavonols, anthocyanins, flavanones and flavones are
622 the most abundant in the diet.
623 Epicatechin is the main flavanol in cocoa and there are many reports on
624 this flavonoid. It has anomeric carbons at positions 2 and 3, making 4
625 possible structures: (-)-epicatechin and (+)-catechin, which occur naturally
626 in plants, and (—)-catechin and (+)-epicatechin, which occur in foods owing
627 to isomerization during processing. Each form is absorbed to different
628 extents (108), supporting the concept of active processes involved in
629 absorption and metabolism. In this review, where the “(—)-epicatechin" form
630 is specified in the paper, then this notation is used. If the form is not
631 specified, then "epicatechin” is used.
632 Cocoa is a dry powdered non-fat component product manufactured from
633 cocoa beans. The full cocoa bean is used to make cocoa liquor, containing
634 the constituent cocoa butter (—55%), and is used to make chocolate after
635 addition of other ingredients such as sugar, emulsifier, milk protein, etc. .
636 CocoanOX is a commercially available polyphenol-rich cocoa powder which
637 has been used in several experimental intervention studies.
638
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Intervention Control Study design Outcomes Ref.
Cu deficient patients 
supplemented with 
10-40 g cocoa 
powder per day until 
improvement 
observed
None Serum trace metal 
concentration monitored s 
24 months post-enteral 
tube insertion in 23 
patients (78.8 ± 10.4 years)
f  serum [Cu] and neu trophil count (109)
One cup of espresso 
coffee and 30 g DC 
(separate occasions)
None 50 term pregnant women 
without complicated 
gestation (31.8 ± 5.05 
years)
1 fetal HR accelerations and 
variability
(110)
15 g pp-rich DC per 
day for 8 weeks
15 g macronutrient 
matched low-pp 
chocolate (3.9 mg 
ECE g>)
Double-blind, randomised 
cross-over; 10 subjects 
diagnosed with CFS (6 
females, 4 males) (52 ± 8 
years)
Improved symptoms of CFS (111)
HF beverage Macronutrient- 
matched LF 
beverage
Cross-over; 10 healthy 
females (18-65 years)
|  cutaneous blood flow (112)
265
20 g HF chocolate 
per day for 12 weeks
20 g LF chocolate 
(<30 mg flavanols)
Double-blind, randomised; 
30 healthy subjects (22 
females, 8 males) (42.7 ± 
10 years)
t  minimal erythema dose (113)
37 g DC and 237 mL 
cocoa beverage per 
day for 6 weeks
Low-pp bar and 
beverage
containing 0.20 mg 
g 1 and 40.87 mg 
g_1 total
proanthocyanidins,
respectively
Double-blind, randomised; 
101 healthy subjects (60 
females, 41 males) (>60 
years)
t  pulse rate at midpoint and end-of- 
treatment
(114)
Flavanol-rich cocoa 
beverage per day for 
1 week >
Flavanol-poor 
cocoa beverage 
(36 mg flavanols 
per day)
Double-blind, randomised; 
21 healthy subjects (10 
females, 11 males) (72.2 ± 
6 years)
f  cerebral blood flow in response to 
acute dose of cocoa beverage
(106)
Cocoa beverage 
containing either 520 
mg or 994 mg cocoa 
flavanols
Macronutrient- 
matched cocoa 
beverage/46 mg 
cocoa flavanols
Double-blind, cross-over; 
30 healthy subjects (17 
females, 13 males) (21.9 ± 
SE 0.61 years)
Improved cognitive performance 
and reduced mental fatigue
(105)
35 g DC 35 g white 
chocolate
Cross-over; 30 subjects 
(22 females, 8 males) (18- 
25 years)
Improved contrast sensitivity, 
motion integration threshold, visual 
spatial working memory, and 
reaction time
(104)
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20 g chocolate 
beverage containing 
MF or HF content per 
day for 30 days
20 g chocolate 
beverage LF 
content
Double-blind, randomised; 
63 subjects (52.30 ± 7.49 
years)
t  posterior parietal activity, synaptic 
excitation and neural information 
processing speed
(103)
Mashed potato 
powder (1 g kg1 BW) 
with cocoa butter (1 g 
kg-1 BW)
Mashed potato 
powder (1 g kg1 
BW) supplemented 
with olive oil (1 g kg- 
1 BW)
Randomised, cross-over; 10 
healthy females (38.2 ± 10.7 
years)
Plasma [TAG] and [IL-6] were altered 
(no significant difference between the 
meals)
(115)
Cocoa beverage twice 
per day for 12 weeks
Cocoa-free
beverage
Randomised; 25 healthy 
males (38 ± SE 1 years)
j. LDL susceptibility to oxidation and 
urinary [dityrosine]; f  HDL cholesterol
(116)
Low-, medium-, or 
high-pp cocoa 
beverage twice per 
day for 4 weeks
Nutrient matched 
beverage (trace 
amounts of cocoa 
PP)
Double-blind; 160normo- 
and mildly
hypercholesterolemic 
subjects (91 females, 69 
males) (20-70 years)
j, [Apo B] in MCP and HCP groups; j, 
oxidised LDL (kU L 1 plasma) in all 
groups
(117)
40 g DC Macronutrient 
matched, flavonoid- 
free chocolate
Double-Wind, randomised, 
22 heart transplant 
recipients (4 females, 18 
males)
f  Coronary artery diameter and % 
change of endothelial-dependent 
vasomotion; j  [8-iso-PGF2a] and 
platelet adherence
(118)
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22 g DC
supplemented with 
1.1 g canola sterol 
esters twice per day 
for 4 weeks
Macro- and 
micronutrient 
matched DC 
without the addition 
of plant sterols
Double-blind, cross-over;
49 subjects (32 females, 17 
males) (24-70 years) with 
elevated cholesterol (5.20- 
7.28 m m olL'1)
l  Serum total- and LDL cholesterol; 
l  SBPand DBP (combined 
intervention and control results)
(119)
MF or HF beverage Macro- and 
micronutrient 
matched LF 
beverage
\!
Double-blind, randomised, 
cross-over; 10 type-2 
diabetic subjects (2 
females, 8 males) (64.7 ± 
9.9 years)
f  FMD (120)
Flavanol containing 
beverage 3 times per 
day for 30 days
Macro- and 
micronutrient 
matched LF 
beverage
Double-blind, randomised; 
41 type-2 diabetic subjects 
(29 females, 12 males) 
(intervention, 63.1 ± 8.3 
years; control, 64.4 ± 8.6 
years)
T FMD (120)
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HF beverage twice 
per day for 12 weeks 
with and without 45 
min physical activity 
3 days per week
Macro- and 
micronutrient 
matched LF 
beverage with and 
without physical 
activity
Double-blind, randomised; 
49 overweight and obese 
subjects (32 females, 17 
males) (40-50 years)
t  FMD (combined exercise and non­
exercise results); |  insulin 
resistance, DBP and MAP (flavanol 
treatment nested in time)
(121)
Phase 1: Acute 
consumption of 74 g 
DC
Phase 2: 2 cups of 
either sugar- 
containing cocoa 
beverage or sugar- 
free cocoa beverage
Phase 1: 74 g
cocoa-free
chocolate
Phase 2: 2 cups of 
sugar-containing 
cocoa-free 
beverage
Single-blind, randomised, 
cross-over; 45 healthy 
subjects (35 females, 10 
males) (52.8 ± 11.0 years)
t FMD; J.SBP and DBP; greatest 
FMD improvement following sugar- 
free cocoa beverage.
(56)
100 g flavanol-rich 
DC per day for 15 
days
100 g flavanoFfree 
white chocolate per 
day
Double-blind, cross-over, 
19 hypertensive, 
prediabetic subjects (8 
females, 11 males) (44.8 ± 
8.0 years)
|  Insulin resistance and |  insulin 
sensitivity; j  clinical SBP and DBP, 
and ambulatory BP; t  FMD and | 
serum total- and LDL cholesterol
(90)
100 g DC per day for 
1 week
None 28 healthy subjects (19 
females, 9 males) (42 ± 12 
years)
i  platelet activated GP llb/llla 
expression; j  LDL cholesterol; f 
HDL cholesterol. J C-reactive 
protein (females only)
(89)
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Cocoa beverage 
twice per day for 2 
weeks
Macro- and 
micronutrient 
matched LF 
beverage
Double-blind, randomised, 
cross-over; 20 
hypertensive subjects (12 
females, 8 males) (51 ± SE 
1.5 years)
t  insulin-stimulated brachial artery 
diameter
(122)
20 g cocoa powder in 
250 mL skimmed milk 
twice per day for 4 
weeks
250 mL skimmed 
milk without cocoa 
powder
Randomised, cross-over; 
42 high-risk of CVD 
subjects (23 females, 19 
males) (69.7 ±11.5 years)
t  HDL cholesterol; j  expression of 
adhesion molecules on the surface 
of monocytes and concentration of 
circulating soluble adhesion 
molecules
(123;
124)
HF cocoa beverage 
followed by 10 min 
cycling
Macronutrient 
matched LF cocoa 
beverage followed 
by cycling
Double-blind, randomised, 
cross-over; 21 healthy 
overweight/obese subjects 
(8 females, 13 males) (54.9 
± SE 2.2 years)
t  FMD; l  AUC for DBP and MAP in 
response to exercise
(125)
Cocoa beverage 
containing 33, 372, 
712, or 1052 mg total 
flavanols per day for 
6 weeks
None Double-blind, randomised; 
52 mildly hypertensive 
subjects (20 females, 32 
males) (42-74 years)
|  24 h ambulatory MAP, SBP and 
DBP (1052 mg); j, Overnight 
ambulatory SBP, DBP and HR
(126)
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6 g or 25 g DC per 
day for 3 months
None Single-blind, randomised; 
91 cardiovascular high-risk 
patients (20 females, 71 
males) (57-74 years)
l  24 h, day- and night-time MAP, 
SBP and DBP (6 g); i  24 h and 
daytime MAP and SBP (25 g)
(127)
HF cocoa beverage 
twice per day for 30 
days
Nutrient matched 
LF cocoa beverage
Double-blind, randomised, 
cross-over; 16 coronary 
artery disease (CAD) 
patients (3 females, 13 
males) (64 ± 3 years)
t  FMD (both conditions), FMD post­
intervention was higher than post­
control; t  % of CACs; |  plasma 
[nitrite]; |  SBP
(128)
15 g DC 3 times per 
day for 8 weeks
Macronutrient 
matched cocoa 
solids-free 
chocolate
Double-blind, randomised, 
cross-over; 12 type-2 
diabetic subjects (5 
females, 7 males) (42-71 
years)
t  Serum [HDL cholesterol]; ]. total 
cholesterol:HDLcholesterol ratio
(92)
Dairy based cocoa 
beverage containing 
either natural-dose 
(NTC) or high-dose 
(TEC) theobromine 
once per day for 3 
weeks
Unspecified dairy 
based placebo 
beverage
Double-blind, randomised, 
cross-over; 42 pre-/stage 1 
hypertensive, healthy 
subjects (10 females, 32 
males) (62 ± 4.5 years)
T 24 h DBP (NTC); 1 24 h SBP, 
daytime DBP, 24 h, day- and night­
time HR (TEC); j  central SBP, HR 
and stroke volume (TEC)
(129)
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Dairy-based high-fat 
liquid meal plus HF 
cocoa powder
Macronutrient 
matched dairy- 
based high-fat liquid 
meal containing LF 
cocoa powder
Double-blind, randomised, 
cross-over; 18 healthy 
subjects (16 females, 2 
males) (25.2 ± 2 .5 years)
f  serum [triglycerides] and [free fatty 
acids] (both conditions); J. FMD (both 
conditions, higher following 
intervention)
(130)
40 g DC twice per day 
for 2 weeks followed 
by 1.5 h cycling
30.4 g bar of sugar- 
and fat-matched 
cocoa liquor-free 
chocolate followed 
by cycling
Single-blind, randomised; 20 
healthy males (22 ± 4  years)
|  Plasma [F^isoprostane] post­
exercise (both conditions, lower 
following intervention); i  oxidised LDL 
pre- and post-exercise
(131)
40  g DC 40 g milk chocolate Single-blind, randomised, 
cross-over; 20 healthy 
subjects (13 females, 7 
males) (33 ± 11 years) and 
20 smokers (13 females, 7 
males) (33 ±1 1  years)
i  Serum sNOx2-dp, urinary 
isoprostane excretion and platelet 
ROS, sNOx2-dp and 8-iso-PGF2a 
(healthy subjects); t  FMD, serum 
[NOx] and platelet NOx production 
(smokers); ] serum sNOx2-dp, urinary 
isoprostane excretion and platelet 
ROS, sNOx2-dp and 8-iso-PGF2a 
(smokers)
(132)
(133)
Cocoa beverage 
containing either 2 ,5 , 
13 o r2 6 g ofcocoa
Macronutrient 
matched beverage 
without cocoa 
powder
Double-blind, randomised; 
23 healthy subjects (14 
females, 9 males) (63 ± SE 
2 years)
Dose-dependent greater change in 
FMD (5 ,1 3  and 26 g); T SBP (2 and 
26 g); t  DBP (2 ,1 3  and 26 g); t  MAP 
(2 ,1 3  and 26 g); |  [glucose] (0 ,2  and 
5g)
(134)
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Sugar-free cocoa 
beverage ora sugar- 
sweetened cocoa 
beverage twice per 
day for 6 weeks
Cocoa-free sugar-
sweetened
beverage
Double-blind, randomised, 
cross-over; 39 overweight, 
healthy subjects (33 
females, 6 males) (41-63 
years)
t  FMD (both conditions) (135)
75 g DC None 16 healthy subjects (6 
females, 10 males) (20-45 
years)
|  Angiotensin-converting enzyme 
activity
(136)
13.5g flavonoid- 
enriched chocolate 
twice per day for 1 
year
Macronutrient 
matched placebo 
chocolate
Double-blind, randomised; 
93 postmenopausal, type-2 
diabetic patients (51-74 
years)
l  Plasma [insulin] and insulin 
resistance; |  insulin sensitivity; i  
[LDL cholesterol]; i  CHD risk (both 
conditions, less following 
intervention)
(137)
100g DC followed by 
2.5 h of cycling
Macronutrient 
matched cocoa 
solids-free bar (71 
g) followed by 
cycling
Single-blind, randomised, 
cross-over, 14 healthy male 
subjects (22 ± 1 years)
t  Plasma total antioxidant status 
(both conditions); f  [insulin] pre­
exercise and 1 h post-exercise; |  
plasma [glucose] post-exercise (both 
conditions)
(138)
100 g high- 
antioxidant dark 
chocolate (HADC) or 
100 g DC
None Double-blind, randomised, 
cross-over, 15 healthy 
subjects (9 females, 6 
males) (30 ± 5 years)
f  Plasma FRAP (both interventions); 
HADC FRAP remained higher at 4 
and 5 h; |  urinary HADC FRAP up to 
12 h; t  [triacylglyceroO (both 
interventions); f  [thiol] at 2- and 4 h 
(both interventions)
(139)
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50 g DC per day for 3 
weeks
None 50 healthy subjects (25 
females, 25 males) (28-45 
years)
t  [HDL cholesterol] and [triglyceride] 
and |  LDL cholesterol (females 
only); |  lipid peroxidation, 
conjugated diene and hydroperoxide 
content of HDL and LDL; f  platelet 
production of NO; j  peroxynitrite
(68)
(B) cocoa+hazelnuts,
(C)
cocoa+haze!nuts+ 
phytosterols, (D) 
cocoa+hazelnuts+phy 
tosterols+soluble 
fibre daily, 4 weeks
(A) Cocoa
■'i
Double-blind, randomised; 
113 pre/stage-1 
hypertensive and 
hypercholesterolemic 
subjects (67 females, 46 
males) (43-65 years)
|  [Total-] and [LDL cholesterol] and 
[Apo B] and Apo B:Apo A ratio (C) 
and (D); j, hsCRP and oxidised LDL 
(D)
(63)
DC and cocoa 
beverage once per 
day for 3 months
None 5 type-2 diabetic patients 
with stage II and III heart 
failure (47-71 years)
Î  [HDL cholesterol]; enhanced 
expression of mitochondrial structure 
markers in skeletal muscle
(140)
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Table 1. Summary of intervention studies on cocoa between 2007 and 2012. 
Only outcomes with a statistical significance of a maximum p<0.05 are 
reported. Mean ± SD unless otherwise stated.
Abbreviations used in the table: increase; |  decrease; DC, dark chocolate; 
HR, heart rate; pp. Polyphenol; CFS, chronic fatigue syndrome; HF, high 
flavanol; LF, lowflavanol; MF, medium flavanol; BW, body weight; TAG, 
triacylglycerol; IL-6, interleukin 6; LDL, low-density lipoprotein; HDL, high- 
density lipoprotein; Apo B, apolipoprotein B; 8-iso-PGF2a, 8-iso­
prostaglandin F2a; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; FMD, flow mediated dilation; MAP, mean arterial pressure; GP, 
glycoprotein; CVD, cardiovascular disease; AUC, area under curve; CACs, 
circulating angiogenic cells; sNOx2-dp, soluble NOx2 derived peptide; ROS, 
reactive oxygen species; FRAP, ferric reducing ability of plasma; NO, nitric 
oxide.
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Figure legends
Figure 1 : Chemical structures of cocoa flavanols
Figure 2: Metabolic pathways of theobromine in humans
Figure 3: General mechanism by which NO affect vasodilation
Figure 4: Possible mechanisms by which epicatechin affects nitric oxide 
levels.
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Abstract
18 We have investigated the inhibition of glucose transporters SGLT1 and GLUT 2 by
19 polyphenol-rich herbal supplement using the well-characterized Caco-2 intestinal model.
20 Glucose absorption under sodium dependent and sodium-free conditions was decreased by
21 54% and 35% respectively in the presence of the water soluble components from the herbal
22 supplement. Using sodium-dependent and sodium-free mechanistic studies, we demonstrate
23 that the inhibition of GLUT2 was greater than SGLT1. Glycosidase and esterase enzymatic
24 hydrolysis was used to assess the impact of human metabolism on the efficacy of activity.
25 Glucose transport across the membrane was reduced by 70% compared to the control and
26 the enhance inhibition was associated with significant increases in flavonoid aglycones,
27 caffeic acid and p-coumaric acid. These results suggest that intact and metabolized
28 polyphenols, likely to be found in the lumen after ingestion of the supplement, play an
29 important role in the attenuation of glucose absorption and may have potentially beneficial
30 anti-glycemic effects in the body.
31
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Introduction
32 Over the past two decades the prevalence of diabetes has risen dramatically, and is
33 estimated to effect 347 million people globally [1]. Type 2 diabetes is the most common
34 form, which can develop following prolonged periods of elevated blood glucose
35 (hyperglycemia); and is a recognized risk factor for metabolic syndrome [2]. Lifestyle
36 modifications including increased fruit and vegetable consumption, weight loss and lowered
37 blood glucose may prevent or delay disease development [3,4].
38 Promising evidence is emerging concerning the use of certain herbs, botanicals and trace
39 elements for the control of blood glucose [5,6]. Currently there is insufficient evidence to
40 draw conclusions on the efficacy of herbal remedies, but beneficial effects on several risk
41 factors have been observed for chromium and Gymnema sylvestre (gymnema) [7],
42 cinnamon [8], green coffee [9] and grape seed [10] in controlled-trials. The mechanism of
43 action is currently unclear, but there is growing evidence that secondary plant metabolites,
44 known as polyphenols, can modulate carbohydrate metabolism [11]. th e  in  v itro  anti-
45 diabetic properties o f a number of extracts have been attributed to polyphenols [12-15],
46 mainly cinnamates, glycosides, procyanidins and flavonol derivatives. Modulation of such
47 metabolic markers by natural botanicals may be beneficial to the treatment or prevention of
48 type 2 diabetes.
49 Previous cell culture studies using plant materials have demonstrated that some
50 polyphenols can attenuate intestinal glucose absorption and potentially “blunt” post-prandial
51 glucose spikes by inhibition of active uptake via sodium-dependent glucose transporter 1
52 (SGLT1) and facilitated transport by sodium-independent transporter 2 (GLUT2) [16,17].
53 However, very few have addressed the issue of identification and efficacy of the in  v iv o  gut
54 lumen metabolites despite established knowledge that following ingestion, polyphenols
55 undergo metabolism by the intestinal p-glycosidase, LPH [18]. Growing evidence suggests
56 that the major forms present in the body are de-glycosylated and metabolized derivatives of
4
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57 the parent aglycones [19,20], which have altered biological activities [21]. Attenuation of
58 glucose transport across the small intestine by polyphenols and their metabolites may be a
59 potential mechanism of glycemic control. Such activity may, in part, explain previous
60 observations of lowered blood glucose concentrations and delayed glucose absorption in
61 human studies [22,23] following consumption of polyphenol-rich foods.
62 The purpose of this study was to investigate the inhibitory potency of a botanical
63 supplement containing a broad spectrum of herbs and spices on glucose uptake by SGLT1
64 and GLUT2 transporters using a Caco-2 cell model of the small intestine. Consumption of
65 this botanical supplement can affect glucose absorption and may be useful for the
66 prevention or management of type 2 diabetes.
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Materials and Methods
67 Chemicals
68 All chemicals were purchased from Sigma-Aldrich (Dorset, UK) unless stated otherwise.
69 D-glucose and HEPES (N-(2-Hydroxyethyl)piperazine-N'-2-ethanesulfonic acid) were
70 purchased from Fisher Scientific (Loughborough, UK). Magnesium sulfate was purchased
71 from VWR International Ltd (Leicestershire, UK). Transwell polycarbonate inserts (6 well,
72 0.4 pm pore size), tissue culture flasks and filter system (500 ml, 0.2 pm nylon membrane)
73 were manufactured by Coming® and supplied by Sigma-Aldrich (Dorset, UK). D-[U-14C]-
74 glucose was purchased from Perkin Elmer (Cambridge, UK) and Exoscint XR scintillation
75 cocktail from National Diagnostic (Yorkshire, UK). Eagle’s Minimum Essential Medium
76 (EMEM, 1000 mg/ L glucose) was purchased from American Type Cell Culture (LGC
77 Promochem, Middlesex, UK). Herbal powders were supplied by NewChapter.com
78 (Vermount, USA).
79 Preparation of cell culture test solutions
80 The herbal supplement used in this study was composed of several herbs, spices and
81 botanicals and was prepared fresh on the day of use. Test solutions used in the sodium
82 dependent/ independent cell culture experiments were prepared as described. Herbal
83 powders equivalent to 1020 mg of extract were solubilized in DMSO and centrifuged at 17,
84 000 xg for 5 min. Supernatants were combined and an aliquot (81 pi) of the mixture was
85 diluted to 20 ml using transport buffer (pH 7.4) of the appropriate sodium content modified
86 1 mM glucose and combined with D-[U-14C] glucose (0.05 pCi/ ml).
87 For the preparation of the polyphenolic extracts with and without enzymatic hydrolysis,
88 an aliquot (81 pi) of the solubilized herbal supplement was combined with ascorbic acid
89 (1 mg/ ml) as a stabilizing agent and then diluted to 20 ml with warm (40 °C) buffer solution
90 (CHjCOOH, 0.2 M: CHjCOONa, 0.2 M, 90:10, v/v, pH 3.8) either with or without
6
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91 hesperidinase from Aspergillus niger (40 U/ L). All samples were incubated at 40 °C for 5 h
92 in a shaking water bath (Grant Aqua 12 Plus, Grant Instruments Ltd, Cambridgeshire, UK).
93 Afterwards, a liquid-liquid extraction procedure was performed by adding 20 ml of warm
94 ethyl acetate. Phases were mixed by vortex (10 min), followed by centrifugation at 4000 *g
95 (5 min) to allow separation and collection of upper ethyl acetate phase. These steps were
96 repeated twice more using 10 ml of ethyl acetate. The combined organic phases were dried
97 under nitrogen flow at 40 °C. The dried extracts were reconstituted with 50 pi DMSO,
98 sonicated (5 min) and vortexed to mix. Reconstituted solutions were then diluted to 20 ml
99 using transport buffer A (see below) modified with 1 mM glucose and D-[U-14C] glucose at
100 0.05 pCi/ ml.
101 In order to calculate the recovery efficacy of the extraction procedure, the above steps
102 were repeated in triplicate using samples that had been spiked with an internal standard,
103 dihydrocaffeic acid (0.01 mg/ ml), immediately before enzyme hydrolysis. Samples were
104 reconstituted in transport buffer A without D-[U-I4C] glucose.
105 Cell culture
106 The human colon adenocarinoma cell line, Caco-2 (IITB-37) was obtained from the
107 American Type Culture Collection at passage 25 (LGC Promochcm, Middlesex, UK).
108 Permeability studies utilized Caco-2 cells between passages 40 and 46. Caco-2 cells were
109 added to Transwell inserts (24 mm diameter, 4.67 cm2 growth area) at a density 6 x 104
110 cells/cm2 and cultured for 21 d at 37°C under a humidified atmosphere of 95% air: 5% C 02.
111 The culture medium, EMEM supplemented with 10% FBS, 1 OOU/ml pcnicillin-
112 streptomycin and 0.25 pg/ml amphotericin B was replaced every other day.
113 Glucose transport measurements
114 On or after 22 d, permeability studies were initiated by careful aspiration of the culture
115 medium from apical and basal compartments and 2 ml of transport buffer A (HEPES, 20
7
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116 mM; NaCl, 137 mM; KC1,4.7 mM; CaCl2, 1.8 mM; and MgS04, 1.2 mM; adjusted to pH
117 7.4 using NaOI I, 10 mM) was added to each compartment to carefully wash cells. After
118 washing, the solutions were removed and fresh transport buffer (A) was added into each
119 compartment. Plates were incubated at 37 °C in a humidified 5% C 02 atmosphere for 30
120 min to allow equilibration of tight junction integrity. Trans-epithelial electrical resistance
121 > (TEER) measurements were recorded using a Millicell ERS volt-ohm meter fitted with a
122 chopstick probe (Millipore Ltd, Watford, UK). Wells with a resistance above 250 Q, after
123 correction for membrane resistance, were used. Afterwards, the liquid was aspirated and
124 replaced with 2 ml of test solution (1 mM glucose and Z)-[U-,4C] glucose at 0.05 pCi/ ml
125 dissolved in transport buffer A with or without the herbal supplement, 0.4% DMSO) at pH
126 7.4; all basal solutions were in transport buffer A (pH 7.4). Plates were incubated at 37 °C in
127 a humidified 5% C 02 atmosphere for 25 min, the TEER measurements were repeated and
128 the solutions removed. Statistical analysis was performed on the final TEER for all test
129 conditions, and addition of herbal supplement had no effect on monolayer resistance
130 compared to respective controls (p >0.22). Apical and basal compartments were washed
131 twice with 1 ml of transport buffer to remove any residual D-[U-,4C] glucose from the cell
132 monolayer or compartment walls and the aliquots were collected. After this, 1 ml of NaOH
133 (1 mM) was added to the apical compartments and shaken for 30 min to lyse the cells. The
134 detached cells were then neutralized with 1 ml of HC1 (1 mM), mixed and the aliquots were
135 collected. Radiochemical detection of D-[U-14C] glucose was performed by combining 5 ml
136 of scintillation cocktail with 0.25 ml of the apical solutions or 0.5 ml of the basal solutions,
137 the apical and basal wash solutions and lysed cell solutions. All samples were analyzed
138 using a Parkard Liquid Scintillation Analyzer 1600TR. A cold sample of transport buffer
139 solution was used to determine background noise and all samples were corrected for the
140 count efficiency of the analyzer. .
141 To investigate the transport of glucose under sodium-free conditions, the experiments
142 above were repeated using transport buffer B; where the formulation of transport buffer A
8
>**
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
307
was modified so that sodium chloride was replaced by potassium chloride (137 mM) and 
adjusted to pH 7.4 using KC1 (10 mM).
To assess the inhibitory potential of the herbal supplement in the native and digested 
forms, the transport experiments described above were repeated using polyphenolic extracts 
prepared with and without enzymatic hydrolysis.
HPLC-DAD and MS analysis
Analysis of the aqueous polyphenol extracts, prepared with and without enzyme 
hydrolysis, was performed using the following HPLC-DAD-MS method. An aliquot (1 ml) 
of each extract was removed to a 2 ml tube and centrifuged at 17,000 *g for 5 min to 
remove particulate matter. A small volume (100 pi) was removed to an amber vial, spiked 
with internal standard and stored in the HPLC autosampler for analysis. A volume (5 pi) 
was injected on to a Rapid Resolution HPLC (1200 series Agilent Technologies, Berkshire, 
UK) with diode array (DAD). The methodology used was based on our previous work [24]. 
Chromatographic separation was achieved on an Eclipse plus Cl 8 column (30 °C, 2.1 mm x 
100 mm, 1.8 pm; Agilent Technologies) using a 75 min gradient of (A) premixed 5% 
acetonitrile in water (5:95, v/v) and (B) premixed 5% water in acetonitrile (5:95, v/v) both 
modified with 0.1% formic acid with a flow rate of 0.26 ml/min. Elution was initiated at 0% 
of solvent B and maintained for 17 min; the percentage of solvent B was then increased to 
35% over the next 43 min and immediately increased to 100% for 5 min before initial 
starting conditions were resumed for a 10 min column re-equilibration. After separation the 
analytes were quantified by DAD based on calibration curves for available standards 
including caffcic acid, 5-O-caffeoylquinic acid, cinnamaldchyde, p-coumaric acid, coumarin 
and dihydrocaffcic acid. Dicaffcoylquinic acid and fcruloylquinic acid were quantified 
based on 5-caffcoylquinic acid, data are expressed as mean ±SD (n =3). Calibration curves 
showed good linearity over the tested range; Pearson’s coefficients were significant at the 
1% level (R2 > 0.99). Caffeic acid was used to determine DAD analytical performance
9
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169 based on triplicate injections on the same day: the limit of quantification was 25 nM,
170 accuracy and precision were calculated at < 2% R.E. and R.S.D respectively.
171 Identification of analytes present in the extracts was confirmed by MS. In brief, after
172 separation the eluate was passed, without splitting, into an Agilent 6410 triple quadrupole
173 MS fitted with an electrospray ionization interface and the operation conditions are
I
174 described elsewhere [24], Samples were analyzed in full scan (100-1000 m/z) mode under
175 both negative and positive ionization conditions to identify the relevant molecular ions.
176 Then the identity of the compounds was then confirmed using multiple reaction monitoring
177 (MRM) mode by comparison of molecular ion and associated fragmentation pattern to
178 available standards. Quercetin and kaempferol could not be determined by DAD due to co-
179 elution interference. Thus these compounds were quantified in MRM mode based on
180 quercetin and kacmpferol reference standards using the response of the major product ion
181 achieved by fragmentation of the 301 and 285 negative molecular ions respectively.
182 Statistical analysis
183 Analysis of variance was used to confirm statistical difference in samples under different
184 experimental conditions and is a test of whether the means of two or more groups are equal.
185 Shilpro-Wilk and Levene’s test were performed to confirm the normality of the data and the
186 equality of variances respectively. The mean difference was statistically significant at the
187 5% level (PASW statistics. 17)
188
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Results
189 Inhibition of glucose transport under sodium dependent/ sodium-free conditions
190 The final concentration of the herbal supplement used in cell transport studies reflected
191 the estimated physiological concentration in the gut lumen following ingestion. In the
192 absence of the aqueous herbal supplement under sodium-dependent conditions, D-[U-UC]
193 glucose was taken up by the cells and transported into the basal chamber at a rate of 4.4
194 ±0.1 nmol/cm2 • min. It is expected that the uptake of glucose in the presence of sodium is
195 mediated by both SGLT1 and GLUT2 located at the apical surface and exported to the
196 serosal side via GLUT2 in the basal membrane. Addition of the herbal supplement
197 significantly (p< 0.001) decreased glucose transport to 45.6 ±3.8% of the control value (Fig.
198 1A), ~55% inhibition. In the absence of aqueous herbal supplement under sodium free
199 conditions, the rate of Z)-[U-14C] glucose transport was reduced to 3.3 ±0.1 nmol/cm2 • min
200 compared to sodium dependent conditions. In the absence of sodium, it is considered that
201 glucose transport is mediated solely by the GLUT2 transporters located at the apical and
202 basal membranes. Incubation of the Caco-2 cells with the herbal supplement under these
203 conditions lead to a significant (p< 0.001) decrease in glucose transport to the basal chamber
204 to 65 ±2.6% of the control value (Fig. 1 A), ~35% inhibition.
205 Under sodium dependent conditions, the supplement had no effect on the accumulation
206 of D-[U-14C] glucose by Caco-2 cells compared to control (Fig. 1B). In contrast, the
207 inhibition of glucose transport by the extract of the herbal supplement under sodium-free
208 conditions was associated with a significantly (p< 0.001) lowered accumulation of glucose
209 in the Caco-2 cells compared to control conditions (Fig. 1B).
210 Effect of de-conjugation on potency of glucose-transporter inhibition
211 Cell transport studies were performed under sodium dependent conditions using
212 polyphenol extracts prepared from the aqueous herbal supplement following a liquid-liquid
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213 extraction with or without an enzymatic de-conjugation step. Extraction efficiencies for
214 dihydrocaffeic acid show that 92 ±0.3% and 93 ±1.4% of the spiked amount was recovered
215 after extract with and without enzymatic de-conjugation respectively. The non-hydrolyzed
216 polyphenol extract efficiently reduced glucose transport to 50 ±1.5% of the control value,
217 which was comparable with the un-extracted herbal supplement. Interestingly, when the
218 hydrolyzed polyphenol extract was used, there was a larger and significant (p< 0.001)
219 decrease in the rate of glucose uptake to 29.3 ±2.1% of the control value (Fig. 2).
220 Polyphenol composition of herbal supplement
221 The herbal supplement used in the current study contained a combination of herbs, spices
222 and botanicals (Fig. 3). A liquid-liquid extraction was performed in the presence or absence
223 of glycosidase and esterase enzyme mixture and resulting polyphenol extracts were
224 analyzed by 11PLC-D AD-MS. A typical chromatogram of the polyphenol profile is shown
225 in Fig. 4A, for details of peak numbers refer to Table 1. The major components of the non-
226 hydrolyzed polyphenol extract appear to be chlorogenic acids and cinnamaldehyde.
227 Following enzymatic de-conjugation, the polyphenol profile is distinctly altered due to
228 liberation of free-aglycone forms (Fig. 4B). A statistically significant increase in response
229 was observed for several of the compounds including caffeic acid, p-coumaric acid,
230 quercetin and kacmpfcrol. The compounds were identified by comparison of the retention
231 time, UV spectra and the molecular ion produced by eicctrospray ionization relative to
232 available standards.
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Discussion
233 There is growing evidence for the in  v itro  interaction of polyphenols with transporters
234 [16,17,25] and enzymes [15,26,27] of importance to glucose absorption and metabolism.
235 These observations indicate that these compounds may have beneficial influence on
236 glycemic control, which is a known risk factor for the development cf type 2 diabetes. The
237 objective of this current study was to assess the capacity of a new herbal supplement to
238 reduce glucose transport across the small intestine, and demonstrate the mechanism of
239 action.
240 The data indicate that the combination of polyphenols from the herbs, spices and seeds in
241 the aqueous herbal supplement were able to decrease the transport of glucose by up to 54%
242 at concentrations predicted after ingestion of a normal dietary serving. Investigations with
243 and without sodium suggest that disruption of GLUT2 mediated uptake is the major apical
244 target for attenuation of glucose transport by Caco-2 cells. The predominant polyphenols
245 identified following HPLC-MS analysis were cinnamaldehyde and dicaffeoylquinic acids
246 derived from cinnamon and coffee beans respectively.
247 Evidence from clinical trials in humans have indicated that a daily high dose (> 3 g) of
248 cinnamon significantly lowered fasting blood glucose concentrations in type 2 diabetic
249 volunteers [28,29]. In other studies using a daily dose of 1 -1.5 g, these effects were not
250 observed [30-32]. The mechanism of action is unclear, but i n  v i t r o  and animal studies, using
251 levels of cinnamon achievable in the diet, suggest these effects may be attributed to
252 enhanced glucose storage by adipocyte cells [33,34], increased glucose conversion to
253 glycogen in the liver [35] and reduced carbohydrate digestion in the small intestine via
254 inhibition of a-glucosidase [15]. Similarly, dicaffeoylquinic acids have been highlighted as
255 the principal compounds responsible for the inhibition of glucose transporters by herbal
256 beverages in the small intestine [16], leading to reduced glucose absorption. These
13
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257 observations suggest that polyphenols found in cinnamon and coffee may improve insulin
258 sensitivity and reduce post-prandial glucose levels.
259 Enzymatic hydrolysis of the aqueous herbal supplement lead to significant increases in
260 the amounts of caffeic acid and p-coumaric acid. These compounds are likely to be released
261 from the caffeoylquinic acids present in the green coffee, resulting from esterase activity
- *
262 within the hespcridinase used in this study. Analysis of the hydrolysed supplement by
263 HPLC-MS also revealed small, yet significant, increases in the amounts of quercetin and
264 kaempfcrol, which were present in small amounts in the unhydrolysed supplement. Overall,
265 glucose uptake across the epithelial cells was reduced by 70% compared to the control.
266 These results sugges that the anti-diabetic activity may be enhanced following metabolism
267 in the intestinal lumen and indicates that the free-aglycones have greater potency to inhibit
268 or delay glucose uptake than their glycosylated forms. However, since the herbal
269 supplement used in our current study was unpurified, it is not possible assign these effects to
270 a specific componcnt(s).
271 Currently, literature evidence for the influence of polyphenols on glucose absorption
272 across Caco-2 cells is limited. Our data are in agreement with those investigating the *
273 inhibition of glucose transporters SGLT1 and GLUT2, by individual polyphenols derived
274 from fruit extracts [17]. The authors reported inhibitory activity of /j-coumaric acid at
275 concentrations in the range of 10 to 500 pM, which is comparable to the levels detected in
276 our current study. In a rodent model of type 2 diabetes, a moderate intake of caffeic acid
277 (approximately 40 mg/kg body weight) induced a reduction in blood glucose levels and
278 lowered glucose-6-phosphatase activity [36]. Interestingly glucose uptake was significantly
279 reduced by 10-100 pM quercetin but not rutin, the glycosidic form, in several transport
280 models mainly via interaction with GLUT2 [25,37]. In contrast to our results, some studies
281 using individual hydroxycinnamic acids including caffeic acid, 5-caffeoylquinic acid and p-
282 coumaric acid, at a concentration of 100 pM, reported no effect on glucose uptake under
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either sodium-dependent or sodium-free conditions [25]. A likely explanation for these 
differences may be the use of a mixture of polyphenols used in the current study, leading to 
enhancement of the inhibitory activity. Co-incubation of polyphenols and their 
physiological effects have received little attention in vitro, but human trials with 
polyphenol-rich beverages offer promising benefits for the reduction of blood glucose in 
healthy volunteers [22,38],
Our study demonstrates that water soluble components from a herbal supplement 
composed of a variety of herbs, spices and seeds, efficiently reduced glucose transport 
across Caco-2 intestinal cells mainly through interaction with the GLUT2 transporter 
family. Since the aglycone metabolites released following enzymatic hydrolysis have 
sustained biological activity, we propose that regular dietary consumption may improve 
glucose control either by limiting or delaying glucose absorption in the intestine. These 
encouraging findings require further evaluation in human controllcd-trials to establish the 
beneficial effects in the body.
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Fig. 1. A: Effect of herbal supplement on glucose transport by Caco-2 cells under sodium 
dependent and sodium-free conditions. B: Effect of herbal supplement on the intracellular 
accumulation of glucose by Caco-2 cells under sodium dependent and sodium-free 
conditions. Values expressed as a percentage of the control value which was the glucose 
transport under each condition in the absence of herbal supplement. Each data point is the 
mean ±SD (n = 3). **: p< 0.001.
Fig. 2. Effect of polyphenol extract prepared with or without enzymatic hydrolysis on 
glucose transport by Caco-2 cells under sodium dependent conditions. Values expressed as a 
percentage of the control value which was the glucose transport under sodium dependent 
conditions in the absence of polyphenol extract. Each data point is the mean ±SD (n = 3).
**:p< 0 001.
Figure 3. Percentage composition of the herbal supplement.
Fig. 4. HPLC-DAD trace (280 nm) showing the phenolic profile of the extracts prepared 
without (A) and with enzymatic hydrolysis (B). For peak numbers refer to Table 1. *: p<
0.01; **: p< 0.001.
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Table 1. Characterization o f the polyphenols in the herbal supplement without and 
after enzyme hydrolysis by IIPLC-DAD-MS
Peak
number Compound
Retcntio 
n time
(min)
X
max
(nm)
Molccu 
lar ion
[M-H]-
Concentration
(HM)
1
dihydrocaffeic 
acid (IS) 10.9 280 181
Without
Hydrolysis
ND
With
Hydrolys
is
*
2
5-0-
caffeoylquinic
acid 13.7
325,
295 353 46 ±0.03
3 caffeic acid 14.5 179 ND
77.1
±0.2**
4 p-coumaric acid 25.6
310,
290 163 1.4 ±0.03
12.8
±0.01**
5
5-0-
feruloylquinic
acid 29.4
325,
295 367 7.7 ±0.06
6 coumarin 33.2
280,
310 [ ! 4 7 f 8.0 ±0.09
7
3,4-di-O-
caffeoylquinic
acid 38.4
325,
295 515 11.4 ±0.03
0.7
±0.06**
8
3,5-di-O-
caffcoylquinic
acid 39.1
325,
295 515 8.3 ±0.09
4.0
±0.03*
9
4,5-di-O-
caffeoylquinic
acid 40.9
325,
295 515 13.5 ±0.07
7.7
±0.07*
10 cinnamaldéhyde 43.5 290 [133]+* 98.2 ±0.05 .
11 quercetin 46.0 370 301 0.1 ±0.004
0.8
±0.03**
12 kaempferol 365 285 0.1 ±0.005
0.7
±0.03**
A statistically significant change in concentration was observed *: p> 
0.01; **: p> 0.001. [ ]+: positive molecular ion.
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